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ABSimCT
Ihe motivatiOTì for the main bocty of work presented in this thesis 
arose fran three sources. Initially, the need to develop and test a 
reliable, portable and unobtrusive method of observing human feeding 
bdiaviour in a clinical setting. SeocHidly, curiosity cxxiceming the 
serotonergic modulation of feeding. In practice, to examine the 
effects of the 5-HT reuptake inhibitor and anti-d^ressant fluoxetine 
food intake and choice, body weight and subjective states in both 
non^^ressed normal-weight and obese subjects. The third and final 
impetus arose from the observation that, in rats, the expression of 
meal-induced satiety offered a background against which to examine the 
possible mechanisms underlying the effects of acute and chronic 
administration of serotonergic agents on oonsummatory and behavioural 
functicxiing. Chapter context and main results eire sunnarized below.
The observation methodology (Chapter 2), was devèloped and tested in a
clinical (ward) and laboratory setting with both patient and volunteer
»
populations and was proved feasible, reliable and acceptable to the 
different subject populations. An additional pharmacological study on 
food intake and feeding behaviour in normal volunteers tested the 
sensitivity of the methodology. D-airphetamine, and the isomers d- and 
1-fenfluramine were tested either alone or in combination, differenoes 
in the feeding behavioural profiles of d-airphetamine and 
d-fenfluramine were found.
/
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Ttie main findings from Chapter 2 were:
il Ctoserver reliability was substantiated relative to pilot work, 
iil D-airphetamine decreased meal duration, number of bites, and time 
spent in chewing and manipulation of food without reductions in eating 
rate. D-fenfluramine reduced eating rate, but not other parameters, 
li-fenfluramine did not alter feeding behaviour. Video-recording was 
used in all but the ward—based sessiOTis.
An automated food dispenser (AFD), rating scales euid roecisurements of
in aphysiological status were used to examine treatment effects 
normal-weight (Chapter 3) and obese (Chapter 4) populations in two 
fluoxetine (FXT) studies. Normal wei^t subjects received placebo 
cxxTtrolled treatment for two weeks, obese subjects for four weeks. 
Obese subjects were offered foods varying in both macronutrient 
content and sweet and savcxiry components. In addition, obese subjects 
)cept diary records of intake vdien not at the experimental unit. 
Video-recordings and behavioural observations were made of 
subjects during lunch meals, ihe main finding of Chapter 3 were:
ii Fluoxetine (FXT) reduced food intake and bocfy wei^t in both 
subject groi;ps.
lil In obese subjects, FOT reduced selection of all three 
macronutrients. Diet diary records supported the laboratoryHDased 
intake suppressive effects of FOT.
.liil Evidence of some sippression of hunger and increases in ratings
/
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of satiety was present in both subject groups. In obese subjects, F3CT 
reduced eating rates on sane days, but did not edter other feeding 
parameters, such as duration and latency.
In the acute animal study in Chapter 5, the ocnparable effects of five 
(hypophagic) serotcxiergic agents were examined via forty minute 
obsezvaticxi sessions, with sucrose intake and post-prandied 
b^iaviours acting l^s d^)endent variables. A sumnary of results from 
ChE^Tter 5 are as follows:
i) FXT caused a dose-d^)endent reducticxi in sucrose intake with a 
ooncxxnitant early introduction of post-prandizd resting. Acute 
fenfluramine reduced sucrose intake but appeared to suppress 
post-prandiaLL resting.
ii) While the effects of femoxetine, paroxetine and eltopreusine 
differered somevhat to each other, reductions in sucrose intake and 
early introduction of post-prandied resting were present, lending 
siifjport for serotonergic involvement in the mediation of satiety.
Ihe animal study in Chapter 6 examined and oonpared the effects of a 
chronic three-week treatment regime with either fluoxetine, 
fenfluramine or vehicle. Rats were similarly observed as for the 
acute studies, with additional measurements of body weight and 
laboratory chow. These measurements continued on cessaticxi of 
medicaticxi. Work carried out in Chapter 6 showed that:
i) Bo(^ weic^t loss oocurred and was sustained with F3CT treatment, 
whereas FF treated animals showed increases in bocty wei^t ooirparable 
to controls. Weight regain, in excess of starting baseline was 
evident in FXT treated animals c»i oessaticxi of drug treatment, 
iii Intake of sucrose in the 40min tests was reduced consistently in 
the F5CT group, and spasmodically in the FF treated animals. On 
cessaticxi of treatment with FXT, increases in ccxisuroptlcxi relative to 
control were seen.
iii) There were noticeable differences in the behavioural profiles of 
chronically administered FXT emd FF relative to control, cmd in 
cdiparison to the acute effects of these drugs in the previous stuc^. 
Animals treated chronically with F3CT eadiibited increased levels of 
non-specific activity relative both to control and to FF treated 
animals, while post-prandial resting behavicur was sli^tly 
suppressed. In carpeirison, chronic treatment with FF resulted in 
increased resting relative to control, generally at the e^qsense of 
grocming, vhich was si^ressed.
A series of esqeriments was caurried out in order to examine the 
hypophagic and oonsunmatory behavioural effects of selected 
serotexiergic agents in rats and humans. These studies have helped to 
clarify respcxise variables in the form of anorectic potentiaLL and 
behavioural profiles for serotonergic agents, some of vhich may be 
clinicedly prescribed for long periods of time. In view of the 
neurochemicad. action of these drugs, the observed effects suggest that
VI
activation of the serotonergic system by FXT and conparable agents is an 
adequate stiirulus for these effects to occur. In addition, 
observational methods in the animal studies have helped to determine 
that these drugs are, on the vhole, capable of enhancing the 
b^iavioural expression of meal-induced satiety in the form of 
post-prandial resting. The chronic animal study charted the develcpment 
of differing effects which may manifest in response to either acute or 
chronic treatment.
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CHAPTER 1
SEROTONIN AND FEEDING
1.1 INraODUCTION
Food intalce, food choice, feeding behaviour and body wei^t
regulation c ir é  essential ooirponents of species survival. Operative 
mechanisms in feeding are accepted as being multifactorial, ccmprising 
both central and peripheral influences (Smith & Gibbs, 1987; Oomura et 
al, 1990; Bliandell, 1991), and controlled Ì3y psychological eind
cultural cxxistriKrts (Rozin, 1976) The rese2m:h area directed at 
operative mechanisms in feeding is motivated by questions relating to 
"normal" physiological feeding/bcxJy-wei^t regulation, and to systems 
vhich aure classified as cfysfunctional, such as anorexic, bulimic aind 
obese states (Robinson, 1990; Garrow, 1991).
Endogenous substances that modulate feeding are numerous. They include 
peripheral peptides and brain p r i d e s  (Morley, 1989), amino-acids, 
and central monoaminergic substances (Leibcwitz, 1986; Leibowitz, 
1988). Initial reseaurcdi cauxied out in ainimal laboratories hais 
contributed to scientific kncwlecige on some of the influential factors 
in feeding. Peripherally aK^ministered p^Dticies, such as
cholec^^txDkinin, glucagon, bontoesin and somatostatin (Gîfctos et al, 
1973; Cooper, 1985) have been shcMi to suf^ress food intake and may 
play a role in termination of feeding and satiety.
Centrally, feeding is increased by site specific, particularly medial 
hypothalamic (paraventricular nucleus), administration of the 
neurotransmitters noradrenaline, neuropeptide Y, peptide YY, galanin, 
the amino acid GAB^ and the cpioid peptides,^-endorphin cuid dynorphin 
(Stanley & leibowitz, 1984; Leibowitz, 1988). Reductions in food 
intake have been described in response to centrally applied 
intraventricular glucagon, bombesin, and OCK (Cooper, 1985; Silver & 
Morley, 1991). In seme cases, depending on site of injection, some 
substances will produce the opposite effect when injected into the 
lateral portion of the hypothalamus, particulcurly the perifomical 
region e.g GAEA or noradrelanine injected into the PIH will suppress 
feeding b ^ v i o u r  (Leibowitz, 1986).
A possible role for serotonin in the nodulation of food intake and 
feeding bdiaviour has been postulated for a number of years (Blundell, 
1977; Blundell, 1984). A substantial number of studies in both 
animals and humans shew that esqjerimentally induced manipulations of 
serotcaiin result in changes in food-intake, feeding behaviour and 
with both suppression and increases in intake described, 
although the latter are more difficult to demonstrate (Blundell, 1992).
/
1,1,1 Perspective on serotonin rs-tfr^
The activities of the neurotransmitter serotonin (5-hydroxytryptamine) 
are discussed chiefly, in this thesis, in the context of modulation of 
food intake and feeding behaviour. 5-HT modulation of other vital 
systems is briefly acknowledged here, e.g. arousal, sexual behaviour, 
pain and thermoregulation (Glennon, 1991; Gorzalka et al., 1990). 
Serotonin, along with other neurotransmitters, may contribute to the 
modulation of affective state (Ccwen, 1991), and appetite disturbances
may be a feature of mental illness (Silverstone, 1983; Silverstone, 
1987a).
Historically, understanding the structure and functioning of the 
serotonin system has been reciprocal with technical advances. The 
developnent of histochemical fluorescence techniques by Falck and 
Hillarp in 1962 facilitated mapping the neuroanatanical location of 
5-HT neurons. More recently, developments in antibody, ligand and 
cloning technology and increasingly sophisticated autoradiogr^iiic 
techniques, all contribute to shape the information we accept about 
this system (Wang & Peroutka, 1988; Glennon & Dukat, 1991).
5-HT is produced both in the periphery euid in the brain. The breakdown 
of 5^ir to 5-hydroxyindoleaoetic acid is due to monoamine oxidase and 
5“HT is removed frcm the synapse by an active pre—synaptic uptake 
mechanism. In the brain, most 5-HT cell bodies are found grxxped in 
^jecific sites in the dorsal and median raphe nuclei with termiral 
projections to the forebrain areas. Nine groups of serotonergic cell 
bodies, B1 - B9, were described by Dahlstrcm & Rixe in 1964 (Molliver, 
1987). Most of the 5-HT neurons and termirals relevant to food intake
are fcxmd in the inedicil hypothadamus and ^»cificedly in the 
paraventricular nucleus of the hypothalamus (FVN) (Leibcwitz, 1986; 
leihcwitz, 1990). Surgical lesions of 5-HT raphe neurons and pathways 
result in increases in food intake and body weight (McDermott et al., 
1977; Geyer et al., 1976), while similarly, depletion of 5-HT with 
selective neurotoxins, (e.g. intraventricular 
5,6-dihydroxytryptamine) opposes fenfluramine induced anorexia 
(Clineschmidt, 1973).
Knowledge of central 5-HT reo^tor identification and classification is 
increasing rapidly. Currently, S-ifT receptors are classified into 
5-«r^, 5-HT^^, 5-HT^, 5-HT2 , S-HT^ and the more recently
described, 5-HT^ (Glennon et al., 1991) . rec^Dtors are present
in animals, while the 5- reo^jtor in humans is thought to be 
functionally similar (Hoyer et al, 1986). Rec^Dtors are classified, on 
the whole, by the affinity of 5-HT or aigcxiists for the receptor ^pe. 
The sub-types of specific reo^jtors are described ìjy reference to 
differences in cintagcxiist profiles cind second messenger systems. The 
second messenger s^^tems aure adenyl cyclase (5-flT^  reo^Ttors except 
®“™'lC^ ' phospholipase C(5-HT^^ and 5-HT2) or ion gating(5-HT3). * As 
classification according to affinity has resulted in the existence of 
sene "orphan” reo^3tors unable to fit the described criteria, it has 
been suggested that receptor classification should be defined by their 
second messenger systems, a classificaticxi vAiich would place 5-HT-- 
and 5^iT2 in the same family as, for both receptor activation is 
linked to the second messenger phospholipase C (Hartig, 1989). The 
current status of the above information has been aided by the advances 
in moleoilar genetic^ with ligand-ligand studies used for cloning of 
^”® 1C receptors; in particular molecular
genetic studies si?}port the re-classification of the 5-HT receptor as 
part of the 5-HT^  r e c t o r  family (Shih et al., 1991; WestJcaenper & 
Glenncsn, 1991).
1.2 Influence of 5-HT drugs on feeding in animals
Uie role of 5-HT in feeding hcis been examined in a continuous series of 
experiments in both animals and man. In animals, injections of 5-HT 
centrally into either the FVN or the third ventricle, suppresses 
feeding (Leibcwitz & Shor-Posner, 1986). Weiss et al. (1986) have shown 
that the ability of centrally injected 5-HT to suppress feeding is 
present in food deprived rats eind that 5-HT can inhibit noradrenaline 
induced feeding. Studies examining the influence of 
5-hydroxytryptophan (5-HTP) the precursor of 5-HT, show that vhen 
administered peripherally to either animals (Blundell & Latham, 1978) 
or obese humams (Ceci et al., 1989), 5-HTP causes a reduction in food 
intake. Similarly, central administration of 5-HTP (Sugrue et al., 
1978) reduces feeding in rats. Tryptophan the amino acid precursor of 
5-HTP, reduces total food intake, euid meal size without effecting meal 
frequency in freely feeding rats (Blundell et al., 1980; Grinker et.al, 
1982). In humans, tryptcphan has been shewn to reduce food intciJce at a 
dose of 2.0g (Silverstcxie & Goodall, 1984) and to reduce carbohydrate 
intake after a protein meal at a l.Og dose (Blundell & Hill, 1987a).
liljJ,__PsritíM3 Lactivi±y
Approximately 95% of endogenous 5-HT exists in the periphery, mostly in 
the gastrointestinal tract. Peripherally injected 5-HT causes a 
reduction in food intake (Fletcher & Burton, 1984) and delays gastric 
easptying. There is experimental evidence to suggest that peripheral 
5-HT, possibly working together with central 5-HT, plays a mediating 
role in the process of satiety. Peripheral injections of 5-HT itself 
have been shewn to produce a dose-dependent reduction in food intake in 
animal studies, and these effects are suggested to be independent of 
motor effects (Pollock & Rowland, 1981; Fletcher & Burtcai, 1985). The 
hypophagic effects of peripherally administered 5-HT, vhich does not 
cross the blood-brain barrier, (Olendorf, 1971), may be mediated by
peripheral reo^xtors.
The peripheral administration of fenfluramine (FF) which acts by both 
releasing and preventing the re-uptake of 5-HT, causes a delay in 
gastric emptying (Davies et al, 1983; Horowitz et al., 1985), increases 
both the relecise emd utilization of lipid stores in adipose tiss^ie 
(Nioolaidis & Even, 1986) emd increcises glucose uptedoe by peripheral 
tissue (Turner & Kirby, 1978). While there appears to be a 
peripherally mediated conpcaient to fenfluramine-induced anorexia, 
centrally acting antagonists effectively diminish the anorexic effect 
(Borsini et al., 1985), but the peripheral antagonist ^^lamidine does 
not (Borsini et ed.., 1982; Carruba et al., 1986).
1*2.2. Central activity
Destruction of central stores of 5^ ,  leads to hyperphagia, 
suggesting an active role for central 5-HT in feeding. For exanple, 
Clineschmidt (1973) has described centrally administered 
neurotoxin-induced attenuaticai of FF anorexia, v ^ l e  central 
electrolytic lesions are similarly capable of weakening FF induced 
anorexia (Davies et al., 1983). Additionally, inhibitim of central 
5^fT synthesis with the 5-HT synthesis inhibitor p-chlorophenyladeuiine 
(p-CPA) increases feeding (Rcwland & Carlton, 1986a).
Activation of central serotonergic sub-rec^jtors have been linked to 
changes in feeding responses. As a general guide, agonists 
cause hyperphagia while 5-HT 5-HT^^ and 5-HT2 agonists have been 
shewn to si^ress food intake. However, 5 ^ ^  ^  5-HT^ rec^jtors do 
not appear to play a significant role in the modulation of feeding 
b ^ v i o u r  (Peroutka et al., 1990). Further indication of a modulatory 
role of serotonin in feeding comes from studies in which the activity 
of serotonin is blocked via pharmacological antag^iism. Antagonists of 
5-flT vhich are relatively non-selective for receptor sub-"^^ e.g. 'the 
5“HT^ dntag^usts metergoline and methysergide, and ritanserin, a 
relatively specific 5-HT2 antagonist, can increase feeding in 
non-deprived rats (Fletcher, 1988a; Neill & Cooper, 1989).
Centrally acting serotcaiergic agents can increase or feeding
thrcxigh reoqjtor activation (Angel, 1990). The 5-HT ^  agonist 8-OH-DPAT 
causes feeding in lew doses, an effect thou^t to be rnpHiat-iad by 
activation of auto-receptors located on rsphe cell bodies,
8since injectÌCTi of 8-(Xi-DPAT into the midbrain raphe increases feeding 
in free-feeding rats (Dcurish et al., 1985; Dourish et al., 1986). 
Ihe increased feeding seen in response to 8-CH-DPAT has been d^^prribed 
as oocuring separately from the marginal motor effects in either 
peripheral (Dourish et al., 1985) or central (raphe) (Hutson et al, 
1986) administration paradigms. As 5-HT^ autoreoeptors are located on 
raphe cell bodies, the hyperphagia induced by 8-OH-DPAT may be a 
COTsequence of decreased levels of endogenous 5-HT which would normally 
serve to modulate and inhibit feeding. Other 5-HT agonists, e.g. 
g^irone (Gilbert & Dourish, 1987), ipsapirone cind buspirone (Dourish 
et al., 1986) ed.so increaise feeding in free-feeding rats.
Activation of 5-HT^g receptors can suppress feeding (Angel, 1990). 
Ihe direct ^plication of the 5-HTj^ agonist, HLI 24969 into the PVN 
causes hypcphagia without inducing hyperlocomotion (Hutson et al., 
1988). AdditicHially, the hypophagic effects of PU 24969 cure seen in 
*3oth food derived and free-feeding rats (Kennett et al., 1987 ; 
Bendotti & Samanin, 1987; Kennett & Curzon, 1988). The 5-Hr^g/^^5HT2 
mixed agonists, l~(3-chlorophenyl) piperazine (m-CPP) and 
l-[3-(trifuorGmethyl)^3henyl]piperazine (TFMPP) also reduce feeding in 
both food derived and free feeding rats (Rennett et cil., 1987; 
Samanin et al., 1979). curzon and collecigues carried out a series of 
e}q)eriments in an attempt to discover whether one peur^iculaur receptor 
determined the e5?>ression of hypophagia with these two agonists 
(Qirzon, 1990). T h ^  concluded that m-CPP and probably TFMPP^ induced 
anorexia were d^)endent on the activation of both 5-HT-* and 5-HT-„ 
receptors, with activaticxi of 5^11^^^ receptors possibly leading to 
activation of receptors (Kennett & Curzon, 1988). Both m-CPP
/
and TFMPP cause hypoloocmotion; hcwever, injection of TiMPP into the 
i W  results in hypophagia without attendant hypolocomotion (Hutson et 
al., 1988).
Consistent with the anorectic effects of 5-HT agonists, drugs v M o h  
increase endogenous levels of 5-HT also cause cuiorexia. These 
increases in 5-HT can occur through the activity of pharmacological 
releasing agents, synthesis enhancers and re-uptake inhibitors. 
P-<iiloroairphetamine and fenfluramine which release 5-HT from 
presynaptic storage pools, reduce food intake (Trulson & Jacobs, 1976; 
Garattini & Samanin, 1976). The inhibition of re-ii^rtake by selective 
5-HT re-i^take inhibitors such as fluoxetine (Goudie et al., 1976; 
Fuller & WOng, 1989), femoxetine (Blundell & Latham, 1978), and 
sertraline (Lucki et al., 1988), can cause einorexia. Angel et al. 
(1988) have shown that the ability of this class of drug to cause 
anorexia is correlated with in vivo inhibition of 5-HT uptake.
ii3— Influence of 5-HT drugs on feeding in humans
Examining the effects of serotonergic agents on feeding in humans has 
been inoportant for two main reasons. Firstly, the research has 
identified serotonergic involvement in the modulation of human feeding 
and food intake. The secmd reascxi is clinically orientated, it has 
lead to safe, effective anorectic drugs which do not have 
stinulant/abuse potentied, and which offer the obese individual help in 
reducing body weight without intolerable adverse effects.
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Oie of the most frequently examined drugs with re^»ct to both 
modulation of food intake/choioe 2uid boc^ wei^t, is fenfluramine. 
Fenfluramine is capable of reducing food intake in humans (Kyriedcides & 
Silverstone, 1979; Blundell & Rogers, 1980), d-fenfluramine has twice 
the anorectic potency of dl-fenfluramine (Silverstone et al., 1987). In 
addition, the d-iscmer hcis been shewn to possess greater anorectic 
potency than the 1-isomer, in animals (Garattini et al., 1988) and in 
humans (Goodall et al., 1992a). D-fenfluramine has been ^ o w n  to
reduce hunger ratings and daily energy intake in healthy, normal wei^t 
woonen, an effect associated with a reduction in the number of snacks 
consumed (Hill & Blundell, 1986a). Metergoline, a non-selective 5-HT 
antagonist, hcis been shewn to attenuate the anorectic effect of 
d-fenfluramine in normal wei^t non-dieting subjects (Goodall & 
Silverstone, 1988), recently, the fat si^ressive effects of d-FF were 
blocked by ritanserin, a 5 - ^ 2  antagonist (Goodall et al., 1992b - 
personal ooninunication). At present, the lack of selective 5-RT^ 
antagcxiists available for use in humcin subjects, mcdce clcurification of 
the action of fenfluramine difficult at this time.
1.3.1 Influence of 5-HT drugs on hunger and satiety
Hunger r^resents a motivational state vhich is generally expressed via 
feelings of hunger emd desire to eat; the normal behavioural 
esqsression of this motivaticaial state is eating/feeding (Blundell, 
1979; Silverstone, 1982). It is worthfchile acknowledging that the 
term '*hunger” ceunries two meeuiings: one is the existence of a state of 
motivation eissessed by reference to the observed e)q>ression of 
b^iaviour; alternatively, the term "hunger” cam stand for ocxiscious
/
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sensations and feeling, the outooroe of vAiich may be eating (Blundell 
& ajrley, 1987). Hunger ratii^ and food intake may show significant 
^^^^^'®l^tion (Goodall et al, 1987), but not always (SilverstCTie & 
Sturikard, 1968; Blundell & Rogers, 1980; Mattes, 1990) and may even be 
dissociated (Trenchard & Silverstcme, 1983). Eatir^ can occur in the 
absence of hunger, and may be more responsive to appetitive factors. 
Ihe o o n o ^  and ejqjressitxi of appetite may be seen to be associated 
more with the gualitative aspects of food such as perceived 
pleasantness and sensory characteristics, e.g. food preference has 
been shewn to have differential effects on hunger and appetite before, 
during and after a meal (Hill & Blundell, 1984). The expression of 
^P®titive eating does not necessaurily need the presence of 
motivational hunger to occur but it is likely that they frequently 
oo-orchestrate initiation and maintenance of food intake and choice.
THie e)pressiCTi of satiation and satiety are the results of interacting 
and reciprocal process, identifiable in the "Satiety Cascade" 
postulated by Blundell et al., (1988a). Satiation refers to the move 
towards "end of play" within a feeding episode whereby eating stops, 
vhile satiety is a state of inhibition during vhich further eating does 
not occur (Blundell & Burley, 1987). A sensitive eoqjerimental design 
can demonstrate modulating influences on selective cureeis of feeding, 
e.g. increasing palatability strengthens hunger, but does not effect 
fullness (Hill et al., 1984). Manipulation of meal inacronutrient 
ocnpositicxi with palatability held constant, hcis shown that fullness at 
® meal can be increased throu^i increasing the protein 
content of the meal (Hill & Blundell, 1986b).
/
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•Die process of satiety, i.e. the food-abstinent inter-meal state, is 
ocnplex. Acxx>rding to Blundell et al., (1989), the identification of 
four mediating processes; sensory, cognitive, postingestive and 
postabsorbptive, expressed throng physiologiczd, neurochemical and 
metabolic substrates, characterizes its egression. Sensory 
ccnponents are influential through the sight, taste, smell and texture 
of foods. Cognitive coirponents are potent, mediated through 
beliefs/ideeis ocxxserning the foods' effects on the consumer. 
Fhysiologiccilly, post-ingestive factors may exert their influence 
throu^ the actim of gut hormones, such as CCK, gastric distension, 
the rate of emptying, and vagally mediated signals (Russek, ' 1971; 
Gibbs et al., 1973).
Food possesses the capacity to induce satiety (Blundell et al., 1989), 
consequently, if a pharmacological agent is successful in reducing food 
intake, it reduces the int2dce of the natural conmodity vhich causes 
satiation, possibly weci]cening the natural process. Identifying 
ocnbinations of drugs cind foods vAiich are reciprocally sipportive of 
enhancing satiation 2u>d satiety, is likely to be of value in the 
phEunnoacological treatment of obesity. Ihe oorobinaticxi of d-FF .amd 
protein have been shewn to possess greater satiating capacity than d-FF 
and C3K) (Hill & Blundell, 1990), and consequently this combinaticxi 
could be used as a stratagem in assisting weic^t loss, before eating 
next occurs.
/
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1.4 MoAilatlcn of food selection
Discussion of the intake and selection of mcrmutrients refers to 
selective choice and diet conposition of fat, carbohydrate (CHO) and 
protein ws consume. 5-HT has been thought to be influentiad in 
regulating the intake of protein (Anderson, 1979), influencing the 
relative proportions of protein emd CHO (Femstrcin & WUrtman, 1973), 
and perhaps roost controversially, modulating ocsTtrol over the intake 
of CHO (WOrtman & WUrtman, 1979). In recent years studies have 
examined the relationship between nutrition, neurctransmitters, 
b^iaviour and subjective states, with the debate focussing on the 
possible existence and functioning of a regulatory loop. The view has 
been put forward that dietary proportions of CHO and protein influence 
the plasma ratio of tryptcphan (Trp) to other lcu:ge neutral amino 
(IHAA) acids. This plasma Tip/INAA ratio contributes to determinii^ 
how nuch Trp enters the brain as access to the brain is via ccnpetition 
for active transport at the blood-brain barrier. Synthesis of 5-HT is 
influenced by the availability of the precursor Trp. Advocates of this 
view suggest that in response to dietary intake and selection, greater 
of 5—HT are synthesized, rele2ised and act on serotOTergic 
receptors. The observed behavioural manifestaticxi of this regulatory 
loop in acticxi would be selective food choice for the macrcaiutrients of 
CHO or protein. A more detailed account of this hypothesis is given by 
WUrtman & WUrtman (1984).
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U L t l — Influepqp of 5 - m  drugs on food c±ioifY>
'Ihe mcronutrient intake of freely feeding, drug-free rats varies 
during the diurnal cycle. In the eeurly dark phase, CHO is the 
preferred macronutrient, vhile during the late dark phase, the intoke 
of protein and fat increases, while the intake of CHO declines (Itogacki 
etal., 1989). Animal studies examining the putative effects of 
serotonergic drugs an food selection have involved direct e^lication 
of 5^fT into the hypothalamus and systemic administration of 
serotonergic agonists and antagonists under varying e5g)eriment£ü. 
conditions (LeiJxwitz et al., 1988; Li & Anderson, 1984; Kanarek & 
IXjshkin, 1988; Blundell 1984; 1986).
laboratory studies in rats allowed ad libitum access to diets of pure 
macronutrients, have shown that centrally administered injections of 
5-HT into the paraventricular, ventro-medial, and suprachiasmatic
nucleus of the hypothalamus, cause specific selective reductions in 
intake of CHO, particularly at the begining of the dark period. Ttotal 
energy consunption is maintained, with trends towards augmentation of 
protein and fat intake (leibowitz et al., 1988; 1989; 1990; Wèiss & 
leibowitz, 1988). The effect of centrally administrated 
d-norfenfluramine, the metabolite of d-fenfluramine, is similarly 
active in suppressing intake of CHO at the beginir^ of the dark phase 
in freely feeding rats (Weiss et al. 1990). Both the central (PVN) 
and peripheral (see below), effects of flixaxetine were examined in rats 
given free access to pure macronutrient diets of CHO, fat and prxjtein.
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PVN administration of FOT resulted in reduction of C3*D intake during
the early dark phase only, intate of protein and fat were not altered 
(Weiss et al., 1991).
peripheral administraticxi of 5-HT (Leibowitz et al., 1989) hcis been 
shown to reduce the intake of CHO. Examination of the action of 
serotonergic agonists on food selectivity has demonstrated the presence 
of phase specific effects. 8-OH-DPAT and buspirone were shown to 
uicrease CHO intake in rats given simultaneous access to CHO and 
protein diets in a two hour test (Luo et al., 1990). In addition, the 
oo-administration of 8 ^ - D P A T  and FCT in a separate experiment, 
«aemcxTstrated the ability of 8-OH-DPAT to block the CHO suppressive 
effects of FJCT (luo et al., 1990). Dl-fenfluramine hcis been shown to 
reduce intake of both high CHO and h i ^  fat diets in freely feeding 
rats given access to both diets, but with greater suppression of the 
hi^-fat diet. (Kanarek et al. 1991). in another study, 
D-fenfluramine, fluoxetine and RQ 24969 reduced intake of a high 
CHO-low protein diet in rats, particularly during the first hour of 
feeding during a 12h c*servation period (Luo & Li, 1990). Ihe same 
serotonergic drugs were examined in a six day study during vtiich rats 
were allowed access, during the dark period, to a high CHO-low 
protein or a low CHO-high protein diet. Again the effects of these 
agonists were to reduce the intake of the h i ^  CHO-low protein diet. 
Peripheral administration of fluoxetine shows oolrp^u:able results to 
that of central administration, with reducticxis in CHO intake during 
the early dark phase only (Weiss et al., 1991). Pharmacological 
chall^ige via the peripheral antagonists oyproheptadine and
/
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»etergolme, results in increases in feedii^ , particularly of CHO and 
fat, withcut oraiocmiiitant Increases in intate of protein (leibowitz et 
al., 1988; Shor-PDsner et al., 1986; Stallone & Nicolaidis, 1989).
It has been possible, by use of sensitive study design, to show that 
the selective effects of serotonergic agonists are not exclusively 
directed at CHO intake. Fenfluramine has been shown to reduce fat 
intake in a self-selection regime (Orthen-Gartoill & Kanarek, 1982), 
and in the Weiss et al. (1991) study (above), peripheral FXI reduced 
both fat, (at 2.5ng/kg-10.0mg/kg) and protein (lO.Omg/kg) intake in the 
••hi^ dose" condition during the late dark period. In a study in 
which rats had been made c*ese ly exposure to either a high-fat or 
hii#KHO si^iplemented diet, d-FF showed ocnparable effects on 
STpression of intake of both these diets (Blundell & Hill, 1989). m
addition, d-FF may reduce the intake of laboratory chow, but ^,ears
less able to reduce either sucrose and non-sweet polycose (lawton & 
Blundell, 1989).
Alterations in macnaiutrient Intake have also been described in 
re^ranse to manipulations of non-serotonergic systems, e.g. central 
administraticxi of a^-adrenoo^itor agcxiists have been shown to
Increases in intake of CHO, in the early dark period. (leibowitz & 
Shor-Posner, 1986).
B^ere is no cxinsistent evidencie fron human studies that serotonergic 
drugs exert a specific si^ressive on dietary CHO in normal volunteers 
(Goodall & Silverstone, 1988; C3oodall et al., I992a; Hill & Blundell, 
1986a). D-FF and flucaxetine^inducied suppression of CHO has been 
reported for obese subjects (WUrtman et al., 1985; Fiji et al. 1991).
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Seme of the work reported above has been carried out to determine 
vAiether the dietary oenponents 2md proporticxis of protein and CHO eoe 
related (via changes in plasma ratios of the 5-HT precursor,
tryptophan), to other large neutral amino acids (iNAAs) (Wurtman, 
1982). Of interest here is whether drugs actir^ on the serotonergic 
system, are able to effect macronutrient intate reliably, the 
theoretical and clinical significance of this relationship, cind under 
'*^t circumstances alteration in intake occurs. The iirportant 
observaticxi that d-fenfluramine sippressed non-sweet CHO vhile
concurrently unable to suppress the intake of sweet CHO suggests that 
seme variables which modulate intake, such as the hedonic aspect of 
foods, may be particularly potent (Goodall et al., 1992a). Recent 
researdi in the animal field has identified faertors such as texture 
which aert as sensory influences (Booth & Baker, 1990).
1^4.2 Influence of oalat-^hil on intake
The term palatability and its descriptive use has raised questions of 
definition (Rogers, 1990; Ramirez, 1990). it is suggested to be a 
hypothetical construct vhich may be experienced subjectively, or 
inferred frem cAxserved behaviour (Blundell & Rogers, 1991). Research 
with laboratory animals has shown that it is possible to increase 
energy intake and body wei^t by offering energy dense diets ve^ying in 
palatability and variety (Grinker, 1988). Postingestional factors 
contribute to this effect, as conditioned flavour preference occurs 
vhen a flavour is paired with an intragastric nutrient infusion 
(Sclafani & Nissentoum, 1988); alternatively, aversion to sucrose 
develops when p a i ^ ^  with nausea (Booth, 1985). Offering animals
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high-CHO, hi^-fat and mixed fat-sugar cxirbinaticxi diets, will, 
depending on age, strain, sex and individu2d  re^xsnse pattern of the 
animal, increase intake and bocfy weight (Sclafani, 1987; Sclafani, 
1988, Grinker, 1988; Marks-Kaufinan & Kzmarek, 1988).
CXaese subjects possess similar thresholds to normals for the detection 
of sucrose (Gririker et eil., 1972), but unlike le0ui counterparts, do 
not e>dnbit a reduction in the rated pleasantness of sucrose after a 
glucose preload (Blundell & Hill, 1988). It has been suggested that 
degree of weight loss may effect ratings, with greater weight loss 
being associated with reduction in aversion to hi^er levels of sucrose 
(Podin et al., 1976). More recently, KLeifield & Lowe (1991), 
relying on self-reported weight status, suggested that weight-loss 
history influenced hedonic ratings. Drewnowski et al. (1985), carried 
out a study in which the taste responsiveness of normal weight (NW), 
Obese (O) and formerly obese (PO) subjects was examined using 20 
mixtures varying in sweetness, creaminess and fattiness. No 
differences were found with respect to ability to rate the intensities 
of the above mixtures, but there were populatioi differences with 
re^ject to hedonic ratings of fat and sucrose content of the mixtures. 
NW subjects preferred stimuli containing 20% lipid and < 10% sucrose, 
obese (O) preferred >34% lipid and <5% sucrose, while subjects who had 
b e ^  obese previously, showed greater respcxisiveness to both fat and 
sucrose.
An animal paradigm i# vhich it is possible to show enhanced energy 
intake, is useful as a means of testing the power of drug effects. 
Drugs vhich have beâi shown to si:ppress the intake of sweet substances 
include those acting to antagonize dopamine, e.g. pimozide reduces
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sucrose sham-feeding (Geary & Smith, 1985) and palatability-induoed 
ingestion (le^ et al., 1991). Hbebel et al., (1989), in microdialysis 
studies, have shewn that the taste of saccharin causes a release of 
dopamine in the nucleus accumbens. The endogenous opiate system has 
been suggested as being instrumental in modulating hedonic respcxises to 
sweet substances, with the opiate antagonist naloxone si^pressing 
glucose and saccharin int2dce (Marks-Kaufinan & KEuiarek 1988). Both 
serotcxiergic agents fenfluramine and fluoxetine have been shown to 
rsduoe palatability-induoed ingestion. Fenfluramine reduced 
oonsunption of sucrose in non-deprived rats, an effect antagonized Yjy 
the centrally acting antagonist metergoline, but not ly xylamidine, 
which has a peripheral locus of action (Bprsini et al., 1985). 
Alternatively, fenfluramine treated rats reduced their intaJee of chow, 
but not sucrose when given access to both food sources (Orthen-Gantoill, 
1985). leander (1987), using saccharin, which provides a sweet taste 
without being a conccmmitant energy source, demonstrated that FXT lead 
to a reduction in intake in freely-feeding rats.
In humans, it is possible to demonstrate a dissociation between 
subjective hunger ratings and hedonic es^ression. The administration 
of the opioid antagonist naloxc^ie to normal volunteers reduced food 
intake without concurrent effects on hunger (Trenchard & Silverstone, 
1983). More recently, the opioid antagonist, nalmefene reduced the 
rated pleasantness of both taste and smell in foods which had been 
rated as palatable (Yeomans & Wright, 1991). The serxjtonergic 
influence on the hedmic a^)ect of intake in humans is less clear than 
that seen in animals. Acute administration of d-fenfluramine 
suppressed the nonsweet cenponent of energy intake, without suppressing
/
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the intake of sweet foods (Goodall & Silverstone, 1988). In addition, 
the d-FF-induoed suppressic»i of hunger ratings can occur without 
altering the hedonic re^xanse to sweet taste (Blundell & Hill, 1988).
Grinker (1988), has pointed out the oonplex nature of the area under 
investigation and drawn attention to the fact that current e}^)eriinental 
methods lacik the sophistication to pin-^int the exact nature of 
metabolic, catecholaminergic and receptor interactions.
Despite these cautions, the approach of using "cafeteria” diets to 
model the development of dietery~induoed obesity in humans has been 
helpful in elucidating energy-enhancing ocnpcxients of <=p<ar»ios 
equivalent, readily available foods. Our knowledge on the effects of 
such diets has grown in recent years, for exanple, dietcury fat may be 
more "efficient" in promoting wei^t gain due to poor oxidation, than 
either CHO or protein (Schütz et ad., 1989).
1.5 Bodv-weicht control
The ccnplexit^ of the irultifactorial regulation of food intake 
(Friedman, 1990) and body wei^t (^felbaum, 1987; Garrow, 1988; 
Vanitallie & Kissileff, 1990), is difficult to represent in most
experimental settings. Within an adequately ftmctioning system we now 
recognize the contribution of central, peripheral, hepatic, hedonic 
and psychological variables (Stellar, 1990).
V#ien it ocmes to examing systems in dysfunction, the task becomes even 
more difficult. McHu^ (1990), assessing the interface between the 
approaches of research scientists and clinicians in this area.
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describes an uneasy and disatisfying liaison. He points to the 
existence of two virtually s^jarate lines of inquiry. While he 
indicates a possible productive unicxi of these di^)erate approaches 
occurrirg in the future, at present, "both lines of investigation are 
still innature". Basic scientific e}q)eriinents describe the "proximate", 
or imnediate physiological substrates of food intake, (vital nerve 
tracts, describing oro-pharangeal, h ^ t i c ,  humoral and 
neurotransmitter modulated conoponents). Influential variables such as 
the gme-environment interactim and socio-cultural determinants are 
the lcng~term, pervasive emd "ultimate" influences on food intake emd 
body wei^t.
An exairple of recent collaboration between Iciboratory cuid clinical 
interests, hcis been the growth of research into cancer 
anorexia/cachexia. Rapidly occurring developments in this field of 
research have shown that the disease state of cancer can be accoirpanied 
by anorexia and weight loss, the latter in excess of what would be 
predicted frcxn energy intake. Laboratory work has identified the area 
postrema in tumour becuring animals as inportant for effects on body 
w ei^t and intadce. The production of endogenous "cachectin", vhich 
acts ultimately to sippress lipogenesis and ocxisequently contributes to 
tissue wasting. Laboratory experiments have also shown that a 
circulating factor ocxitributes to the euiorexia/cachexic state: a 
healthy animal joined parabiotically with a tumour bezuring animal will 
exhibit wei^t loss without developing a tumour (Me Hugh, 1990).
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1*5.1 Disortter of eating and body weicdit cxmtrol
Under the heading "Disorders of Eating", the Oxford Ttextbook of 
Psychiatry (Gelder et al., 1989), describes the conditions of 
psychogenic vomiting (not discussed here), anorexia nervosa, bulimia 
nervosa and obesity. Diagnosis of anorexic and bulimic ccaiditions is 
made by reference to criteria in DSM-lll-R, which is currently being 
updated, both conditions au:e oonoplex and patients risk disordered 
physiological functioning relative to type and severity of the disorxJer 
(Robinson, 1990). A brief mention of anorexia and bulimia nervosa is 
made below, neither condition being addressed experimentcdly in this 
thesis.
Anorexic patients may have compromised neuroendocrine and metabolic 
systems (Robinson, 1990). Evidence of both reduced ability to monitor 
gastric contents and disordered interpretation of fullness and satiety, 
compared to controls, have been described in anorexia nervosa. Althou^ 
a large number of fharmacological agents acting on the serotonergic 
system have been shown to cause hypophagia, increasing intake has been 
less easy to demonstrate (Blundell, 1987). Cyproheptadine has been 
to be clinically effective in nonbulimic anorexics relative to 
placebo or amitriptyline (Halmi et al., 1986). Drug treatment of 
anorexia nervosa whioh was directed at increasing food intake without 
attempts to address the possible attending cognitive factors in this 
condition, have not so fcu: proved successful (Russell, 1985).
23
Patients with bulimia nervcasa may fall within the nonnal weight 
category althou^ may have been previously overweight, will engage in 
frequent ^isodes of bingeing and vomiting, possibly misuse laxatives 
and r ^ r t  mood disorder and consequently suffer disn:5Jtion to both 
their own, and relatives, lives (Fairbum & Oooper, 1984). Russell et 
al., writing in 1986, described a fairly limited use for drugs in the 
treabnent of eating disorders. Both fenfluramine (RQbins<xi et al., 
1985) and fluoxetine (Fava et al., 1989; Wilcox, 1990; Trygstad, 1990), 
have been reported as assisting in reducing ^isodes of bulimic 
b^viour. Recently, Marcus et al., (1990) have reported that 
fluoxetine is not particulzurly helpful in obese subjects binge.
The un^jecif ied sub-^t of obese individuals \^ io binge may soon be 
ac2knowledged in DEM-iv. Wilson & Walsh (1991) r ^ r t e d  on recoranended 
changes suggested by the Eating Disorders Work Groi?), for inclusion in 
the diagnostic criteria of these conditions for DSM-IV. The working 
group has attempted to establish diagnostic criteria for that subject 
population vho binge without purging - Binge Eating Disorder. As 
mentioned above, Marcus et al. (1990) reported that binge eatir^ 
occurred in 46% of of obese subjects in a trial they conducted, and 
this sub-set were more resistent to therpeutic intervention than r^oge 
non-bingers.
la^ Li2— Animal models gf obesity
A  significant amount of experimental effort has been expended on 
developing animals^models of obesity, and some clinicans suggest that 
the onus falls on laboratory-based scientists to provide, at least.
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partial answers to this cxnplex ocxidition in humans (Garrow, 1988), 
Ihe diverse areas of research on animal models of obesity have arisen 
from questions on, aetiology, physiological cind behavioural 
substrates which operate to maintain obesity, and the mechanisms and 
effect of potential treatment regimes. Animal pcuradigms include; e.g. 
genetic obesity, surgically-induced obesity, diet-induced obesities, 
environmental (e.g., stress, isolation), and drug-induced obesitities.
The genetic expression of dbesity results from; a single gene, 
doninant, (e.g. Yellow mouse), single gene, recessive (e.g. fatty rat), 
polygenic: spontaneously obese (e.g. Paul Bailey black mouse) and 
polygenic: obesity prone (e.g. Osbome-mendel rat) (Sclafani, 1984). 
There is wide variation in severity of obesity, nairoendocrine and 
metabolic dysfunction and chromosomal location of the genetic defect 
between genetically obese animals (Bray, 1984). Availability of 
genetically-e5q>ressed animcil models of obesi'^ heis increased knowledge 
of, for exaiiple, the presence of iirpaired syirpathetic function and poor 
mnervaticxi of brown adipose tissue in some 2uiimcils. Bray (1990) 
reports that when brown adipose tissue of ob/ob mice is electrically 
sturulated, heat production is considerably less than that of lean 
litter controls. Many other differences, relative to strain under 
examination, have been described: e.g. endocrine: hypothermia, 
elevated corticosterone, elevated levels of insulin euid glucose (ob/ob 
mouse), Cerebral neurotransmitter and peptide function can be 
different; increased levels of 7^-endorphin have been reported in the 
pituitary of ob/ob mouse, the opiate antagcxiist naloxone suppresses 
food intake in ob/ob mice (Shimomura et al., 1982).
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It should be asked whether there are any tentitive analogies between 
genetic obesities in animals and the human condition? The obese Zuciker 
rat may be ccxisidered as being a reasonable mcxlel for juvenile-cxiset 
obesity, the obesity is expressed in the Zucker rat via a single gene; 
increased fat cell number (hyperplasia) and fat cell size (hypertrtDphy) 
are both present, these animals defend a h i ^  boc^ weic^t and will 
beocroe hyperphagic when &qposed to a palatable diet. The possibility 
of genetically e^ressed euiiml dbesity being suitable for modelling 
human obesity can be acknowledged, although limitations on the human 
ejq)ression of this condition, and the weight of gene-envirx3nment 
interactioTs, make this difficult (Montgomery, 1991).
Obesity has been reliably produced in animals by locedized cerebral 
lesions, particularly of the ventroroedied hypothedainus (\WH), resulting 
in increased food intake and body weic^t gain (Sclaf2uii, 1984, Bray, 
1984). Hyperphagia and body weight gain are also seen with lesions of 
the paraventricular nucleus (Leibcwitz et al., 1981) and ventral 
noradrenergic bundle, although the increeuse in int£0ce 2uid wei^t gain 
is not as dramatic as that seen with VMH lesions. VMH -lesicaied 
animals are described as esdiibiting inmediate increcises in food intcike 
and body w ei^t during a dynamic phase, followed by a static phase 
during which the gained wei^t is maintained and food intake relatively 
nonnal (Montgaanery, 1991).
The iiiportanoe of acknowledging the potential influence of environment 
on the development and maintenance of obesity, has been afV»T^«?od in 
ejq)eriments in which external factors are manipulated. For exanple, 
over-feeding in weanling Zucker rats can result in hyperplasia in both
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Zucker (obese) and their lean littermates (Johnson et al., 1 9 7 3). 
Other exanples of environmental manipulations include force-feeding to 
induce obesity (Rothwell & stock, 1978) and tail pinch, which causes 
hyperphagia and wei^t gain (Rowland & Antelman, 1976).
An environmental manipulatiai vhich holds reasonable nodel validity for 
human obesity, is that of "cafeteria,” or diet-induced obesity 
(Sclafani & Springer, 1976). Originally rats were offered the sorts of 
fcxxas freely available to most Westerners e.g. cheese, chocolate-chip 
biscuits, peanut butter and sweetened condensed milk (Sclafani & 
Springer, 1976). Ihe type of diet has been varied in esq^erinental 
procedures with an available chow component and alternative hi^-fat, 
hi^-sugar options, a CHO solution option, 32% sucrose or Polycose, or 
self-select diets offering s^»rate sources of fat, prx>tein and CHO. 
The range of wei^t gain in these ejqjeriments was from 30% to 200% 
excess, with some diets causing considerably more weight gain compared 
to control than others (Sclafani, 1990). Both strain and individual 
differences in weight gain have been observed in rats. in one 
ejqjeriment, only approximately 50% of animals fed the high fat/high 
sugar combination gained significant amounts of weight conpared to 
controls (i^in & Sullivan, 1987). Some metabolic and neurological 
differences have been established between animals likely to gain 
weight, and those which appear resistant. Levin & Sullivan were able 
to pinpoint a "biological marker" in the form of a plasma noradrelanine 
respcx)se to a gluooose load when rats were fed chow, this correlated
with their later weight gain when &qposed to the calorifically dense 
diet (levin & Sullivan, 1987).
/
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The inductic»! of obesity in animcils in respcxise to drug treatment is 
another valid model for a perh^ss, small, but vulnerable group of 
humans. In humans, both antid^ressant- and neurol^jtic-induoed weight 
gain has been described (Paykel, 1977; Silverstone, 1987a;
Silverstone et al., 1988). The agonist 8-OH-DPAT increases
oonsuirption in rats, although how specific this effect is has been the 
topic of sane discussion (Montgomery et al., 1988). The anxiolytic 
gepirone causes a robust increcise in feeding in freely feeding rats,
while bu^irone and ipsapirone do so marginally (Gilbert & Dourish, 
1987).
Baptista. et al. (1987) chroniccLLly administered the dopamine 
antagcxiist sulpiride to rats, resulting in hyperphagia and wei^t 
gain; these effects were blocked by pre-treatment with the dopamine 
agonist brcroocriptine. low doses of opiates have been shown to 
increase feeding in rats, an effect suppressed by opiate antagonists, 
although Zucdcer rats who have reached the obese state, do not eppear to 
be as responsive to the anorectic effects of naloxone as they were 
before (Mclaughlin & Baile, 1984). Shimoraura et al. (1982) have shown 
that the effects of chronically administered naloxone in ob/ob mice and 
lean caitrols, is to increase feeding.
1x5*2— Definition of Obesity
women who fall within the normal boc^ weic^t range p~>gcuajc;<; ^5 — 
18% and 20 - 25% body fat re^>ectively (Gray & Bray, 1988). The state 
of obesity can be defined vhen b o ^  fat is greater than 25% of total 
bocfy w e i ^ t  for men and greater thaui 30% for women. The accurate
/
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neasuresment of body fat requires specialist techniques, e.g. 
isotopic/chemical dilution, oonductivity/bioelectrical hrpedenoe, or 
alternatively, measurement of skin-fold thicdaiess. However, as
assessing bocfy ocnpositicxi is not the main focus of most obesity 
clinicians, bocfy weic^t may be the more likely meaisureroent taken.
Oie of the most frequently used classification systems of body weight 
is the C^jetelet or Boc^ Mass Index, defined as weic^t divided by 
hei^t squared (W/H^). Garrow (1981) has defined grades of obesity by 
reference to EMI ranging from normal wei^t; grade 0 = 20.0 - 24.9, 
through to the upper range of obesity of grade III, W/H^ >40.
The definiticxi of obesity 1:^  reference to EMI is a sinple guide and 
does not supply information on regional distribution of body fat, a 
risk factor for cardiovascular disease in men with a waist-hip ratio 
>0.95 (larsscxi et al., 1984) 2uid women with a waist-4iip ration >0.85 
(lapidus et al., 1984). Bjorntorp (1990) has suggested that, in 
effect, obesity should be ctefined with respect to relative risk factor 
for disease, and consequently those with abdominal, as opposed to 
femoral or gluteal, fat depots would be defined as medically obèse. 
Overwei^t in men tends to be abdominally situated, while in women 
overweight is more likely to gluteofemorally disposed. It is possible 
to find a high W/H ratio in nonobese individuals, but the presence of 
obesity maJces a high W/H ratio a greater risk factor for metabolic 
abnormalities, e.g. hyperinsulaemia, diabetes and raised blood 
pressure (Landin et al., 1989).
/
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Active obesity research areas in recent years have attenpted to assess 
both the sole and interactive oonponents of genetics, metabolism, 
environmental and psychological factors of the obese state.
in
Studies on the genetics of obesity have established a strong 
relationship between degree of fatness for biological mother and adult 
off-spring adopted during the first year of birth (Price et al., 1987). 
In another study, Sorensen et al. (1989) studied adoptees s^arated 
early in life and ocnpared them with siblings and half—siblings reared 
by their natural parents. Strcxig relaticaiships between Body Mass Index 
(EMI) were found across all wei^t categories, with fat adoptees havii^ 
fat siblings in the original hone. In studies of botfy weight status 
twins, Stunkard et al., (1986) found h i ^  cc«oordanoe rates (0.8) for 
degree of overweight with mOTozygotic twins having strxDnger 
oorxelations than dizygotic twins. Strong genetic expression for 
regional fat distribution, subcutaneous fat and fat-free mass have been 
established (Bouchard et al, 1988). Bray (1990) has argued for a 
contributory role for reduced synpathetic activity in obesity, with 
attendent less efficient responses to nutrient intake. The possibility 
of (^functiOTal status in the autcnomic system for both the 
synpathetic and the parasynpathetic oorpaient in some obese 
individuals, has been suggested by a stuc^ Peterscxi et cil. (1988). 
Measurements of both noradrenaline and adrenaline concentrations in 
fif^-six men showed negative correlaticxis between these variables and 
bocfy fat in healthy obese men.
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1.5.4 The treatment of obesity
The cxsndition of csbesity has been observed to be chronic and refractory 
and, despite an enomous range of previous and currently available 
treatments (Garrow, 1988; Bray, 1989), there are few ccnpletely 
convincing success stories (Blundell & Hill, 1986). Depending on the 
level of overwei^t, perceived aetiological source of obesity and 
treatment bias of the clinician, the obese patient may be offered 
either any one, or a oonbination of the following treatments.
(i) Dietary restrictic»i, either oonventiorad or very low calorie, 
support from a nutrition2dist may be available.
(ii) B^iavioural modificatic»i
(iii) £hooursigement to exercise
(iv) Drug treatment
(v) Jaw wiring
(v) Surgical intervention
An evEduation of the benefits of drug treatment of obesity, would be 
e}g)ected to take into account the seriousness of side effects, 'and 
proof of long-term efficacy, and off-set these considerations aigednst 
the continuing harmful effects of obesity, the unattractive proposition 
of wei^t-cycling and the effects the latter would have cxi both the 
physiologic2d  and psychological status of the obese individual. Drug 
treatment of obesity has been mainly towards the approach of reducing 
food intake through changes in levels of hunger and satiety. Other
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drug approaches focus on the dynamics of thermogenesis (Cawthome, 
1990), and the possible use of fat synthesis inhibitors (Sepinwall & 
Sullivan, 1991).
Neeurly twenty yeeurs ago, eui evaluative study cauxied cut by a working 
p a r ^  under the aegis of the Federal Drug administraticxi, examined 170 
studies involving lOOCH- subjects who had been treated in doubleHDlind 
conditions, with either an anti-obesity drug or placebo. Ihe 
additional loss seen eis a result of drug treatment amounted to 200g per 
week (Sooville, 1973). While this supported the therapeutic vcilue of 
anti-obesity medication, the repeatedly observed wei^t loss placebo 
effect seen in most drug trieds should edso be acknowledged.
Sgrotoneioic agents in the treatment of obesity
As serotonergic agents do not possess stimulant properties, they lack 
abuse potentied, and consequently provide clinicians with a reasonably 
efficient therpeutic tool to tackle obesity (Silverstone & lyriakides, 
1982). Fenfluramine reduces hunger ratings, (Silverstme et 2d., 
1975); the current prescribing practice is towards the use ‘ of 
d-fenfluramine, vhich acts with greater selectivity cn the serotonergic 
system and in suppressing food intake in animals (Garattini et al., 
1988) 2ffid humans (Goodall et 2d., 1992a). D-fenfluramine h2us been 
described as having twice the anorectic potency as that of 
dl-fenfluramine in nomal volunteers (Silverstone et 2d., 1987). In 
clinical tri2ds with 2ui obese populatim, d-fenfluramine h2is been used 
for periods of three months (Finer et al, 1985; Goodall et al., 1988), 
up to a year (Guy-Gr2uid et al., 1989). Clinical prescribing guidelines 
reocmnend treatment periods of twelve to sixteen weeks duration, 2uid
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suggest cxaxxinmitant use of exercise euxi chemges in dietcury habits. 
Slewing of weight loss in response to longer treatment periods has been 
^^ s^po^ '^ted (Finer et al., 1987), cuid after six months a stable wei^t 
•level cxxild be seen as a continuing treatment effect. The tendency for 
patients to regain wei^t ai oessati^ of treatment appecirs aOmost 
inevitable vhen drug treatment is used as a sole treatment (Giy-Grand 
et al., 1990).
Antid^ressants which act to inhibit the ret^ DtaJoe of 5-HT, have been 
shewn to possess some wei^t reducing properties, stimulating interest 
with reflect to their possible future use as anti-obesity agents. 
Abell et al., (1986), describe a study in which fluvoxamine maleate, 
initially at 50mg and ultimately at lOOmg, twice daily, was given to 
40 females with refractory obesity, in a placebo-controlled trial. 
Subjects received dietary advice to help them to adhere to 
approximately 1,000 kc/d, 29 subjects conpleted the 12 weeks, of whom 
13 had received the drug. Subjects in both the placebo and the drug 
groi^ lost wei^t, and significant differences between the two groups 
were not found. The placdxj group had a hic^ier starting EMI, fadling 
just inside grade III at EMI of 40.7, vAiile the starting wei^t o f ‘the 
drug group was 36.8, but according to the authors, this difference was 
not significant (Abell et al., 1986). This stuc^ is a good exanple of 
the value of non-pharmacological dietary treatment, as while the 
placeta group started heavier, their loss was 2.8kg, the loss with the 
drug group being 3.5kg.
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1.6 Sunmarv
“Ihe ej?)erlinental studies described in this thesis ate oonoemed 
primarily with the anorectic effect of the 5-HT rei^jtate inhibitor and 
antidepressant fluoxetine. Placebo-controlled studies carried out and 
described in Chapters 3 (normal volunteers) and Chapter 4 (obese 
volunteers) examine both anorectic and subjective effects of this d n ^  
in respOTse to two (Chapter 3) and four (Chapter 4) weeks treatment. 
'The developnent of an observational methodology suitable for laboratory 
and field work with both volunteers and clinical populations is first 
described in Chapter 2; Chapter 4 describes the application of this 
"ethodology in obese patients treated with EXT. Subsequent studies 
examined the effects of fluoxetine on food intake, body w ei^t and 
satiety behaviour in rats followii^ acute (Chapter 5) and chronic 
(Chapter 6) administration and ocnpared the effects of pxr with those 
Of fenfluramine and other serotonergic agonists.
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CHAPTER 2
DEVELOPMENT AMD TESTING OF AN OBSERVATIGMAL METHODOLOGY 
FOR STUDYING lEEDIMG BEHAVIOUR
2.1 METHODS OF EXPERIMENTAL INQUIRY INTO FEEDINS
The develGpnnent of methods to study feeding in animals and humans has 
been prcnpted by inquiry into both the determinants of functional feeding 
control systems, and of systems vhich appear to be (tysfunctional for the 
host. For exanple, vhile population surveys may show that the selected 
population eat more fat than .the current recoinmended 33% of total daily 
energy (Gregory et al., 1990), the majority of pecóle do not appagr to 
food intake and body weight regulation a seriously intrusive 
ocsisideration in daily life, vhich can be the Ccise for those suffering 
from anorexia nervosa, bulimia nervosa (Robinson, 1990) or obesity 
(Garrow, 1991).
In general, investigation of influential factors in feeding have centred 
on (i) short-term meal-specific activity, laboratory based and 
frequently using "direct" dajective measures. Efforts to evciluate 
measurement of (ii) longer-term feeding(24h and upwards) relied more on 
subjective measures and "indirect" field/observational work. Experimental 
methodologies have been develcped to study feeding over a period of yeeurs 
(Hetherington & Rolls, 1987), At present, reseeuxh methodology is 
advancing and is increasingly able to facilitate long-term objective
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measurements via carputerized techniques (Blundell & McArthur, 1981, 
Foltin et al., 1990). This continuing methodologicxil refinement reflects 
the awareness and acx^^tance by researchers of the cxxtplex and 
interactive nature of their subject.
loaies in animals
The focus on oonponent, or micacostructural analysis of behaviour 
(Wi^dcema 1971) encouraged the development of experimental methodologies 
with the capacity to dissect the structure and processes of behaviour. 
With respect to the effects of drugs on oonsunmatory behaviour, this 
allowed reseauxhers to examine (qualitative and interactive as well as 
(quantitative and absolute expressions of behaviour. In effect, this 
meant moving away fron the analysis and presentation of data as absolutes 
(e.g. total grams), and towards analyzing and interpreting data in the 
context of interactive "behavioural flux" (Blundell & McArthur, 1981). 
The latter term refers to the conc:^ of behaviour as linked, supported 
and modified by the continuously vital schema of the host.
Microstructural analysis in the pharmacx>lcDgical cxxtext was originally 
used to examine the effects on feeding of ecquipotent doses of amphetamine 
and fenfluramine, the former, at a dose of l.Qmg/kg producing an 
increased latency to ^ eat, and rate of eating, while the latter
i
(3.0mg/kg) reduced the rate of eating (Blundell & Latham, 1978; 1980). 
A  refinement to the rec3ording of intake methodology was the pellet 
detecting eatometer (Blundell & Leshem, 1975) which allowed (continuous 
reccording and cx>nse<quently was able to elucidate differences in the 
profile of effects over 24 hours of anphetamine and fenfluramine in 
non-(3eprived rats. This approach (iemonstrated that fenfluramine
/
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decreased meal size, while amphetamine resulted in a small increase in 
intei>meal interval (Blundell et al., 1976). The use of computerized 
ccntiruois recording has helped to describe variables such as size 
and Intra-meal eating rates (Blundell & Latham, 1980)
The observation that, on cessation of feeding, a rat will generally 
engage in a series of behaviours ooitprising grooming, being active and 
finally resting, which is considered to indicate the presence of
satiety, has been demonstrated . in freely feeding rats, but does not 
occur in sham-fed rats (Antin et al., 1975). This sequence of
bdiaviours has provided a background on which to examine and characterize 
the effects of anorectic agents on consummatory behaviours. Drugs 
inducing anorexia were known to act mainly on either the 
catecholaminergic (amphetamine) or serotonergic (fenfluramine) systems, 
but there was little initial information on behaviourally relevant 
effects. Microstructural analysis of consunmatory behavior has assisted 
in both the identification of the critical components in initiation, 
maintenance and termination of feeding (Rowland, 1987), and
additionally, is usefully enployed in clarifying differing mechanisms of 
action between anorectic agents. %
A drug which is predicted to enhance satiety should not only induce a 
suppression in intake, but also enhance the behavioural correlates of 
satiety. A classic study, including video-taping, was carried out to 
examine and compare the effects of fenfluramine and amphetamine on 
energy intake, choice and consummatory behaviour in rats (Blundell & 
McArthur, 1981). Amphetamine-treated animals did not reduce energy 
intake but showed increases in grooming and activity, which were 
intrusive to the usually expressed sequence of eating, grxxming.
/
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activity and resting. Hie meal took longer, and it was suggested that 
there was no direct effect on eating. Hie effect of fenfluramine on 
energy intake over 24h period was to reduce total intake but maintain 
protein intake (offered from two sources). Fenfluramine increased the 
tune ^)ent eating, decreased the time spent grooming,cind fvinsed cin early 
introduction of post-meal resting suggesting fenfluramine possessed 
satiety-mimetic qualities (Blundell & McArthur, 1981).
Greater sophistication in currently available recording methodology 
mainly through computerization, has helped to integrate the previous 
short-term observational studies with longer term field type studies.
observations^.^t^jjer^^ the discrete
unit of a meal, can now be targeted both on the meal (pre-prandial, 
intra-prandial, post-prandial) and over longer periods of time 
(intra-meal, circadian, and longer-term regulation). Hie work of Foltin 
and colleagues, carried out with both primate and human populatiois, is a 
good exanple of eiperimental procedures which have been shown to be both 
flexible and sensitive to a variety of anorectic challenges. Recent 
developments include monitoring primates over period of 22 hours using 
continuous recording techniques to examine the effects of a selecticai of
drugs (Foltin, 1989; Foltin & Fischman, 1988) and caloric 
manipulations (Foltin & Fisohmein, 1990).
/
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2tlf2__Methcxioloqies in humans - laboratory
a)— Measurements using a liquid souroe of intake
In humans, the initial studies on energy intake and feeding behaviour 
tended to focus on attempts to establish differences between lean and 
obese subjects. For example, in a study by Price & Grinker, (1973), food 
was used as the main dependent variable, with level of deprivation 
(preloa^deprived) as the independent variable.
The use of liquid energy sources allowed direct "on-line” measurement of 
nutrient intake, in a hidden reservoir, and connected by tubing v^ich 
allowed the subject to "feed" (Jordan et al, 1966, Jordan, 1969). This 
methodology allowed covert mcinipulation of energy density and its effecrt 
on meal size (Speigel, 1973), a tactic now possible with solid foods 
through fat substitutes (Blundell & Burley, 1991). This method was 
to rocHiitor the develc^xnent of satiation in c^^ese subjects (Pudel & 
Getting, 1977), and was used to test intcikes in response to stress in 
normal and obese subjects (Meyer & Pudel, 1972). Kissileff & Krai (1986) 
used' this method to examine eating behaviour and energy intake in 75 
patients who were more than 100% overweight (morbid obesity). Obese 
subjects, and 41 controls consumed a standard 300 kcal breakfast and 
three hours later were given access to a milk-shake style liquid meal 
from an opaque container. No significant differences between nhpse cuid 
non-obese were found in either energy intake or duration of the "meal", 
eating rate was faster in the obese than the non—dsese, and mean both
%
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both consumed more than women, and had a hitler eating rate. O m o e m s  
about the field validity of this method due to the absence of solid foods 
encouraged developments of more recilistic methods.
b) Develocments in Automatic monitoring of Intake
Kissileff et al., (1980) developed the Universad eating monitor (U.E.M), 
comprizing a continuously wei^ied (every 3 seomds) bowl vdiich rests on 
an electronic scales set into a surface. Ihe changing wei^t of which is 
used to plot inta)oe across time, and hence to describe a cumulative 
intake curve (Kissileff et ad., 1980). Either solid, (fruit, nuts and 
yogurt) or a semi-solid (liquid) version, could be offered to subjects, 
using a plate or bowl. Kissileff & Thornton, (1982) suggested that 
excitatory neural processes and their "cognitive” correlate of hunger 
were reflected in initial rates of eating, while state of neural 
inhibition, "cognitively" expressed as satiety, was reflected in a 
negatively accelerating intake curve. Derivation (21h) (Kissileff et 
ad., 1980) and the use of palatable food (Bobroff & Kissileff, 1986), 
were found to increase initiad rate of eating, offering some si;pport for 
this hypothesis. This method is sensitive enou^ to show drug effects: 
slew infusions of lew doses of CCK in lean men resulted in subjects 
eating less and stopping eating sooner (Kissileff et ad., 1981).
Kissileff hais suggested that this method is also sensitive enou^ to 
demenstrate aberrant patterns of intaOce in bulimic patients. 
Interestingly, the type of instruction given to the patients played an 
influentiad part in the behavioural outcome, in that vhen ice-cream was 
offered with the instructicxi to eat as much ais they could, bulimic 
patients ate both more rapidly and ocaisumed greater amounts than
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cxxTitrols. When offered yogurt shake and asked to consume it as if it 
were a normal meal, there were no differences between normEd and bulimic 
patients' intake or b ^ v i o u r  (Kissileff, 1988).
Vfesterterp et al. (1988) and Westerterp-Plantenga et al., (1990) have 
utilized the universal Eating Monitor of Kissilef (1980) to examine the 
eating behaviour of both normal and cd^ese subjects vtio are offered an 
aco^jtably palatable pasta dish. No consistent differences between normal 
and obese subjects were found in meal, meal length or changes in the 
slope of the cunulative intake curve. They suggest that deceleration or 
non-deceleration (linear) intake curves are related to cognitive state, 
as measured by Stunkard & Messick's (1985) Eating Restraint Scale. In 
normal wei^t subjects non-decelerated eating rate was related to 
^®9Tii.tive restraint and disinhibition factors of the scale, suggesting
that this greup was partly restrained (Westerterp-Plantenga et al., 
1990).
Another automatic device of a different nature, was the Bite-Indicating 
Telemetering Eatcmeter (BITE) (Moon, 1979). This device uses the ocxitact 
of eating utensils with the subject's mouth to register the number of 
bites. Information on inter-bite interval cind changing rates of eating, 
can be recorded. It has not been ccxifirmed vhether this device is 
suitable for a wide variety of food-stuffs, and it does not appear to be 
widely used (or referred to) in feedir^ research.
The Edogram, (Bellisle & le Magnen, 1980), measured chewing and 
swallowing by monitoring movements of the Adaires's apple and jaw, using 
this technique it was possible to show that palatable foods resulted in a 
bigger meal size; shorter amounts of time were i^)ent chewing palatable
/
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foods, and increases in inter-bite intervals occurred as the meal 
progressed, indicating a decrease in appetitive state and the 
development state of satiety (Bellisle et al., 1984).
c) Solid Food Dispensers
The conoems about validity of measurement using liquid sourx^es of 
energy, prorpted development of the more realistic Automated Solid Food 
Dispenser (AFD) by Silverstone et al. (1980). This method facilitated 
monitoring during a lunch meal in vhich subjects could choose from a 
four items; (e.g. sandwich portions, crackers plus cheese, 
grapes, chocolate biscuits), by pushing a button (see Chapter 3) This 
method has proved sensitive enough to detect pharmacologically-induced 
changes in food intake and choice in healthy male subjects (Goodall & 
Silverstcxie, 1988). A more elaborate version of the AFD was later 
develop)ed in vhich ten items of food varying in macronutrient conpositi^ 
and sweet/savoury ccmponents were available to subjects, thus allowing 
within-meal analysis of pharmacological effects on food intake (Goodall 
et al., 1992a).
An analysis of the influential factors in food intake and feeding 
research constitutes an experimental paradox, in that validity, is 
invariably reduced in a laboratory setting (Rolls & Hetherington, 1990) .
Field settings, while offering greater external validity (representing 
subjects eating habits), are difficult to control for extraneous 
influenoes/demand characteristics. Rolls & Hetherington (1990) make the 
point that a laboratory setting offers the opportunity to control and 
manipulate variables with far greater sensitivity than possible in a 
setting. For example examination of the complex relationship 
between hedonics and energy content (Blundell et al., 1988b), could prove 
difficult to organize in a naturalistic setting. One of the aims of a
cxarprehensive research "model'' cxxald be to i d ^ i f y  priority aspects in a 
laboratory setting, and then attempt to confirm this finding in a 
naturalistic setting. The use of diet diary records as an adjunct to an 
e>g)eriinentally roMiitored meal, is an example of this approach.
Poltin et al., (1988; 1990) have used a residenticil laboratory setting to 
examine the effects of both caloric dilution (1988) and d-anphetamine 
(1990) on food intake in normal males for fourteen and fifteen days 
respectively. All behaviours ( e x c ^  dressing and toilet activities), 
were recorded via a computerized • observation system. Althou^ this type 
of experimental design is working towards the ideal of examining 
behaviour in a natural setting while being able to make accurate 
recordings, the lack of access to television, radio, mail or newpapers 
detracts from the field validity of an otherwise comprehensive design.
— Field methodologies in Humans
The reasoning behind the organization of field, or naturalistic studies 
is that the ciDserved behaviour is more likely to show external validity. 
^^ oiaever the researcher generally forfeits both accuracy and the 
liJcelihood of acc^jtably ccxitrolled manipulatic«. In the 1970's, a 
ccxisiderable number of field studies were carried out with a view to 
determining the existence of leaiVobese differences in eating behaviour 
and intake. For example, the study of Stunkard et al (1980a) carried out 
in a fast-food restaurant, made attempts to control for porticxi size and 
in addition, to detect the presence of restraint in subjects. In this 
stucfy, unobtrusive observers weeuring dsurk glasses, purportedly reading
/
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newspapers, recorded the feeding behaviour of an unsuspecting "subject" 
every 30s using a hand-held counter and by marking paper. Information on 
the possibility of restraint was gleaned by researchers, posing as market 
researchers, asking subjects "do you usually eat less at meals than you 
would liJce?" Subjects were 30 obese (visually determined) and 37
5 3 5 3 ^ ^ . *»prize" meal. In this
study, the eating style of the normal and obese subjects were 
with ccnparable rates of eating. The obese subjects who chose to eat the 
large meal consumed more kilocalories per mouthful than controls, the 
opposite was true for the small meal. The point was made by the author 
of this study, that there was great variability in eating from subject 
to subject. It had not been possible to control for deprivation level. 
Attempts were made to control the energy content of the food by making 
two similar meals (hamburger/fries/soft drink) available. Subjects could 
dnoosB a small meal comprising of one of each of the above and amounting 
to 985 kc, or a large meal, comprising of l,800kc, comprizing two of the 
mentioned solid foods and a large soft drink. More normal weight (19) 
than obese (ll) women ate the large meal. Another study examined over 
5,000 episodes of food choice in nine different sites, to include four 
sites offering meals and five offering snack foods (Coll et al, 1979). 
Again, weight category of normal, overwei^t and obese, was 
visually. At one snack site, obese people choose more calorifically 
dense foods than non-<*ese but, in general, food choice was dictated by
type of site being observed, as opposed to weight category (Coll et al., 
1979).
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2.1.3.1 The use of diet diaries
Diet diary records and histories can provide useful insists into intake 
brfiaviour of selected sub-grot^, although accuracy in reporting over 
long periods of tiine is unlikely. De Castro (1987) used diet diary 
intakes to examine the spontaneous intake of e i ^ t  normal male and thirty 
female subjects over a nine day period. In this study daily rhythms were 
evident, with intate of CHO and fat varied with pea)ced intakes at meed 
time, protein intake was more consistent. Some suggestion, particularly 
in males, of greater energy consuirption during the evening, De Castro 
felt that this may be in anticipation of the night fast, however, it may 
be just as likely to be in response to social context or response to 
television advertizing. Diet dicury recoreJs have been used in an atteiipt 
to determine c±>ese/lean differerences in intake. Lansky & Brownell (1982) 
carried out a study in vhich obese subjects self-r^xjrted consuming less 
te than lean subjects. However, vhen intake wcis aggyagctfad by ah 
esqperienced third party at interview, obese subjects were found to 
consume ^proximately 600kc more than non-<±)ese. It is not unexpected to 
find that obese subjects in energy baleuice consume more them non-obese 
subjects. Prentice et al.(1986), have shewn under-r^x>rting in the .obese 
using doubly-labelled water. Laessle et al. (1989) used information 
from 7 day diet diary records kept by restained cind non-restrained young 
wemen to show the presence of a reduced intake of 400kc in the former 
C9cn|)ared to the latter. Protein int£dce wem found to be hi^er in 
restrained subjects, records also suggested that restrained subjects 
C3onsumed less hi^-fat/CHO energy dense foods. Diet dieury records cem 
certainly provide indications of intake behaviour but accuracy in 
recording intake is unlikely to persist over long periods of time, emd
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the recording of consuirption of foods will in effect, become an 
ind^)endent variable. More recently diet diary intake has been used to 
examine the effects of serotonergic drugs on diet selection (Fiji et eH., 
1991). Perhaps one of more vzdid uses of diet diaries can be directed 
towards establishing the presence of drug/placebo differences in re^xxise 
to dnjg treatment (see Chapter 4).
2.2 An observaticyi methodology for studying feeding bdiaviour
The act of observing behaviour as an experimental methodology has 
ethologiczd roots; being used in field studies with animcils in the 
1920's and 1930's. Analysis of behavioural sequences in animeds hcis 
become increasingly sophisticated and therefore allows a more 
conprehensive approach to examining behaviour (Douglas & TWeed, 1979). 
In psychological research, observational techniques are not widely used. 
Hutt and Iftitt (1970) suggest such studies cxdy represent a smzdl 
proportion (approximately 8%) of total experimental work. In c±)servationcd 
studies the observed behaviour is likely to occur naturally, be recorded 
at a molar level with fewer subjects but for a Imger period of time 
(Fassnacht, 1982). In addition, observers need training and must' work 
together until acceptable levels of inter-rater reliability have been 
achieved, and periodically record further behaviour together for a 
recomnended 20% of observations (Sackett, 1978). Observers are likely to 
record large amounts of data, thus ma]dng h i ^  agreement levels more 
difficult to achieve. The latter requirement is invariably esq)ensive in 
time as the research staff are needed for both training and e^qserimentzd 
work. Exanples of observational studies in human subjects focussed on 
children in the form of mother/infant interacticai studies (Olvera et zd., 
1990), pre-school play and hyperkinetic (Hutt & Hutt, 1970); as well
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as mentally retarded and autistic children (Goodall & Corbett, 1982). In 
adults, observational techniques have been used for example, in an 
attesirpt to determine obese/lean differences in feeding behaviour, an 
issue which has previously demonstrated inconsistent experimental 
findings (Stunkard & Kaplan, 1977).
The main aim of the present three part study was to establish a reliable 
and portable observational method suitable for studying feeding behaviour 
in varied sub-populations of humans. Suitable target areas for 
^plication of this methodology would be monitoring cheuiges in feeding 
behaviour during the course of depressive illness and detecting changes 
in feeding b ^ v i o u r  under specific drug conditions. A continuous, as 
opposed to a sanpling method of observation was choosen, as the latter 
(both vhole-interval and partial interval recording) can underestimate or 
overestimate the true percentage of observed behaviour (Murphy & Goodzdl, 
1980). In continuous recording each occurrence of cill ^»cified 
bdiaviours is recorded with exact information on total time, latency, 
frequency and the start and finish of each behaviour (Martin & Bateson, 
1988). In an initial pilot study (Me Guirk, 1985), ebserver agreement 
was determined using Cohen's Kappa Statistic, a strir^ent measure of 
inter-rater reliability which analyses areas of besth agreement and 
disagreeflnnent (Hollenbeck, 1978). Observer agreement levels using Kappa 
in the video-recorded ooiditions were .78 to .96 and .72 to .91 in the 
live conditions. Percentage agreement was choosen for subsequent studies 
as an acc^jtable agreement measure for observers who had previously 
demonstrated satisfactory agreement levels under stringent ccaiditions. 
The first experiment had two purposes: firstly, to establish acc^jtable
47
levels of observer inter-rater reliability; secondly, to examine the
feasibility of live recording of feeding behaviour in a psychiatric 
setting.
SubsequenUy, the observational methodology was applied in the context 
of a dreg trial. A study examining the differential anorectic, 
psychanotor, and hormonal effects of the d- and 1- isoners of FF and 
anphetamine (Goodall et al., 1992a; Feeney et al., in prep. ) provided a 
suitable basis for testing the method. This had the advantage of testing 
the methodology against previcxisly observed drug effects (Rogers &
Blundell, 1979; I^iakides & silverstone, 1979), with the additional 
inclusion of 1-FF.
mayThe gross measurement of amount of food consumed during an experiment 
conceal subtle differences in the b^vioural mechanisms of anorretic 
drug action. Drugs that reduce food intake may do so by bringing itiaaig 
to a premature end, by decreasing the rate of food ingestion, or by a 
variety of other means. For exairple, a difference in the behavioural 
mechanism of action between catecholaminergic and serotonergic anorectics 
is now well established. Thus the prototypical catecholaminergic drug, 
d-anphetamine, has been found to decrease food intake, the duration of 
meals and feeding bouts within meals, edthough, as reported in qr«no 
studies, has increased the rate of food intake within bouts. In 
contrast, the prototypical serotonergic anorectic, dl-fenfluramine, 
decreases food intake and the rate of eating, but does not alter inp^ l
duration (Blundell & Latham, 1978, 1980; Cooper & Francis, 1979;
Blundell & McArthur, 1981; airton et al., 1981; Towell et al, 
Foltin & Fischman, 1988).
1988;
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When this drug-pair has been tested in human subjects under laboratory 
conditions, the difference in action of d-araphetamine auid 
dl-fenfluramine has been oonfinned, but not always identical (Blundell et 
al., 1979; Rogers & Blundell, 1979; l^iakides & Silverstone, 1979), The 
*guesticxis ranaining oti the differential effects of these drugs surround 
their capacity to sustain effect in a fairly wide food choice situation, 
and as similar as possible to buffet-style foods available in public 
eating venues or at heme.
In effect, there were three main objectives in setting-i:p this 
es^)eriinent: the developnent of a suitable methcxiology for stuctying human 
eating behaviour in a variety of settings; to detemine the effects of 
d- and 1-fenfluramine on eating behaviour; and to examine the interaction 
between fenfluramine and airphetamine. On the basis of the available 
literature, it was predicted that both d-anphetamine and d-fenfluramine 
would reduce food intake, but with evidence of differential effects in 
feeding b^iaviour, and that 1—fenfluramine would be largely ineffective.
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2.3 MEMQDB
2.3.1 Subjects:
^qpeyunent__1 : Fifteen subjects in total volunteered. These were mixod
male and female, oonprizir^ of seven psychiatric patients and e i^t 
normal volunteers, subjects were matched as far as possible in the 
circumstances, for age and body mass index. The normal volunteers were 
frcm the hospital staff, the incentive being a free ho^it2Ll 
lunch. On reconmendation from the nursing staff, patients who were well 
enough to attend Occupational Therapy sessions were asked if they would 
be willing to eat their lunch vhile being observed. The resecuxh staff 
were introduced to individual patients and answered questions concerning 
the intended project. Patients suffering from florid psychosis or 
disturbed behaviour were excluded. The patient population were of mixed 
diagnoses, ocnprizing schizophrenic(n=3), schizo-affective(n=2), and
affective disorded(n=2) patients. The need to establish observer 
agreement was given as the reascxi for the study to eUl subjects.
^gperjjnent 2: Six psychiatric patients made ip the live ward—based 
subject population of schizcphrenic(n=4) and affective 
disordered(n=2)patients. As in E>periment 1, the nursing staff tnado the 
initial reocnmendation as to which patients would be suitable for 
observation on the ward. C^Dserver agreement was again given as the 
rationale for the study.
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^ gjerjunent---3j. IV^lve healthy male subjects participated in the
pharmacological study, iheir mean age was 28.4 years, s.d. 2 .9 (range 24
to 32). They underwent a medical and had no history of psychiatric 
illness.
¿^3.2 ^JservabicaTal methoctolocrv!
In order to gain an applicable behavioural taxoncniy prior to the 
eJ5 )eriment, video-tapes of normal volunteers eating a meal were made and 
viewed hy d^artmental staff. The specific acts of manipulation (food and 
utensils), biting and chewing of food were classified as eating 
b ^ v i o u r s  and specified as follows:
ifeOlpylatioD: C3ontact with food by fingers or eating utensils.
Biting; Food enters mouth.
Visible jaw movement while food is in mouth.
Similiar behavioural taxonany has been used in an attempt to 
establish obese/normal differences (Stunkard et ed.., 1980a).
B^optding of behaviour:— Each observer used a portable Epson HX20 "lap” 
ocnputer to make recordings of the lunch meal. A customized verson of D 
Feloe's "lunch" program enabled the two observers to record the start and 
finish of each bout of feeding behaviour, e.e. manipulatir^, biting and 
Viewing of food, using keyboard input. The summary data on print-out 
gave duration of the total meal, duration of each feeding behaviour,
frequency per minute and percentage of total time occupied by each eating 
behaviour.
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¿±3-3 Experijiental s<.|-<-ings and nTTvv>^nr^.
Subjects ate their lunch in a twelve foot ly sixteen foot
roan in the Occupational Iherapy Departnent. Ihis scttü^ was chosen 
for the recording site as the patients attended there d a U y  arxj prepared
and ate lundi there once a week as a part of rehabUitation therapy, m  
addition, the patients were familiar with the use Of a video camera in
this setting as filmed sessions formed part of the social skills training 
progranme. ihe video camera was positioned in a comer of the roan. It 
was mcunted on a tripod and directed at the dining table in the cfposite 
comer of the roan. The television monitor and recorder were on a trolly 
positioned outside the roan and out of view of the subjects. Participants
ware asked to arrive at the specified roan in the Occupational Iherapy 
D^artment at twelve noon. iwo participants, either two psychiatric 
patients or two controls ate together. While both participants were 
filmed, oily one was a subject for live observation. Subjects were 
seated at the table and served their choice of lunch. The observer using 
the portable coiputer was seated beside the tripod and in the opposite 
comer of the roan to the subjects. The video-recorded was activated 
just before the subjects were served their lunch. Psychiatric patients 
ate a standard hospital lunch. They were offered a choice of two
different meals being served on the ward that day. Normal volunteer 
subjects ate a hôpital lunch. They selected fron a choice of two
lundies being served in the canteen. Eating behaviour, as previously 
defined, was recorded using the portable ooiputer. Mien both subjects
had finished their meal they were asked if they would like to view the 
of their meal on the monitor.
/
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— 2j. The dining eurea of the acute admissimi wEund was the
setting for the live observation. Each observer used eui Epson lc^}top 
microocnputer to reœrd feeding behaviour as before. The dining area 
consisted of a rectangular roan with approximately six circular dining 
tables. The observers sat in two of the easy chairs normsd-ly 
against the walls of the ward. The usuea lunch-time rxxitine was 
maintained in which patients went to a serving hatch, collected their own 
lunch, returned to a table and ate there. Patients taJdng part in the 
observation session sat at a table near the observers. On
cessaticai of the observaticai session, the patients were thanked for 
their co-operation and the observers left the ward.
fixperifflept---2l “Ihe pharmacological study was a within subjects
double-blind and counter-balanced design, each subject received all six 
treatments caiditicHTS as follows: 30mg d-FT & amphetamine placebo; 3Qmg 
b-FF & amphetamine placebo; FF placebo & 15mg amphetamine; 30mg d-FF & 
15mg amphetamine; FF placebo & amphetamine plaodso. Subjects attended 
the laboratory weekly on six occasions and were tested individually, 
there was a one week interval between treatments. Subjects feisted 
overnight and arrived at approximately 0845h. At 0900h (approx) visual 
analogue scales (VAS) were ccnpleted, followed by tests of psychonotor 
function, and a blood sample was taken. VAS were administered hourly 
thererafter and blood withdrawn at 2h intervzds. At 0930h, the subject 
took two identical capsules, containing 1-fenfluramine (2 X 15mg), 
d-fenfluramine (2 x 15mg), or placebo; at llOOh a further capsule was 
given, containing either placebo or d-amphetamine(15mg).
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At 1400h subjects ate lunch in a room approximately 14' 6" by 6 ' 6". The 
room contained a table with eating inplements, a chair, a wall mounted 
scny video camera and a Wittenborg food dispensing machine adapted for 
experimental purposes (Wittehborg UK Ltd, Horley, Surrey). This was 
similar in appeaurance to most modem automatic food dispensers seen, for 
exairple, in airports or hospital ni^t-staff dining areas (Fig 2.1). 
This ten-channel automated food dispenser(AFD) allcwed subjects to input 
a code number and help themselves to a small porticai of either aie 
individual food or a selection of different foods. Table 2.1 describes 
the available foods with energy contents. A specific program(A 
Leach-Ocnpular) recorded details of food intake on an Apricot ocnputer 
linked to the Wittenborg and housed in an adjacent room. The T.V. 
iKMiitor and video recorder were also in an adjacent room vhich cdlcwed 
observers to record the meal and make observaticxis of feeding bdiaviour 
using an £pscxi laptop microociniputer cis described in the previous 
stuc^(Fig 2.2).
V»
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3r One experimenter viewed all video-tapes and two observers 
viewed 27% of tapes to determine percentage agreement levels for 
reli9bility(IRR) (Sackett, 1978). Feeding behaviours were 
analyzed by 2^way within-subjects analysis of variance supplemented by 
tests of sinple main effects emd plcinned oonpariscxis.
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0//o
Agreement
Overall Agreement
Fig 2.3 Mean percent overall agreement (2 observers) 
represent range of percent agreement.
Bars
Reading from left to right histograms show progression from two 
observers viewing a video twice (V-V); through two observers making 
a live observation and later viewing the video» called live versus 
Video (L-V); (L-V) with rater number given in brackets, refers
to within rater agreement (observer test-re-test reliability. (L-L) 
refers to two observers making live observations; and the final 
histogram on the right represents the field based live observations 
on the ward (L-L). (L-L) is ‘hatched to indicate the final settingof a live environment
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Table 2.2 Reliability of cA)servations of eating behaviour^'
OverzQl Manipulation Biting Cbewing
Method^ Start Finish Start Finish Start Finish
.80(2.4) .79(2.9).73(3.5) .8 8(2 .0).87(1.8) .85(2.8) .68(5.3)
L-V 82(2.8) 81(2.9) 72(3.8) 91(3.0) 88(3.8) 85(3.9) 65(5.4)
L-L(lab) 81(4.2) 85(1.7) 82(4.1) 96(0.8) 97(0.6) 95(0.7) 65(3.8)
L-L(ward) 82(2.6) 82(2.8) 75(5.1) 90(1.5) 89(1.7) 84(5.4) 69(4.5)
V-V^ 92(0.5) 84(2.1) 76(2.5) 98(0.6) 97(0.6) 92(2.0) 75(3.2)
1 The first four sets of values are inean(with s.d.) of the kappa 
statistic for overall agreement between the two observers, cind for 
the start and finish of individual behavious, from the preliminary 
validation study.
2 The final set of figures shew percentage agreement between the 
observers (mean emd s.d.) in the pharmacological study.
3 Inter-rater reliability for live versus live(L-L) and video versus 
video(V-V) sessions; and intra-rater reliability between live and 
video sessions(L-V).
4 laboratory setting, n=15; ward setting, n=6 .
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^ 3S6Ever 39^6€in6n^ on 'tho finish of chewing in video and live oonditiais 
ranged from 65% to 68%; agreement scores on the finish of manipulation 
ranged iron 71.8% to 82% (Fig 2.4).
Observed differences between patients and controls: Fifteen subjects(8 
control and 7 seven patients) formed the subject population of the 
laboratory based observations. Differences in eating behaviour between 
the two populations are shewn in Fig 2.5. Figures are the meems aró. 
standard deviaticxis. Patients took more bites than aaitrols vAiich 
towards significanoe[t=-2 .1 ; p<0.06, significant at 2 .3 ), althou^ their 
meal course time was slightly shorter (Fig 2.5). Control subjects had a 
longer inter^bite interval, possibly attributable to higher levels of 
conversaticai absent from the predominantly schizophrenic patient 
population. In the initial pilot study, not reported here, control 
subjects spent approximately 28% of meal-time in conversation conpared to 
1% in the patient population (Me Guirk, 1985); there was significant 
subject variability due to differing levels of conversation.
2.4.2 Experiment 3
2.4.2.1 Food intake: The effects of anphetamine and fenfluramine oti food 
intake and eating behaviour are summarized in Table 2.3, and the 
statistical an2dysis of these data are sumnarized in Table 2.4. Both 
anphetamine and d-fenfluramine significantly reduced food intaJce(g) and 
aiergy intake (kj). The amphetamine/fenfluramine interacticMi terms were 
non-significant, indicating that the effects of amphetamine and 
d-fenfluramine were additive (Table 2.3, see Table 2.4 and note). 
L-fenfluramine was essentially inactive. The effect of 1-fenfluramine on 
food intake was rpn-significant; and while l-fenfluramine caused an 8%
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Table 2.3 Effects of airphetamine and fenfluramine on eating behaviour^
PIACEBO 3tt!PHETaMINE
PLC
Inta)ce:
Grams 
)noules 
IXirationfsec^: 
Ttotal meal
chewing 8 9 0 (43
Bites f number^ 72(6)
i*
Eating rate;
Ir-FF d—FF PLC Ir-TF d-TF
556(49) 494(44)** 452(56)*** 434(36) 402(58)
4251(387) • 3908(431)** 3492(439)**3221(395) 2985(486)
1343(69) 1342(74) 1197(96)* 1101(103) 1155(138)
952(55) 941(56) 819(66)** 790(82) 815(93)
852(44) 826(31) 727(62)* 662(59) 794(76)
68(5) 63(5) 58(6)* 59(5) 53(5)
40.2(0.9) 36.2(3.3)* 37.6(3.4) 40.4(2.5) 31(3.3)
309(31) 275(30)* 288(28) 300(25) 277(34)
1 Values are means(with s.d.). PLOplacebo; AME^-amphetamine; 
L-FF^fenfluramine; d-FP=d-fenfluramine.
2 Significance levels are shown for differences from the Pt£/PLC condition 
for AMP alone (simple main effect) and for each of the FF isomers 
(pairwise ccjiparisons, given a significant sinple main effect). 
Significance levels with respect to PLC are not shown for the AMP/FF
combinations: these comparisons are not possible within a factorial 
design.
*=f)<0.05;
**=p<0 .0 1; ***=p<0 .0 0 1.
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Table 2.4 F-values for analysis of energy intake and feeding behaviour^
Treatment L-FF
Decrrees of freedom (1 ,2 1)
AMP A X F
(1 , 11) (2 . 22)
Intake:
Grams 1 .2 • 11.3** 20.9*** 0.5
kioules 4.9* 17.2*** 23.0*** 0 .2
iration:
Total meal 3.1 1 .6 10.7** 0 .1
Manimlation 6.2* 1 .8 13.6** 0 .8
Chewing 2 .6 0 .0 6.9* 2 .2
Bites 0 .2 4.2 6.3* 0.5
Eating rate:
Local (g/min^
Local nd/min)
1 The table shows F-values for main effects of drugs on the various 
measures. Values for amphetamine (AMP) are the main effect of 
amEAietamine; values for 1-fenfluramine (L-FF) and d-fenfluramine (d-FF) 
are pairwise comparisons of 1-FF and d-FF versus placebo within the 
fenfluramine main effect; A X F is the amphetamine/fenfluramine 
interaction term. *=p<0.05; **=p<0.01; ***=p<0.001.
/
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decrease in energy intake, which was irarginally significant in the 
overall analysis, oonparisons of 1-fenfluramine with 
plao^X3[F(l,44)=2 .9] and of the 1-fenflurandrie/aiiphetamine contoination 
with amphetamine alone [F(l,44)=l.4] did not show significant 
differences.
2.4.2 .2— Microstructural analysis: Microstructural analysis of eating 
behaviour shewed that amphetamine and d-fenfluramine reduced food intate 
by different and ind^)endent b^vioural mechanisms. Amphetamine 
significantly decreased both the total meal duraticai, and that of all of 
the individual behaviours; the time spent manipulating food, nuntoer of 
and chewing time (Tables 2.3/. 4). However, d-fenfluramine had no 
significant effect on einy duraticai meaisure, and the 
aarphetamine/fenfluramine interacticxi terms were edso non-significant.
By contrast, d-fenfluramine reduced the rate of eating. The measures 
presented in Table 2.3 are the local eating rates(total intake or totad 
energy divided by chewing duration), which describe the rate at vAiich 
food is disposed of once inside the mouth; both nKaagnyiPjc; were 
significantly decreased by d-fenfluramine (Table 2.4). Howler, 
amphetamine had no significant effect on either rate measure, and the 
anphetamine/fenfluramine interaction terms were eigain non-significant.
significant effect of 1—fenfluramine on the behavioural Tnpagimpg 
was a 9% reduction in the time spent manipulating food. However, this 
was derived from a non-significant main effect [F(2,22)=3.1], and 
oenparisions of 1-fenfluramine with p l a o ^  [F(l,44)=2.0] and of the 
1-fenfluramine/aiiphetamine combination with amphetamine adone 
[F(1.44)=3.0] were also ncxi-significamt. A number of behavioural
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parameters were unaffected any of the three drugs, including the 
latency to ocninenoe eating(time to first bite; overall mean = 125 
seconds) the rate at v«uch food was loaded into the mouth(total 
intake/maniFulation time: overall mean = 32.2 g/min), and the size of 
eadi bite(total intake/nunber of bites: overall mean = 7 . 8  gi/bite).
/
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2.5 DISCPSSIOW
2.5»! Methodology develocroenti
The aim of this study was to develop an observatiOTal methodology 
^»cific to the recording of feeding behaviour and suitable for both 
laboratory and field settings for a variety of subject populations. It 
was a further aim to demonstrate acceptable levels of intra- and 
inter-observer reliability in both settings. Vie demonstrated that this 
method of behavioural ciDservation was suitable for an environment as 
unpredictable as an acute psychiatric ward vhere experimental work with 
psychiatric patients is acknowledged as being a difficult exercise (Hutt 
& Hutt, 1970). Viith a psychiatric patient population it is more ooranon 
to use subjective, e.g. visual analogue scales (Robins^ et cil., 1975), 
than objective meeisures.
While the pharmacological study was carried out in the leiboratory the 
initial methodology was established and tested in the less controlled 
envircaiment of a psychiatric ward and therefore is suitable for recording 
b ^ v i o u r  in a field setting (cf Stunkard & Kaplan, 1977; Foltiri et
> 1990). Inter—rater reliabilities were ooistant irrespective of
vhether the data were derived from observations of pre-recorded 
laboratory videotapes, from live observations in the laboratory, or 
fran live observaticxis in the dining room of a busy ho^it2d  ward. The 
absence of a decrease in the reliability of live observations, relative 
to video, is of. particular importance, since there are many
non-laboratory situations in vhich a video camera would be unaoceptcibly 
obstrusive but a snail lap-top ooirputer can pass unnoticed.
/
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Martin & Bateson(1988) raise the question of feasibility of observaticml 
methodology as a s^>arate consideration to reliability and vcilidity. In 
effect, cbservers need to consider the practiczd e^lication of their 
methodology, is it a worthwhile experimented exercise; are we liJoely to 
detect changes from vhich our knowledge of an area is (even marginsdly) 
increased? The present results suggest that it is possible to detect 
differences in behavioural status within or between groups using this 
ebsezvatien methodology.
In this study, observer agreement levels were not consistently uniform. 
There are a variety of reascxis vhy observers may not agree (assuming that 
the training period and behavioural taxononiy are not at fault with 
respect to identification of a behaviour); protocol alignment (starting 
together, Sellitiz et al, 1976), or inccxisistencies in volume and 
frequencies of behaviour. Caro et al (1979) r^»rt that changes in 
reliability of observation will occur as the frequency of behaviour 
increases, or conversely, decreases to very lew levels. In this study 
we found that with simultaneous oocuring behaviours e.g. manipulating 
and chewing, inter-rater reliability on the finish of chewing decreased. 
Of these two feeding behaviours (manipulating and chewing) manipulating 
food vhich involves hand movements, appeared to be more”suocessful” at 
drawing attenticai. The effect of attenticxial oonpetition was to decrease 
observation efficiency.
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2.5.2 Fharmacoloaical study
The pharmacxDlcjgical cJata confirm d-fenflurcunine as the active isomer, in 
humans as in animals (Garattini et al., 1988). Although the use of 
dose limits the generality of these conclusions, these 
results also represent the first demonstration that the anorectic effects 
of d-fenfluramine and d-airphetamine appear additive. The analysis of 
variance interaction terms were non-significant.
^^®wever, it is clear frcm the behavioural analysis that these two agents 
achieve their anorectic effect by different behavioural mechanisms. The 
results confirm the earlier report of Rogers and Blundell (1979), using 
racemic dl-fenfluramine, that the anorectic effect of d-fenfluramine is 
mediated by a decrease in eating rate, vhereas the anorectic efffect of 
d-anphetamine is mediated by a decrecise in eating time, exactly as 
observed in animal studies (see Introduction). Both of these effects were 
present follcwing co-administration of d—airfhetamine ai^ d—fenfluramine, 
as indicated by the absence of statistically singi^icant interactions in 
any of the analysis of variance. Although most of the effects of 
d-axiphetamine or d-fenfluramine alone on the structure of eating 
b ^ v i o u r  were only significant at the p<0.05 level, all were exactly as 
PJ^^icted a priori on the basis of the cinimal literature (see 
Introduction) and the results of Rogers and Blundell (1979). That 
differences in the behavioural mechanisms underlying d—airfhetamine and
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d-fenfluramine anorexia were apparent in a subject group of healthy males 
in a varied free-choice feeding ocxidition demonstrates the potency of 
these effects.
These results are relevant to the theoretical interpretation of 
fenfluramine emorexia. On the basis of observations studies of 
postprandial btìiaviour in rats, it has been hypothesized that 
fenfluramine suppresses food intaloe by hastening the onset of 
postprandial satiety (Thurll:^ et al., 1983; BluncJell, 1986; Kirkham & 
Blundell, 1986; Blundell & Hill, 1987b). However, other studies of 
postprandicd behaviour have produced data inocnpatible with the satiety 
hypothesis (Neill & Cooper, 1988; Itontgoroery & Willner, 1988; Winner et 
al., 1990). The results of the present stucty au?e consistent with 
previous work in showing that in human subjects, d-fenfluramine reduces 
the rate of eating, but does not decrease the duration of the meal 
(Rogers & Blundell, 1979). The same pattern of effects was observed in 
animal studies (Blundell et al, 1979: Cooper & Francis, 1979; Blundell 
& McArthur, 1981; Burton et al., 1981; Blundell, 1986; Poltin & 
Fischman, 1988), provided that a solid food diet is used (Montgomery & 
Willner, 1988).
The satiety hypothesis predicts strongly that fenfluramine should hasten 
the cessaticn of eating, as has been observed, for example, with the 5^ir 
re-uptake inhibitor fluoxetine (Cliftcai et al., 1989; Willner et al., 
1990). The failure of fenfluramine to reduce meal duraticmi 2u?gues 
agednst a potentiaticxi of intra-meal satiety as the mech2uiism of 
fenfluramine anorexia in humans, and suggests that some other process may 
be responsible. uch as a subtle motor impairment (Montgomery & Willner, 
1988; Fletcher, 1988b), a decrease in food palatability (Cooper & Neill, 
1987; Samanin, 1989). We return to this question in the euiimal studies 
in Chapter 5 and Chapter 6.
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In a chapter entitled "The Value and Validity of Laboratory Studies of 
Human Eating Behavior", Kissileff (1988) concludes that 25 years of 
laboratory research hcis confirmed for him the oonplexity of ocaitrol 
mecheuiisms in human feeding, 2uid the necessity of exercising constraint 
vihen tenpted to generalize from one set of e)^)erimental results to 
another. Yet, like Rolls & Hetheringtcxi (1990), similcirly esq)erienced 
researchers, he is convinced of the value of laboratory-based research. 
as an effective tool to delineate both functicxial and dysfuncticxicd. 
factors in human feeding.
73
CHAETOR 3
AN3RBCTIC ACTIGM C3F FLUOXETINE IN NORMAL VOUJmEEBS
U L
There has been an increasingly active research focus in recent years, on 
the effects of serotonergic agents on food intake and body weight. This 
interest is motivated both by scientific and practiced applications, with 
some degree of overlap. Alteration of food intake and body wei^t in 
animal experiments generate hypotheses on the role of serotonin in 
feeding (Blundell, 1977). The general practitioner(G.P), sitting 
opposite a markedly obese patient, may be more concerned with the 
ability of a phaimacological agent to reduce weight without unpleasant 
side-effects and, equally as inportant, to hold no abuse potentied 
(Silverstone, 1982; Garrow, 1988).
Serotonergic agents vhich demonstrate specificity, such as fluoxetine 
(Fuller & Wong, 1977, Fuller, 1982) generate focussed experimentsd 
questions OOTcerning their action and possible therapeutic use. Both 
this chapter and the next attenpt to examine the activity of fluoxetine, 
a specific 5-HT re-uptake inhibitor in both normal w ei^t and obese 
human subjects. CXir initial enquiry is centered on the activity of 
fluoxetine in normal weic^t volunteers.
/
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5-hydrDxytryptximine (5-HT) pathways have been inplicated in the 
regulatic3n of feeding behavior (Blundell, 1977; Blundell, 1984) and in 
the pathogenesis of mood disorders (Asberg-Wistedt, 1989). Factors which 
influence 5 ^  neurotransmission can affect mood, appetite and food 
intake (Goodall & Silverstone, 1988). Fluoxetine (FXT) is a highly 
selective pre-synaptic 5-HT re-iptake inhibitor (Fuller, 1982) vhich 
^)ecifically inhibits 5-HT iptciJce in rat brain syn^stosomes (Fuller & 
Wong, 1977). In clinical trials it has been shown to be an effective 
antidepressant (Cohn & Wilcox, 1985; Lader, 1988; Noguera et al., 1991) 
which does not cause weight gain (Chouinard, 1985). Overweight patients 
lose w ei^t on F3CT, an effect r ^ r t e d  to be related to initial weight
or no wei^t loss for normal wei^t and underwei^t patients 
(Cooper, 1988; Qrzack et al., 1990).
When given to rats, FOT suppresses food intake (Goudie et al., 1976) 
particularly of carbohydrate (Wurtman & Wurtinan, 1977; Kim & WUrtman, 
1988). In chese subjects FOT promotes weight loss (Ferguson & Feighner, 
1987; levine et al., 1989; Fiji et al., 1991) cind hcis been investigated 
as a possible treatment for bulimia (Freeman & Hanpson, 1987; Wilcox, 
1990). Thus FOT would appeeu: to have anorectic properties, although tliis 
J’^ot presently been tested directly in normal volunteers.
The present study was designed to examine the effects on appetite, food 
intate and body wei^t of FOT in normal subjects. Normal weight male 
subjects were chosen for this study as male subjects were thought less 
likely than females to confound the results by being overx3oncemed with 
food intake and body wei^t (Wardle & Beales, 1986). Our hypothesis was
/
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that the weight loss reported in the clinical literature would also
• ♦
be present in non-depressed and non-obese subjects and therefore could 
be ascribed to the effect of fluoxetine as opposed to the effects of 
either depression (in patients) or linked to strong initial levels of 
m o t i v a t i o n  to r e d u c e  food intake^ as p o s s i b l y  p r e s e n t  in obese 
subjects. The likelihood of changes in^,.subjective state in response 
to FXT in normal subjects was, in addition, a 'focus of examination.
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3.2. MEMDD6
3.2.1. Subjects!
Eleven healthy male volunteers, age 18-40 years with no history of 
psychiatric illness participated. Subjects were recruited via hôpital 
r*otioe“board posters and were paid e^^)enses on ocnpleticxi. Their mean 
w ei^t was 73.1)^ (range 58.4 - 95.31og), their mean body mass index(EMI) 
was 23.5. Subjects underwent a medical examination including an 
electrocardiogram and haematology cind biochemistry screening. The stuc^ 
was approved by the loced ethical conmittee and all subjects gave written 
informed consent. Twelve subjects were recruited originally for this 
but one subject had a car accident vhile oti placebo; the partially 
ocnpleted tri2d  data for this subject was excluded.
3.2.2. Desicm:
trial was of a randcmised, double—blind, crossover design. The 
pharmacokinetics of F5CT are such that it ta)ces approximately two to three 
weeks to reach plasma steady state; it has a half-life of 1 - 3 days and 
NbrFXT the active metabolite, has a half-life of 7 - 15 days (Lenberger, 
1988). Each subject was given either 60mg of FJCT or matching placebo 
daily for two weeks followed ly a miniraiim one month drug free period, 
after which the alternative treatment was given for a further two weeks. 
Subjects attended on Day 1 , 8 and 15 of each treatment phase for 
detailed measurements of appetite, food intake and body weight.
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Tllble 3.x Foods offered in the Autanated Food Dispenser(AFD)
Nurrber of sub iecrts )d ikci oer 
offered this choice 100a
KlQcc) per 
averaae 
portion
wt» per 
averaae 
portion
Roast Beef sandwich 5 624(149) 249(60) 40g
ChicJcen sandwich 2 875(209) 350(84) 40g
Prawn sandwich 1 1046(250) 314(75) 30g
Salmon sandwich 3 854(204) 256(61) 30g
Sausage roll 5 1712(409) 548(131) 32g
Slice of Quiche 1 1256(300) 565(135) 45g
Chicken lea 5 904(216) 588(140) 65g
Tomato 7 59(14) 35(8) 60g
Raw carrot 1 42(10) 10(3) 25g
CUcuntoer 3 42(10) 19(5) 35g
Apple (fruit) 1 147(35) 168(40) 115g
Orange (fruit) 1 167(40) 75(18) 45g
Trifle dessert 2 691(165) 877(210) 127g
Chocolate dessert 5 532(127) 553(132) 104g .
Apple tart 2 1352(323) 757(181) 56g
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Table 3.2 Foods available to three subjects from four channels of 
the Autcroated Food Dispenser.
CHANNEL
1 2 3 4
Subject
•
è sandwich (beef) sausage roll cucumber apple tart
2 " (chicken) sausage roll tomato dessert (choc)
9 " (salmon) drum-sticks tomato trifle
Subjective measurements; Visual Analogue Scales (VAS) for hunger, 
arousal, mood, thirst, and satiety were ocnpleted hourly. Visual 
Analogue Scales ccnprise of lOOnrn lines with subjective statements at 
either end; "I do not feel at all hungry"- I feel as hungry as I have 
ever felt"; "I feel very empty"- "I feel extremely full". Each hourly VAS 
scale for the above were presented on one page, previous scales were not 
visible. Ratings for nausea and geistric discomfort were presented at the 
begining and end of the experimental session. VAS have been shown to be 
reliable and valid for quantifying a variety of subjective states 
including hunger (Silverstone & Stunkard, 1968; Goodall et al,. 1987).
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Blood pressure, pulse, pcpil dieimeter euid boc^ 
weight in indoor clothing were meéisured c»i assessment days. Fluid intake 
was measured by determining how much water or low cedorie oordieú. 
subjects consumed from a measuring jug which was available throughout the 
esqjerimental day. A blood sanple(5-10ml) was taken for plcistna levels of 
FOT and NorFOT. Plasma levels were measured by gas chromatography with 
electron-cc^jture detection (Nash et al., 1982).
3.2.4 Procedure
Before the trial proper, subjects spent two hours becoming famili2u: with 
the experimental surroundings, including using the VAS and the automated 
food dispenser. On day 1, 8 and 15 of each two week experimentad phase 
subjects arrived at the unit at 0850h having fasted from 2100h the 
previous evening. Subjects were weighed, and their blood pressure and 
pulse recorded. At 0900h subjects were given that day's capsule to take 
in the presence of the experimenter. Hourly VAS were conpleted 
throughout the day until isooh. At 1200h a 10ml saitple of blood was 
taken and lupil diameter measured using a plastic pupil gauge. Subjects 
spent the morning in a lounge with comfortable chairs where, aooorxiii^ 
to inclination, they could watch television, read, listen to the 
radio, or do paper-work. F*rcm 1300h to 1500h subjects had •to the
AFD \hich was in a separate room with a table and chairs. Eating
inplements were provided. Aliguots of food were obtained by pressing one 
the four buttons cai the AFD. This activated a pen recorder such that the 
time and nature of the food selected was recorded. Subjects were 
to select one item of food at a time 2ind finish eating that before 
replenishing their plates. At 1500h after a brief interview to determine
/
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the incidence of any adverse experiences, subjects were given enou^ 
medication to last until the next visit, with instructions to take a 
capsule with fluid at 0900h daily from day 2 to 7, and day 9 to 14 of 
each treatment phase. They were then free to go.
3.2.5 Data analysis
jfipod jnta)^: Qjnulative food intake in ]cilojoules(kJ) was at
ten minute intervals throughout the 2 hour feeding period on day 1, 8
and 15 of each treatment phcise. As some subjects ate ocxTsiderably more 
than others in the 10 minute intervals the data did not have a normal 
distribution. Wilooxon tests, appropriate for such a distribution, 
were performed at specific intervals to test for differences in intake 
between drug and plac^xi omditicxis. Aneü.ysis was carried out at 10, 20, 
30, 40, 50, 60, 70, 90, and 120 minutes. A Wilooxcxi test was performed
on the difference in the area under the curve for drug and placebo 
conditions, after transformation of the data trEpezoidal rule.
Subiective VAS ratings: Non-parametric statistics were used as subjective 
ratings did not adhere to a normal distribution. Hourly changes* from 
baseline in VAS ratings of hunger, mood, arousal, satiety and thirst 
were calculated, as were the change in VAS ratir^gs frxxn 0900h to ISOGti 
in nausea and gastric discomfort. Wilooxon tests were performed on the 
differences in the change from baseline between placebo and drug 
conditions. Differences in total area under the curve for placebo and 
drug conditicxTs were also euialyzed, after trEUTsformaticxi ïyy trepezoidal 
rule, and a Wilooxw test was performed oti the differences between the 
two conditions. To allcM for the possibility that initial starting
/
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scores on the subjective rating scales may have been different, a 
Wilooxon test was performed on the incremental area under the curve for 
both treatment ocxiditicMis.
Body weic^t; Having confirmed that there was no significant difference 
in the starting wei^t in each phase, analysis of variance (ANOVA) was
used with subject, treatment and time(day 1, 8 and 15) being the main 
factors.
Ogrrelatto— between__food intake/nlasma level of FXT and betwefyi body
wg3,qht/pj.aana— level— Qf__FXT: Pearson's correlaticxi coefficients were
calculated between food intake and plasma levels of FXT at 10, 20, 30 and 
120 minutes after access to the AFD. OorrelatiCTis between body weight 
and mean plaana levels of FOT/NorFXT were calculated confining all 
iDBasurement da^, and chi days 8 and 15 s^>arately. Changes in boc^ 
weight were cx5rrelated with changes in plasma levels of FOT/NbrFXr and 
acJditicHially percentage changes in body weight were correlated with 
percentage changes in plasma levels of FOT/NOrnCT.
/
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3.3 RE8ULTB 
3f3tl Body weight;
At the end of the two weeks- treatnient, the mean wei^t change on p l a c ^  
was a gain of 0.15kg(± o.35kg) while treatment with FOT resulted in a 
i»an weight loss of 1.07kg(±0 .25kg). Nine of the eleven subjects(8 1%)
lost weight during FXT treatm^. Of the two remainii^ subjects, one 
maintained his weight on m  While gaining 0.3kg cn placebo; the other
gained 0.25kg on FXT and o.4kg on placebo. Fig 3.1 shows the mean weight
changes(kg) observed during the first and second week of each treatment
phase. Analysis of Variance (ANOVA) yielded a drug-time 
Interaction [F(2,10)=3.78, p<0 .0 5].
3^3.2 Food intake and fluid intake.
■mere was a modest decrease in food intake following FXT on days 1(»=7.0, 
P<-0.04) and 8(»=7.o, p<0.02), which reached significance at one time 
point on each day(Fig 3.2 Table 3.3). There was no difference between 
the two groups on Day 1 5 .
/
86
“ri maxima kilojoule(kj) ijitake at lunch
EAY 1
Median
PlAtJKhn min 
nax 8435
DMT 8 DAY 15
FtXPXEijjng Median 4550*
m u  2126
max 6861
**p<0.04(day 1), *=p<0.02(day 8)
Subjects less thirsty a, rar at hourly measured thne points cn days
1. 8 and 15, significant differences in change scores fran 0900h to 
ISOOh were present on day l[w=9.o, p<o.03], and significant differences
in incremental area under the curve between drug and placebo were present
on daystv^.o, p<0.05] (Fig 3.3). An increase in fluid intake wa¿ seen 
on day 8(Pig 3.4), but this was mainly due to one subject drinkirq 
170Oj1, and the difference was n«i-significant[I^ 33.5, j^ -0 .5 7 5].
h 2 ^ — Subjective ratings
flO ^ l i n q s  Of huprier- No significant differences were found between m
and plao^ at hourly time points on Day i(Fig 3.5). On Day 8 subjects
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tended to be less hungry on FXT [W=53.5, p<0.07], while on Day 15 
subjects started the experimental day more hungry on FXT[W=42.0, p<0.02], 
scores on hunger ratings were similar by lunch-time (Table 3,4).
fe) of fuln^^sx There were no significant differences between FXT
and plac3^x} in the subjective ratings of fulness [day 1; W=l4.o, p<0.1; 
day 8; W=19.0, p<0.23; day 15; W=25.0, p<0.81]. Change scores (Pig
3.6), and actual ratings are shown (Table 3.4)
S)— Ratings of mood; Subjects did not show discemable changes in ratings 
of mocxi in response to two weeks treatment with F3CT. Table 3.5 shows 
hourly median ratings thrcuc^out the e3^)erimental days.
— af|d fVistric disocinfort: With redact to ayYTiig;^ i 
subjects on FXT rated themselves ais more drowsy during the 
morning on experimental day 8 [W=7.5, p<0.026] and day 15 [W^3.5,‘
p<0.01]. This drowsiness was not present at the pre-lunch rating at 
1300h. Analyses of rating scares (change from 0900 to 1500h) for nausea 
and gastric discomfort on day 1, and 8 showed no significant differences 
between placebo and FXT treatment. Subjects taking FXT started day 15 
feeling more gastric discxxnfort on F5CT cxmpared to plac:ebo [W^2.0, 
p<0.03]. Change scores from 0900h to 1500h were not significantly 
dlfferenct from plaoö» for either nausea [W=8.0, p<0.35] or gastric
discxaonfort [W=27.0, p<0.23].
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3.4 POMTlY V?y$ yatipcrs for huncrer and f b e l c w ^  f u l n e s s
K)DRS
0900h lOOOh llOOh 1200h 1300h 1400h
Placebo: 
fiav 1 median 65.0 70.0 71.0 79.0 80.0 11.0
Day 8 median 56.0 63.0 70.0 73.0 80.0 14.0
Day 15 median 56.0 59.0 71.0 75.0 76.0 9.0
Fluoxetine:
Day 1 median 61.0 74.0 78.0 78.0 82.0 19.0
Day 8 median 67.0 70.0 72.0 70.0 80.0 20.0
Day 15 median 61.0 68.0 70.0 78.0 80.0 16.0
Values are median absolute scores; O=not hungry, 10Q=very hungry 
HSMTIy  W  ra1;inqs for fulness during the experimental Hay
0900h lOOOh llOOh 1200h 1300h 1400h
Elaoebo:
Day 1 median 
Day 8 median 
I^v 15 median
ELuoxetine!
28.0 22.0 20.0 12.0 18.0 80.0
27.0 23.0 27.0 20.0 15.0 72.0
31.0 26.0 26.0 15.0 17.0 74.0
I^v 1 median 
Day 8 median 
I3ay 15 median
28.0 21.0 16.0 24.0 20.0 75.0
32.0 26.0 29.0 18.0 20.0 71.0
28.0 25.0 23.0 14.0 17.0 71.0
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Hourly VAS ratings for mood during the experimental day
HOURS
0900h lOOOh llOOh 1200h 1300h 1400h
Placebo:
Day 1 median 
Day 8 median 
Day 15 median
52.0 57.0 54.0 57.0 51.0 58.0
60.0 60.0 54.0 57.0 61.0 60.0
54.4 48.5 59.0 54.0 60.0 51.0
Fluoxetine:
Day 1 median 
8 median 
■Day 15 median
49.0 54.0 58.0 53.0 53.0 53.0
55.0 53.0 59.0 57.0 58.0 59.0
55.0 55.5 52.0 58.0 59.0 59.0
/
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3.3.4 Plasapa jevels
Mean plasma levels for FXT and N o r m  on Day 1 , 8 and 15 are shown in 
Figure 3.7. Statistically significant negative corrélatifs were found 
between food intake and m  plasma levels on Day 1 at 20 minutes 
(r-0.6), at 30 minutes (r=-0.7), at 60 minutes (r=-0.8) and at 120
***^ ^^ *'^ ^^  0.8) [t 4.18, p<0.01]. On Day 1 plasma levels of nCT were
low, mean 23.4ngAnl,range 9 - 54ng/ml. when measuranents for Day l, 8
and 15 were ocmtoined the correlation disappeared as plasma levels of m  
increased.
a a gma levels of m / n o r m  and body weinhh- plasma levels of
F X T / N O r m  tended to correlate inversely with body weight for all three 
»easurement days, ihe low corrélatif f  Day l (r=-0.2) reflects the low 
plasma levels that day. Corrélatifs between plasma levels of m  and 
body weic^t f  Days 8 and 15 approach significanoe(r= -0.59) for both 
days, with a lower body weicjit tending to be associated with a hiÿier 
plasma level of m .  m e r e  was also a trend towards a decrease in mean 
body weight to be associated with an increase in mean plasma levels of 
rar f  day 8(r=-0.39). Percentage mean body weight change and percentage
mean plasma levels of m  also showed a slight negative corrélatif f
Day 8 (r^0.31) and Day 15(r=-o.38).
PlQOd pipesfairP. pulse and pupil diamef^r
No changes in either ^stolic or diastolic blood pressure were observed. 
Treatment with m  resulted in a reductif in pulse rate of approximately 
three beats per minute, this was present f  day 8 [W-3.0, p<0.04] and
/
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day 15 [W=8.0, p<0.05]. Subjects taking FXT shewed an increase in pupil 
size of appi\j>dinately Inn by the end of treatment (Pig 3.8). This 
differaioe frem p l a o ^  was significant on day 8 [W=56.5, p<0.04] and day 
15 [W=44.5, p<0.01],
3t3.6 Adverse experiences
Table 3.6 gives a sunroary of adverse experiences reported by subjects at 
end of experimental Days 8 and 15. Drowsiness was r^Dorted by the 
greatest nurober of subjects (4 on Day 8) conpared to 2 subjects r^jorting 
drowsiness on Day 8 vAiile cti placebo. Stomach discomfort, r^xDrted by 
the next largest nurrber of subjects(3) was r^xjrted cxi Day 8 2nd  15 of 
FXF treatment.
Subjects self-reported adverse experiences during treatment
FUnXETINB
DAY 1 DAY 8 DAY 15 DAY 1 DAY 8 DAY 15
Drowsiness 2 4 2
Headaohe 3
Stomach discomfort 1 1 3 3
1 1 1 1
Oonoentration 1 1
Inscndnla 1 1
Tiredness 1
Beduoed desire to eat c h q 1
Sfciff lay ^  • 1
AwaJoeninci early 1 2 1 1 1
Feeling low 1
Anxiety 1
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3.4 DiaCDSSIOti
Hie prinaxy aim of this stuc^ was to quantify the putative anorectic 
activity of FXT in a normal, non-dieting population. For this purpose 
changes in subjective hunger, food intake and body weight were recorded
on three occasions during two weeks treatment with FXT and with matching 
plao^x).
The most robust finding was wei^t loss, in what was basically a 
non-overwei<^t healthy population. Reductions in food intake on 
ejq)erimental days were present, althou^ kilojoule intake on day 15 was 
too near placebo levels to be significantly different. The subjective 
VAS ratings shew that vhile FXT reduces feelings of hunger on day 8 of 
treatment, it does not appear to effect this variable strongly. This 
m i ^ t  suggest that FXT does not influence wei^t primarily throu^ 
affecting subjective hunger, a not too distressing finding considering 
the possibility that sensaticxis of hunger may not alwa>^ correlate to 
energy intaJee (Mattes, 1990).
While FXT showed an anorectic effect on Day 1 and Day 8 when subjects ate 
less and stopped eating sooner, by Day 15 of treatment, food intake had 
returned to placebo levels. Tolerance is not an appropriate explanation 
as wei^t loss accelerated in response to ccxitinued FXT treatment 
suggesting FXT is continuing to have an effect. A study of chreme 
fluoxetine treatment in rats, described in Chapter 5 sipports this view.
Serotonergic drugs can act both centrally cuyJ peripherally (Ceirruba 
et al, 1986), and it is possible that fluoxetine may act in part, 
like fenfluramine, by slewing the rate of gastric esrptying (Horowitz et
/
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al-, 1985) and reducing the freque^y Of s a »  neals (HiU & Blundell, 
1986a). A  »etabolic effect sued, as increased glucose transport inti 
nuscle (lümer et al., 1982) would contribute to weiejit loss and has been 
cited as a contributory cause for the weight loss in rats which continues 
after the anorectic effect of fenfluramine wears off (Burton et al., 
1981). Hewever we have no evidence to that m  was causing a l
l«=rease in metabolic rate, ani the loured pulse rate would argue
against such an explanation. PUrthemore, m  did not cause Increased
thermogenesis in a small number of mice (Yen et al., 1987).
m  »ay be having a specific eff«,t on food choice. In recent years the 
dynamics of 5-«r in »acronutrient choice and dietary self selection has 
ed cxnsiderable critical attention (Femstron, 1987; Blundell &
Hill, 1987b; «urtman, 1987; leathwocd, 1987a; Peters 6 Harpers, 1987).
m  animals, serotonergic drugs may selectively reduce o e  intaJee and
spare or increase protein inta)ce de^endir^ on the proffered diet (WUrtman 
Hhrtman, 1977, 1979). HCwever research ircreasingly suggests that a 
selection of factors such as test-time within the l i g h t - ^  cycle 
(lelbowltz et al., 1990; Ino s U ,  1990) and texture of offered foods 
(Booth S BaJœr, 1990) can exert influence on choice.
In humans, wurtman et al (1985) have reported that d-fenfluramine which 
«nhanœs 5-HT neurotransmission by increasing release from pre-synaptic 
neurones as well as blocking re-uptake (Garattini s Samanin, 1976), 
«duced Intake of CHO but not of protein. However, this effect on 0 »  
intake has been shevn ,to be differential in that d-fenfluramine reduced
nonsweet kilojoule intake, but did not have a suppressive effect on sweet 
foods (Goodall S Silverstone, 1988). while we did not examine in detail
the preferertOal effect Of Pxr in reducing CHO-containir^ foods, it is
/
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interesting to note that one subject r ^ r t e d  a decreased urge to eat
bread and other stardiy foods while on FXT. This point warrants further 
examination.
On all e)?)eriinental days, subjects felt less thirsty on EXT oonpared to 
plaodx) although fluid intake was not affected. One interpretation of 
this finding supports the role of learning and conditioned responses in 
feeding and drinking behaviour (Booth, 1981). Subjects drank 
approximately the same amount and would only alter intake if they became 
aware of physiological signals for dehydration. Alternatively, FXT may 
be exerting an unspecified physiological effect on the thirst mechanisms. 
The observed FCT-induced effects on subjectively reported thirst may be 
in keeping with the general "tonic suppression" effect of serotonin on 
selected brain functions, such as temperature, pain and feeding 
(Leathwood, 1987b).
This esqjeriment has shown that FXT possesses weight altering and sane 
anorectic properties as evident in a normal wei^t non-dietii^ male 
subject group. The next line of enquiry therefore centres on the activity 
of FXT in an obese group of subjects, includii^ women, and with a more 
detailed analysis of food intake throughout the experimental period.
/
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CHASTER 4
FUDQXETIME in QBESITÏ
4 > i nmaoDocnoM
Sane of the literature discussed so far strongly siçports the contention 
that serotonin is one of the neurotransmitters iirplicated in both the 
modulation of food intate (Blundell, 1977) and affective states 
(Asberg-Wistedt, 1989) 1986) It is not surprising therefore, that the 
anti-depressant fluoxetine was found to cause weight loss in some 
depressed patients (Cohn & Wilcox, 1985; Harto et al., 1988). C o m e  & 
Hall, (1989) carried out a double-blind six week study on d^ressed 
outpatients who lost weight while taking FXT (-0.874kg); however, no 
mention is made of starting weight status in these patients. In the 
previous chapter, an experiment involving normal weight non-depressed 
male volunteers was described which found a greater reduction in food 
intake and body weight during two weeks' treatment with FXT conpared to 
placebo (McGuirk & Silverstone, 1990). This experiment confirmed that 
subjects whose physiological and psychological status is free from the
effects of a d^ressive episode respond to fluoxetine, with weight 
loss.
/
The "side effect” of weight loss during clinical testing spawned 
experiments designed to examine the possible anorexic action of this 
drug in obese subjects. Work so far suggests that FXT is more effective 
than placebo in helping patients lose wei^t (Ferguson & Feighner 1987; 
levine et al., 1989 Fiji et al., 1991). The changes in body wei^t and 
reported changes in food intake and choice (Fiji et ed., 1991) indicated
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3 possible selective effect of RCT on tbese vsuriebles. The ’’selective** 
influence of serotonergic drugs on food choice has been a focus of 
ddaate in recent years. In animal studies, some esq^eriments have 
supported the view that modulation of 5-HT results in reductic»i of 
carbohydrate vhile the intake of protein is maintained (Wurtman & 
WUrtinan, 1977; Kim & Wurtman) , Ifcwever, critics of this view point out 
that such findings are influenced by experimental settings cuid 
conclusions need to be set within this context (Blundell, 1983; Booth, 
1987).
More recently, research has demcnstrated that while food choice may be 
influenced by the modulation of 5-HT, the r e ^ n s e  is not a sinplistic 
reduction (or non-reduction) in macronutrients. D-FF does not result in a 
honogenous overall reduction in carbohydrate, but is capable of 
reducing intake of non-sweet food, while having less of an effect on 
sweet food (Goodall & Silverstone, 1988). In addition, it is becoming 
clear that other factors, such as the texture of available foods can 
modify drug effects and food choice (Booth & Baker, 1990).
An obese p^xilation gualifies as a long-range target for drugs which 
have been shewn to modify appetite and body weight. Charting the body 
wei^t and dietary response to fluoxetine should provide information to 
add to current knowledge of response systems in obese subjects. Hill & 
Blundell (1990) have ^own that obese subjects respond, like lean 
subjects, to the potent effects of a d—FF/protein pre-load challenge and 
it is of interest to chart the effects of F3CT in obese subjects, as 
they will be a target group for treatment.
/
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Obese subjects taking part in the Fiji et al (1991) stucJy did not 
receive any instructions to change their diet yet all subjects receiving 
FXr lost weight, reduced kj intake for both meal and intra-meal 
oonsunption and were reported to consume less carbohydrate during 
"snack” ccxisuirption. However, these findings were based records of 
diary intakes and were not based on objective measures of food intake.
The previous chapter established that fluoxetine has the capacity to 
reduce boc^ wei^t in nomel wei^t subjects, cuid ccxiseguently, it Tnayop 
sense to focus on the effects of this 6njg in a possible target 
population - cbese subjects. The present study was designed to aHHyoge 
questions conceming weight, food intake and choice, mood status and 
feeding b^iaviour in obese subjects. Oorparisons were inaHo on the 
effects of cHie month treatment with fluoxetine to that of placebo in 
male and feanale subjects. The stuc^ uses objective meesures of food 
intate and feeding behaviour established in Chapter 2.
104
4*2 MEMDDS 
4>2.1 Subjects:
IWenty clinically obese subjects (10 men and 10 wonen) with a boc^ maco 
index(EMI) over 30 were recniited thrxxi^ hospital staff notice boartte. 
An initial ocnprehensive medicca examination including E.C.G., 
biochemical and haematological tests was carried out. The mean weight 
of the whole group was 97.4kg(S.D. 11.9kg, range 78.5-121.5kg and the
mean EMI 34(S.D. 2.5, range 30.9-38.8). The mean age was 33.4
years(S.D. 7.9 years, range 23-48 years). The mean EMI for the ten men 
and ten women was 34.1 and 33.9 respectively. All subjects gave written
informed consent and the study had the 2^ roval of the local ethical 
ocmnittee.
±iZt2— Design:
The trial was of a randomized, double-blind cross-over design. Subjects 
received either 60mg FJCT or matching placebo for a one month period,
followed by a minimum of one month wash-out, followed by the alternative 
treatment.
4.2.3
These included objective measurements of food intake, choice and 
feeding b^viour, body weight, pulse, blood pressure, pupil 
diameter, plasma levels of FXr and assessment of the subjective
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variables of hunger, satiety, mood, arousal, thirst, nausea and 
gastric disocmfort, using visual analogue scales (VAS). Subjects were 
asked to k e ^  daily diet diary records. Side effect profiles were 
ocnpiled by interview at the end of each experimental day. Approximately 
one year after the trial had finished, subjects received a follow^^jp 
letter and staiiped addressed envelope askii^ them to record their 
current weight in indoor clothing.
A^2t3tl Ft?Pd intake - experimental Unit
A choice of foods was available from a ten-channel automated food
di^)enser (AFD) adapted for e)q)eriinental purposes and as described in
Chester 2 (Fig 2 .1). In the adjacent room, a micro-conputer (Apricot
FI, Apricot, Halesowen, West Midlands) recorded food intake hy means
of a progranme (A leach, Ocnpular Ltd, Ewell, Surrey). Fbod
ocnpasition tables (Paul & Southgate, 1978) and manufacturers
information were used to determine energy and macronutrient content.
The aim was to be able to offer subjects varied familiar food-stuffs
%
from which they could choose either a variety of foods in small or large 
amounts (e.g. bread, meat or cheese, tomatoes and dessert) or foods 
such as cradkers, cheese, chocolate biscuits, dessert (Fig 4 .1).
Table 4.1 shows that foods offered were, for exanple non-sweet (cream 
crackers and hovis rolls) two foods in which carbohydrate had a higher 
percentage representation than other macronutrients(58.8% and 6 4.1% 
re^»ctively). TVo other non-sweet foods, chicken and ham, contained a 
high percentage of protein(67.8% and 71.1%) conpared to other 
roacronutrients. Flora is mainly fat(99.1%), the available Cheddar
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cheese also provided more fat(73.7%) than other macronutrients. The 
offered sweet foods, chocolate biscuits and strawberry desserts, 
contained both carbohydrate and fat, with a slight greater perx3entage 
of carbodyrate available in each (Table 4.1) Dessert apples (Golden 
Delicious) provided nearly all sweet carbohydrate (97%) while 
^»rovided 74.5% carbohydrate and 25.5% prxatein.
4.2.3.2 Food intake - diet diarif>g
Subjects were supplied with records to fill-in for daily intate other
than at the ejqjerimental Records were filled in every day for the
duration of the trial in both conditions. Subjects were asked to supply
information on amount e.g. teaspoons, cups, grams/ozs and supply brand
names of convenience foods consumed. Diet diaries were examined (blind
to condition) with a view to analyzing those which supplied adequate
quantities and descriptions of foods. The diet diaries of ten subjects,
six men and four women were considered fit for analysis in that amounts,
such as grams, cupfuls, etc were supplied. Food manufacturers of
%
brand name products were approached by letter with requests for 
nutritional information. Significant amounts of time were spent in
si^)ermarkets noting down nutriticxied informaticxi in notebooks. Asking 
subjects to bring in information on convenience foods they had consumed 
was considered unwise as this may have drawn undue attention to both 
energy and oonstitutent ocirponents of food.
The information from product manufacturers was used to build an 
additional data-base to a food aralysis progranine (Lifeline NutritionEd 
Services ltd). The data-base of the nutritionsd anedysis program
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'•cmp-eat'' was based on nutritional information published in Paul & 
Southgate, 4th edition (1978). In case of subjects sillying no 
measured portion size, reference was made to Crawley (1988) where "Fbod 
Portion Sizes” guidelines cire si;^ ]plied.
Pood intake for week one and week four of each phase was selected for 
analysis in order to determine initial onset of drug effect on food 
intake and to determine if the effect remained for the duration of the 
trial. Wiile still blind to condition, information in the form of 
^^®®^iptions and quantities of foods consumed in each phase was auTed.yzed 
for each day of the selected weeks. The sumnary print-out supplied 
information on total kj, grams and percentages of fat protein and 
carbohydrates. These sunmaries were later used for purposes of analysis 
once the trial was ccnpleted and subject codes broken.
4.2.3.3 Feeding b^iaviour
The observaticMTal methodology for feeding behaviour as described in 
ch^jter 2 was carried out for the duration of the trial. On each 
experimental day during the lunch meal, feeding bdiaviour was recorded 
using the portable Q>son HX20 microconpiter cind measurements of moai 
parameters taken as described. The meal was recorded via a discrete 
wall-mounted camera, onto video-tape, which was later viewed by the 
trained experimenter (Chapter 2, Figure 2.3). 12.5% of the video tapes 
were again viewed at a later date ky two observers to establish levels 
of inter—rater reliability, 8.5% of tapes were also again viewed by the 
experimenter to determine test-re-test reliability (Table 4.2). Overall 
percentage levels of agreement were 88.3% and 88.4% re^jectively. The
lio
reocxnnended goal o£ two observers viewing 20% of behaviours (Sackett, 
1978) could not be achieved: hcwever, the two observers did view 20% of 
tapes over a period of years while the methodology was being 
established. As in the earlier studies (Ch 2), h i ^  levels of 
agreement were obtained for all of the individuad means with the 
exception of the end of chewing episodes.
4
Takde 4.2 Inter-rater and test-retest reliability: percent agreement levels
MAMIPÜIATE BITE CHEWING OVERMIi %
a) IRR Start finish start finish start finish
X(S.d) 84.9(11.9) 75.6(14.9) 96.5(2.8) 94.8(4.3) 86.8(12.1) 56.5(16.6) 88.3(5.2 
b) Test R s-tast
X(S.d) 84.0(12.8) 67.7(22.5) 93.7(4.3) 91.7(4.7) 88.5(15.7) 52.8(22.2) 88.4(4.8
values are: a) percent agreement between two observers viewing 12.5% of tapes 
b) percent agreement for main observer on 8.5% of tapes, (reviewed)
■4i2t3t4__Qttigr mgaffMraftgnt.?
visual Anadogue Scades(VAS) (lOOmn lines) were used to assess hunger (not 
at adl hungry - hungry as I have ever felt); satiety (very empty - 
extremely full); mood (very depresed - very elated); aurousad (very adert 
- very sleepy); thirst(not at adl thirsty - as thirsty as I have ever 
felt); nausea (very nauseous - not at adl nauseous) and gastric
discomfort (do not feel any gastric discomfort - feel extreme gastric
Ill
disocmfort). Body weight in inck»r clothii^, pulse, blood pressure and 
pupil diameter were recorded on experimental days. A 5-lOml fasting 
sample of blood was taken to assess plasma levels of FXT and NbrFOT,
vduch was measured by gas dircinatography with electron-capture detection 
(Nash et al, 1982).
4.2.4 Procedure
Subjects underwent a familieurizatic« session prior to the start of the 
trial which involved using the AFD and becoming aware of what an 
experimental day would involve (no drug was administered or blood taken 
during familiarization). iXiring the trial proper subjects attended on 
days 1, 8, 15, 22 and 29 of each treatment phase, arriving at
approximately 0845h having fasted from 2100h the previous evening. At 
0900h a fasting blood sample (10ml) was taken, the medication 
administered, and v»ei^t, blcxxi pressure auid pulse recorded. VAS for 
hunger, satiety, mood, arousal, and thirst were completed hourly; VAS 
for nausea and gastric discomfort were completed at the begining and end 
of each esperimental ciay. Pupil diameter was measured at 1200h using a 
simple pupil gauge. The subjects spent most of the experimentaa day in 
the library of the unit which had comfortable chairs, a radio and T.V.
lunch was provicied in a s^jarate room cxaitaining the AFD. Subjects 
helped themselves to food from the ten-channel AFD by pressing their 
ocxSe number (previously given) and then removing the fcxxi from the 
machine. Subjects were asked to remove only the foods they wanted to 
eat immediately; they were permitted to return to the AFD for further 
fcxxJ as often as recjuired ciuring the meal. The time edlowed for lunch
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was csie hour, with subjects eusked to i^)end a miniinum of thirty minutes 
in the feeding roan. If they had finished by then they could return to 
the library in the knowledge that they had further access to the AFD 
until the hour was up. At approximately 1430h, subjects oonpleted the 
final VAS, were given a brief interview for the purpose of eissessing 
the incidence of side effects, received the following weeks' 
medicaticxi, v^ich they were requested to take each morning with water, 
and were supplied with new diet diary sheets. They then left the unit.
Recording of feeding behaviour: The observaticxial methodology described 
in cha^Tter 2 was employed to examine the effect of FXT on feeding 
bdiaviour. Video-recordings were taken via a discrete wall-mounted 
camera in the experimental laboratory and the behavioural recordings 
were made in the adjacent room using an Epson HX20 and monitor (Chapter 
2, Fig 2.3). Feeding bdiaviours recorded included: latency to 
manipulate, latency to bite, duration of mead., duraticxi of chewing and 
chewing rates. The observaticxial methodology is described in detail in 
Chapter 2. Subjects were asked to adlcw the mead to be video-taped in 
order to build files of control vadues for a possible future stuc^ of 
appetite in d^ressed patients. It was made very clear to subjects that 
this was not a compulsory part of the triad and they were free to say 
no. All agreed to be filmed.
4.2.5 Data Treatment
Food intake-experimental davs. Normal probability plots were drawn for 
kj data and adl other variables. Using standard tables, total food 
intaüœ kiloj ouïes ()g ), shewed no significant departure from normadity.
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Tests for periocVcarry ever effec±s proved negative. Data were anEdyzed 
hy aralysis of variance, suppleanented by tests of sirople m i n  effects 
and planned conparisais. T-tests were performed on the difference in 
incresnental area under the curve between drug and plac^x) ccxiditions on 
this variable, and those described below.
Diet diary data: Data from the diet diaries was logged and anedyzed as 
for the above.
Feeding behaviour: Observational data were tested for normality of 
distribution, following v^ich anedysis of variance was performed on edl 
measures with the exo^stion of latency to manipulate an vAiich Wilooxon 
tests were performed.
VAS ratings. T-tests were performed on the differences between the drug 
and placebo conditions both at selected time points and on the overall 
changes from 0900h to 1300h.
Body weicdit. Subjects vho had received F5CT as the first treatment, lost 
wei^t vhich was not regained by the start of their second treatment 
phase (plao^x>), consequently these subjects still sustained a treatment 
effect (Pooock, 1985). Vtei^t data were ti^refore analysed as for a 
between subjects design in vAiich the ten subjects vho had fluoxetine 
first were conpared to the ten subjects who had plao^x) first. Ansdysis 
of variance si:pplemented by tests of sinple m i n  effects and planned 
oenparisions were carried out.
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4.3 RESOI/TS
4.3.1 Body weicdit:
One month's treatment with fluoxetine resulted in all subjects losing 
weight; mean wei^t loss was ~3.26kg(s.d.±2.1). Seven of the ten 
subjects in the placebo group cdso lost weight; the total mean weight 
loss during placebo treatment was -0.66kg (s.d.±1.38). The difference 
between the two treatments with respect to weic^t loss was 
-2.601og(-2.98%). There were significant main effects of drug 
[F(l,18)=10.94,p<0.005]; days [F(3,54)=8.04, p<0.005] and drug x days 
interaction [F(3,54) =5.27, p<0.005]. Significant differences between 
treatment conditions were present on measurement days 15 [F(l,72)=10.24, 
p<0.005]; day 22 [F(l,72)=12.17, p<0.005] and 29 [F(l,72)=15.45, 
p<0.005](Fig 4.2). The difference between drug and placebo in 
incremental area under the curve was significant [t=-3.26, d.f.=18.0, 
p<0.01]. In additic»!, drug/placebo differences in auiea under the curve 
for percent body weight change were also significant [t=-3.12, d.f. 
18.0, p<0.01]. There was a significcuit correlation (PeEurson's 
correlation coefficient) between decreases in body wei^t throu^iout the 
treatment period and increases in plasma levels of FXT [r^O.725, 
tF=-2.78, p<0.05].
Analysis of wei^t change with respect to gender (n=5), showed greater 
weight loss for FOT treated male subjects (nF5) who lost -3.98kg 
(-3.69%) ccnpared to the -2.175kg (-2.27%) lost by FXT treated female 
subjects. Wei^t loss in the placebo ocxidition was -0.44kg (-0.44%) for
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mles, and -0.8kg (-0.93%) for females. A similar ansilysis with 
respect to percent body wei^t chcmge between male and female subjects 
was ncxi-signifleant.
Eleven subjects (55%), responded to the query on post-triad wei^t 
status. These conprized seven men and four women, all subjects had 
returned to approximate starting, wei^t, except one woman vho reported 
herself as 1.51^ below starting wei^t.
4.3.2 Food intate and choice;
Effects of FXI cm toted energy intaJee and on each of the three 
macrcxiutrients in the test mead au:e shewn in Figures 4.3/4.4 and Table 
4.3. FXT significantly reduced both overall kj intake [F(l,19)=7.22, 
p<0.05], and intake of all three macronutrients; fat [F(l,19)=4.81, 
p<0.05]; carbohydrate; [F(l,19)=9.50, p<0.01] and protein [F(l,19)=4.91, 
p<0.05]. None of the drug x day interactions were significant [maximum 
F-value found for total kj for fat, [F(4,76)=1.14, N.S]. However, tests 
of siirple main effects shewed that the reduction caused by FXT on day 1 
was not significant; [maximum [F(l,95)=1.46, N.S]. Total energy intake 
was significantly reduced on day 8 [F(l,95)=5.44, p<0.05]; day 15 
[F(l,95)^5.54, p<0.05] and day 22 [F(l,95)=6.21, p<0.05]. A t-test on 
the difference in incremental curea under the curve between drug and 
placebo was non-significant [t=-0.66, p<0.52]. FXT caused significant 
reductions in total grams consumed relative to placebo, main drug 
effects [F(l,19)=20.07, p<0.001], with significant reduction present on 
all days with the exception of day 1.
^^tiLe_4^3 Total and macronutrient intake on experimental days 119
Day 1 Day 8 Day 15 Day 22 Day 29
Total Icirx + 
Placebo
s.e)
3446(311) 3457(309) 3690(302) 3904(304) 3754(305)
Fluoxetine 3196(272) 2899(264) 3128(238) 3309(280) 3416(290)
Difference -250(308) -557(209)* -562(221)* -595(208)* -338(249)
% reduction -7.2% -16.1% -15.2% -15.2% -9.0%
Fftt:
Plac^so 1470(177) 1537(158) 1659(162) 1773(145) 1694(150)
Fluoxetine 1437(139) 1291(134) 1391(131) 1503(148) 1501(147)
Difference -33(165) -246(100)* -268(112)* -270(98)* -193(134)
% reduction -2.2% -16.0% -16.2% -15.2% -11.4
Carbohydrate:
Placebo 1283(108) 1283(105) 1396(116) 1440(112) 1375(113)
Fluoxetine 1204(102) 1115.3(100) 1170(78) 1210(101) 1224(112)
Difference -79(94) -167.7(81) -226(92)** -230(79)** -151(90)
% reduction -6.2% -13.1% -16.2% -15.9% -9.8%
Protein:
P l a o ^ 629(58) 652(61) 655(70) 698(76) 688(78)
Fluoxetine 557(47) 494(45) 568(49) 596(52) 597(47)
Difference -69(65) -158(40)** -87(57) -102(55) -91(70)
-11.4% -24.2% -13.2% -14.6% -13.2%
Values are means(+s.e.) with percentage reductiai. *=p<0.05; **=p<0.01
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Significcuit reductic3ns were present in fat intaJce on day 8 [F(l,95)=3.9, 
p<0.05]; day 15 [F(l,95)=4.65, p<0.05]; and day 22 [F(l,95)=4.71,
p<0.05]. a »  kj intake was significantly reduced on day 15
[F(l,95)=7.01, p<0.01] and day 22 [F(l,95)=7.22, p<0.01]; and
approached significance on day 8 [F(l,95)=3.85, p<0.06]. Significant
reduction in intake of protein kj was present on day 8 [F(l,95)=7.61,
p<0.01]. Tdble 4.3 shews the effects of FXT expressed, as percent 
reducticxi from the ocxitrol baseline. The mecui reducticxis, raimiatiad 
across the final four test days, were; fat, -14.7%; CHO, -13.8% and 
protein -16.3%. Intake of the .three macrcaiutrients, e>q>ressed as
percent of total kj intake was reasc»^ly consistent across both days 
and omditions(Table 4.4). Differences in incrementad areas under the 
curve were ncsv-significant [t=-1.12, p<0.28; t=-0.67, p<0.51; t=-0.64,
p<0.53 respectively].
TBjPle 4.4 Macronutrient intake estpressed as percent of total intake
Fat
Placebo
CHD Protein
Fliicacetine 
Fat CHO Protein
Cftv 1 42.6% 37.2% 18.2% 44.9% 37.6% 17.4%
m o 44.4% 37.1% 18.8% 44.5% 38.4% 17.0%
m v  15 44.9% 37.8% 17.7% 44.5% 37.4% 18.1%
CftY 22 45.4% 36.8% 17.8% 45.4% 36.5% 18.0%
EftY 29 45.1% 36.6% 18.3% 43.9% 35.8% 17.5%
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The division of total kj intake into savoury and sweet oonponents showed 
that FXr had ocnparable effects with a tendency towards reduction of 
savoury kj, [F(l,19)=2.82. N.S], and a significant reduction in sweet 
^  [F(1,19)=4.22, p <0.05]. Sweet kj intake was significantly reduced 
on day 15 [F(l,95)=6.46,p<0.05] and day 22 [F(l,95)=4.99, p<0.05](Fig 
4.5). Further breakdown of savoury and sweet kj into mcronutrient 
ocnponents shewed changes similar to the overall picture (Pig 4.6). 
Drug/plaoebo difference in incremental area under the curve for savoury 
[t=0.21, p<0.84] and sweet intate [t=-0.50, p<0.62], was 
non-significant.
Intakes (total intake, and sweet and savoury oerpenents) were analyzed 
with respect to sex (Fig 4.7). Main effects of sex [F(l,18)=6.14, 
p<0.02], day [F(4,72)=3.43, pcO.Ol] and a trend in drug effects were 
present [F(l,18)=3.06, p<0.09]. FXT reduced the inteOoe of savoury kj 
in male [F(l,18)=5.08, p<0.05], but not females [F(l,18)=0.05, N.S.] 
Subjects. Male and females had similcur intakes of sweet calories, and 
the effects of FXT were also similar (Fig 4.7).
4.3.3 Food diary intake and choice
Total kilojoule(kj) intake was analyzed for week one and week four. Diet 
diary macronutrient intaJee was analyzed for week cxie cxily. There were 
significant main effects of FOT on total kj intake[F(l,9)=35.5, P<0.001] 
and a significant drug by day interaction[F(6,54)=2.76, P<0.05]. 
Peroent reduction in mean overall intake in week one was -21.3% (78.7% 
of control). In week one, FXT reduced kj intaJoe on day 5 [F(l,9)=12.02,
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P<0.001], day 6 [F(l,9)=14.98, P<0.001] and day 7 [F(l,9)=6.14, 
P<0.05](Fig 4*8). Overall percent reductic^ in kj int2dce in week four 
was -16.1% (83.9% of control). Significant reductions in )cilojoule 
intake was present on days 26[F(1,9)=9.03, P<0.01], day 27 
[F(l,9)=7.59, P<0.01] and day 28 [F(l,9)=8.66, P<0.01]. Table 4.5 
shews daily energy intake [day 1 includes intake at the eogDerimental 
unit]: reducticMTs in intake were present frem day 1, and significantly 
different from day 5 onwards. T-tests performed oti the differences in 
incremental area under the curve for logged placebo and drug were 
significant in week one [t=10.55, p<0.001) and week four [t=9.28, 
p<0.001).
Analysis of macronutrient intake for week am  showed that FXT 
significantly reduced diet diary intake of all three maermutrients: 
[fat:F (1,9)=21.88, peO.OOl; CHO: F(l,9)=18.27, p<0.002; protein:
p<004]^ The drug by day interactiOTi terms approached 
significance for fat [F(6,54)=2.04, p<0.07] and prxjtein [F(6,54)=2.09,
p<0.07], but not for CHO [F(6,54)=1.82, p<0.11]. Significant
reductions were seen in fat intake on day 5 [F(l,9)=12.55, P>0.01],
day 6 [F(l,9)=12.84, P<0.01] and day 7 [F(l,63)=7.50, p<0.05] (Pig
4.9). Table 4.5 shews the kj energy intake of fat, CHO and protein 
with percent reductions frem placebo. CHO was reduced on day 5 
[F(l,9)=4.66, P<0.05], and day 6 [F(l,9)=15.76, P<0.001], and FXT
reduced protein on days 5 [F(l,9)=7.30, P<0.05], day 6 [F(l,9)=8.81,
P<0.05] and day 7 [F(l,9)=7.50, P<0.05] (Pig 4.9). Table 4.6 gives
reported intakes of macronutrients expressed as percentaiges of totad
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Tttjle 4*5 Daily reported intake(kj) in diet diaries(i^io)
VKX 1 DAY 2 DAY 3 DAY 4 DAY 5 DAY 6
Total fcj(x4^.e.)
£1 8536(1181) 6685(534) 7332(735) 8167(721) 8401(1047) 9088(1092) 7695(601)
EST 7527(961) 6222(680) 6469(784) 6948(831) 5448(670) 5791(636) 5584(601) 
diff -1010(576) -464(722) -863(457)-1212(1019)-2953(916)-3296(1105)-2111(381)
3 U S ^  -11.8% -6.9% -11.7% -14.9% -35.1% -36.3% -24.4%
£1 3802(529)
1221 3378(317)
i^tt. -424(361) 
% red ^-11.2%
3038(313) 3079(380) 4140(462) 3931(652) 4354(579) 3655(298) 
2863(304) 3005(492) 3495(530) 2096(242) 2468(287) 2494(238) 
-176(398) -74(536) -613(784)-1834(595) -1886(632)*-1076(264)
-5.7% -2.4% -15.6% -46.6% -43.5% -31.7%
^ItrtYfTAte;
£1 3516(614) 2452(191) 2886(357) 2545(300) 2929(322) 3821(632) 2926(348)
f2Sr 3007(374) 2467(307) 2170(253) 2484(449) 2105(306) 2305(308) 2216(251)
-509(345) +15(336) -717(238) -61(411) -672(309) -1516(623) **^68(301)
i_E6d. -14.5% +0.6% -24.8% -2.3% -28.1% -39.7% -24.2%
ggotein;
£i 1173(112) 
E2T 1154(101) 
difft -19(85)
% red. -1.6%
1053(128) 1103(159) 1467(151) 1276(180) 1322(224) 1255(139) 
1029(142) 1152(159) 1141(154) 869(148) 825(141) 842(120)
-24(162) +45(155) -325(158) -555(234)* -493(250) * -459(99) *
-2.3% +3.9% -22.2% -31.8% -37.6% -32.9%
DAY 22 DAY 23 DAY 24 DAY 25 DAY 26 Day 27 Day 28
T3iaUkLssBHxiy±s.e.)
£L 8435(682) 7563(989) 6873(928) 7189(637) 8249(926) 7952(1051) 9599(1569)
f2ff 7083(666) 7473(966) 6171(803) 8037(1510) 5689(727) 5606(735) 7093(825) 
Siiff.“1158(399) -189(1105) -839(985) +987(1716)-2917(817)**-2541(1051)*-2309(168** 
Juaidr “16% -1.2% -10.2% +10.5% -31% -29.5% -26.1%
Values are means (+s.e.). * =p<0.05; ** p<=0.01; *** =p<0.001.
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Makes. As in the food intake data recorded in the experimental unit 
(Table 4 .4 ), there is no evidence that m  had differential on 
mcronutxient choice.
4*6 Hacronutrient intake as peroentage of total intake
FIACEDO
Fat C»D protein
FLDQkETINE
Fat CH3 Protein
44.8% 40.0% 
46.0% 39.6% 
46.4% 33.5% 
50.3% 35.7% 
38.4% 38.6% 
42.6% 39.8% 
44.6% 39.6%
Values are mean percent (itfIO) .
Day 22 to day 26 are not significanUy different fran plaod» [maximum 
F(1,9)=2.52, N.S.). Significant reductions were present on day 26 
[F(l,90)=9.03, p<0.01], day 27 [F{1,9)=7.59, p<0.01] and day 28
[F(1.9)=8.66, p<0.01].(Fig 4.8).
/
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4*3.4 Feeding B^iaviour
Pseding rates esq)ressed either as kj/min or grains/min were by
FXr, main effects [F(l,19)=11.03, p<0.004] and [F(l,19)=10.46, p<0.004] 
reqjectively. ExaminaticMi of the data for individual days showed 
significant reducticais in chewing rate(kj/min) an day 1 [F[l,19)=4.39,
p<0.05], day 15 [F(1,19)=10.97, p<0 .0 0 1]. (Pig 4.10). Chewing rate
grams/min was significantly decreased on day 15 only [F(l,95)=9.32, 
^0.01], other days were ncxi-signifleant; e.g. day 1 [F(l,95)=2.96, 
N.S.]. FXT significantly reduced number of bites taken on day 15 
[F(l,19)=6.36, p<0.02] and day 29 [F(l,19)=7.10, p<0.02]. Other
measured variables: latency to start manipulation, latency to bite, 
meal length, kj/per mouthful emd grams/per mouthful were not 
significantly different from placebo (Table 4.7).
liDcal eating rates (grams/min) for male/female subjects were 
differentially effected by RCT. Main effects of drug [F(l,18)=21.7, 
p<0.005], and a drug X sex interaction [F(1.18)=4.44, p<0.04]. FXT 
slewed chewing (granv/min) in female subjects [F(l,18)=22.89, p>0.005], 
hut effects for male subjects were ncxi-significant [F(l,18)=3.26, N.S.]. 
Table 4.8 shows eating rates for grams on experimental days.
Table 4.7 Observed feeding behaviour in obese subjects(n=20) at a lunch
1 32
DAY 1 DAY 8 DAY 15 DAY 22 DAY 29
Latency to maniculatefseconds* iranqi»)
a  median 60.0(37-93) 59.0(37-173) 59.0(31-191) 51.0(33-87) 47.0(9-95)
median 69.5(18-167) 57.5(25-134) 56.5(7-122) 56.0(26-201) 56.5(18-148)
Latency to bitefsecsi
a  X(s.e.) 128(9.8) 130(12.5) 118(12.8) 121(13.1) 111(13.9)
X(s.e.) 126(11.9) 133(11.8) 128(13.1) 122(11.7) 119(11.7)
Lenoth of maalimin)
a  X(s.e.) 26.9(8.8) 24.1(7.3) 26.0(5.3) 28.4(10.4) 24.4(6.7)
Fxt X(s.e.) 28.1(10.3) 28.4(12.1) 26.9(9.7) 25.7(8.8) 23.8(6.8)
Rndser of bites
a  X(s.e.) 56(3.8) 54(4.2) 63(4.2) 60(3.9) 63(5.3)
X(s.e.) 56(4.9) 54(5.3) 52(4.8)* 51(3.7) 51(4.5)*
W/touthful
a  X(s.e.) 60.7(4.8) 65.9(6.4) 63.4(4.6) 66.9(5.1) 62.3(4.9)
X(s.e.) 58.2(3.6) 57.2(4.6) 63.9(4.3) 65.5(4.7) 73.9(6.3)
Grams/toouthful
a  X(s.e.) 7.4(0.5) 7.4(0.6) 7.4(0.5) 7.2(0.6) 7.2(0.5)
X(s.e.) 6.8(0.3) 6.1(0.5) 6.6(0.5) 6.8(0.5) 7.5(0.5)
Chewincr rates dn/chewincr time)
a  X(s.e.) 233.4(17.1) 249.4(19.5) 245.0(15.6) 240.5(15.7) 246.3(17.5)
X(s.e.) 204.6(12.8) 222.4(27.9) 199.5(13.2) 221.2(17.4) 246.4(17.3)
differencaefs.e.) -28.8(13.8) *-26.3(22.6) -44.7(10.6)***18.4(11.2) -5.4(11.4)
Cheiiinci raterorams/cheidiia time)
a  X(s.e.) 29.0(2.3) 28.5(2.4) 28.7(2.4) 26.9(2.4) 28.6(2.3)
X(s.e.) 24.6(1.8) 25.7(3.4) 21.3(1.7) 23.8(2.5) 26.3(2.5)
differenoefs.e.) -4.3(1.5) -3.4(3.3) -6.5(2.58)** -2.5(1.4) -2.9(1.2)
*®p<0.05; *=p<0.02. (no. of bites); **= p < o .o i; **<fc=p<o.ooi
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Table 4.8 Cbewing rates grams/tain for male and female subjects
DAY 1 DAY 8 DAY 15 DAY 22 DAY 29
Cbswinci rate (arams/chewinq time) for all subiects
£1 X(s.e.) 29.0(2.3) 28.5(2.4) 28.7(2.4) 26.9(2.4) 28.6(2.3)
X(s.e.) 24.6(1.8) 25.7(3.4) 21.3(1.7)** 23.8(2.5) 26.3(2.5)
Female chewina rates
£1 X(s.e.)% 27.1(9.6) 27.9(11.3) 27.3(10.8) 23.9(10.6) 26.3(9.5)
FXt X(s.e.) 22.0(7.6) 21.1(15.9) 18.4(7.4) 19.8(10.6) 23.3(10.6)
Male chewina rates
X(s.e.) 30.8(11.0) 29.2(10.3) 29.9(9.4) 29.6(10.2) 31.0(9.7)
FXt X(s.e.) 27.2(7.8) 30.4(11.9) 24.5(6.1) 27.7(9.9) 28.8(9.7)
*e= p<0.005.
No differenticd drug effects between male/female subjects were found for 
kj/min chewing rates.
4.3.5 Feelings of hunger and fulness
Subjects rated themselves as less hungry on day 8, [t=-3.01, p<0.03], 
and day 22 [t=-3.03, p<0.03], but incremental area under the curve was 
not statistically different, maximum t=1.25, p<0.23(Pig 4.11). On day 
1 [t=0.46, p<0.46], day 15 [t=1.25, p<0.23], and day 29 of EXT
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[t=>-0.06, 1X0.95] hunger ratings were not statistically different frxxn 
placebo. There was no strong or consistent association between feelings 
of hunger and kj consumed for either placebo [r=0.27] or FOT [r=0.28].
Subjective ratings of fullness were also affected by FXT, Data fran day 
8 and day 22 are shown in Figure 4.11; but differences (area under the 
curve) were not statistically different from placebo, day 8: [t=0.98,
p<0.34; day 22 [t=-1.04, p<0.31]. The trend towards higher subjective 
ratings of satiety was also present on day 29 [t=2.35, p<0.06]. If the
satiety data are displayed as change (within condition) from baselines at 
0900h to pre-meal ratings at 1300h, subjects showed a greater drop from 
baseline in feelings of fullness as the morning wore on (Pig 4.12). The
exc^>tion to this is day 8, when subjects shewed less of a move towards 
feelings of emptiness.
4.3.6 Other measurements;
There were no significant differences in mood ratings in re^xaise to 
continuing treatment with FXT [maximum t=-1.72, p<0.10] (Fig 4 .13).
Change scores from 0900h to 1300h in subjective ratings of
acsysal (sleepy-alert) showed non-significant increases in levels of 
drowsiness [maximum t=1.94, p<0.07], which tended to occur within 2-3 
hours of taking the medication [eurea under the curve: t=0.93, p<0.37, 
n.s. ]. (>i day 1, subjects on FXT rated themselves as more th^r!g^Y
oenpared to p l a o ^  [t-1 .8 2, p<0 .0 8]. On day 22 the opposite occurred 
with subjects rating themselves as less thirsty [change scores 0900h to 
1300h :t?»-1.96, p<0.06]. No differences were present on the other days
/
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[e.g. day 8: t^.47, p<0.64]. Subjects did not rate themselves as 
feeling either nauseated [t=-1.32, p<0.20] or sufferii^ frtxn gastric 
discomfort [t=0.83, p<0.42].
a p o d  pressure,___rxilse and pupil diameter; Mydriasis occurred in
response to F3CT treatment, pi^jil size increased by 0.87mn by day 29 
[^ "=2.54, p<0.02]. A slewing in pulse rate was evident by day 22 [mean 
-3.06, t=-2.39, p<0.02]. FXT did not affect systolic or diastolic blood 
pressure. Plasma levels of FXT and norFXT cure shown in Table 4.9
Table 4.9 Plasma levels of FXT and norm* (ng/ml)
m o CftY 8 CftY 15 CftY 22 D?VY 29
NorF3CT
0(0.0)
0(0.0)
111. 6 (±55.5) 
73.3(±33.4)
190.3(±59.8) 
131.3(±34.1)
246.6(±73.9) 
167.4 (±51.0)
263.1(±87.2) 
186.7(±52.6)
Vedues are means (+s.d.)
Adverse experiences: The incidence of reported adverse e}g)erienoes/side 
effects was lew. The most frequently r^»rted effects related to sle^ 
and ociiprised of early awakening anchor early pm drowsiness.
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4.4 DISCOB8IOM
Consistent with previous studies in obese animals (Yen et al., 1987) and 
humans (Levine et al, 1987; Fiji et al, 1991), FXT significantly
wei<ÿit during a one month treatment period. Strong stpport 
for the involvement of serotonin in body weight control has been 
demcxTstated in studies with other 5-HT agonists, noticeeüDly 
d-fenfluramine, with v^ich clinical efficacy has been maintained for 
periods of three months (Goodall et al, 1988, Finer et al, 1985) or a 
year (Guy-Grand et al., 1989). Long-term studies should be viewed as
if wei^t loss, vhich ccui plateau at cibout six mmths of 
treatment, is maintained under medicatici (Guy-Grand et eü.., 1989). 
•Hie reporting of wei^t gain on cessation of medication (Guy-Grand et 
1990) is perhaps an indication that chronic treatment may be 
considered as a possbility for patients whose health is affected \jy 
excess wei^t and vho need help in wei^t loss maintenance (lUmer, 
1990). Subjects who responded to requests for informatici on weight 
status had regained wei^t, and it is liJoely that those who did not 
re^xind were also at pre-trial level.
Ihe ideal of avoiding wei^t gain hcis been suggested as a goal of 
preventative medicine by Rissanen and colleagues, who have identified 
overwei^t(EMI >25.0) as a risk factor for eeurly disabilities, mainly 
related to the cardiovascular and musculoskeletal systems (Rissanen et 
1991). It may become acceptable to treat patients in order to 
avoid obesity developing as it is generally accepted that rates of 
recidivism are disheau±eningly h i ^  in obese patients.
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In this study, objectively measured reductions in total food inta)ce on 
experimental days confirms the anorectic potential of FXF in an obese 
population (Fiji et al., 1991). The anorectic response of normal 
weic^t subjects to FXT eppeared to d i m i n i s h  over a two week 
period(Ch^jter 3), 2ú.thou^ wei^t loss continued: in obese subjects 
reducticMTs in food intake cai FXT were present oti all experiment¿ü. days 
edthough the effects were less potent on day 1 and day 29. On day 29, 
subjects on placebo reduced their kj intake, thus decreasing the 
difference between the two ocxiditicxis. As the e3q>eriment it 
is possible to see an increase in energy intake in both placebo and FXT 
conditions during the esqjerimental meals. As this occurs in both 
conditions, it may represent a disinhibitory effect on intaJce over time. 
Irrespective of familiarization prior to the start of the triad, 
subjects graduadly consumed more as the month progressed. This raises 
the issue of hew r^resentative laboratory-based studies are of food 
intaüœ in the field. A study v^iich addressed this question was that of 
Obarzanek & Levit^çy (1985) vho asked e i ^ t  subjects (4 made, 4 femade) 
to k e ^  diaries extemedly for four da>^, Mexiday to Thursday, and then 
eat their food in a laboratory. Whereas significant between-subject 
differences were found, there wais no significamt within-subject 
differences between energy intake at hone and in the laboratory setting.
FXT induced changes in macroTutrient intake an experlmentad days show 
that firstly, adl three maermutrients were reduced 1^ FXT; secondly, 
there was no evidence that CHO intake is preferentiadly reduced cenpared 
to reductions in fat and protein; and thirdly, the observed reduction 
in savoury intadee is largely generated by the made subjects. As
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mentiOTied in the IntrxDduction, the issue of serotonergic modulation of 
macronutrient choice has been controversi2d  for a nuntoer of years. 
Animal studies have demonstrated that there is a conplex interation 
between serotonergic function and the regulation of preteiiVCHO intake 
(Femstrcxn & Wurtman, 1973). The modulatory role of 5-HT in 
macronutrient choice has been examined via pharmacological challenges. 
Animal studies shewing a selective suppressive effect of FXT and 
fenfluramine on CHO, with the concomitant sparing of protein (WUrtroan & 
Wbrtman, 1977), have not been clearly r^roducible in human studies. 
The present ciata provide no support for the protein-sparir^ hypothesis.
on
on
D-fenfluramine reduces total food intake with differential effects 
ncaTsweet/sweet conponents shewing a more potent st^ressive effect 
nonsweet foods than sweet (Goodall & Silverstone, 1988); the intake 
suppressive effects of d-fenfluramine occur both within and between 
meals (Hill & Blundell, 1986a). In addition, d-fenfluramine appears to 
enhance the satiating capacity of food, with the combination of d-FF and 
a h i ^  protein content (=54% of total energy), capable of suppressing 
later energy intake in obese subjects (Hill & Blundell, 1990). The 
general suppressive effects of FXT on all macronutrients including fat 
may be noteworthy, fat being both more calorific per gram than either 
CHO or protein and more capable than CHO at promoting storage of energy 
(Boozer, 1991). Short-term reductions or increcises in total 
intake have been achieved by manipulating the amount of fat in the diet 
(Lissner et al, 1987). Deliberate reductions in fat intake may result
energy
in
FXTpreference for lower levels of fat in the diet (Mattes, 1991), and 
could be used as an adjunct to dietary advice for individuals 
susceptible to weight gain.
/
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CSonsiderable effort is being esg^ended in finding an acceptable 
fat-mimetic vAiich has minimal energy but oonparable qusdity of taste 
(Drewnowski, 1991), and there is evidence that fat substitutes may be 
beneficial in reducing amount of fat consumed in the short term 
(Blundell & Burley, 1991).
Irrespective of v^ther or not it is possible to demonstrate a clear 
relationship between inacronutrient choice and neurotransmitter synthesis 
^  humans, there are nyriad extraneous influences on food choice, with 
culture (Bozin, 1976), exposure to food-stuffs in childhood (Birch & 
Marlin, 1982) and mood state (Geliebter & Aversa, 1991), being strong 
influences.
The effects of F7CT on savoury )dlojoule intake shows this effect was 
mainly male generated. Serotonergic drugs like d-FF have been shown to 
exert anorectic effects on nonsweet foods without being capable of 
reducing sweet foods in animals (Orthen-Gambill, 1985; Blundell & Hill, 
1989; lawtcxi & Blundell, 1989) and humans (Goodall & Silverstcxie, 1988). 
FX£ appeared to exert some marginally stppressive effect on sweet kj as 
the trial continues: whereas kj inta)ces for sweet foods were similar on 
day 1, by day 29 intake in the placebo condition had. risen, while 
intake of sweet kj in the FXT oonditicai remained stable. This effect is 
sli^t however, and overall, the pictures for sweet and savoury kj 
appear very similar (Fig 4.5). FOT has been shown to reduce 
pEdatability-induoed drinking in rats (Leander, 1987), and this aspect 
of possible functioning of FXT in humans deserves examinaticxi, possibly 
looking at highly preferred items or non-caloric pedatable foods. 
Another 5-HT agcxiist, d-FF did not reduce the perceived pleasantness of
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a sweet taste (Blundell & Hill, 1988). ihere is a stronger line of
argument for the role of endogenous opiates in palatability-induoed
eating, with esq^erimental evidence that the opioid receptor antagonist
nalinefene reduced the pleasantness of both the smell and taste of
palatable foods in human (Yeonans & Wright, 1991). in addition,
dopaminergic mechanisms may play a role in palatability-induoed
ingestion; dopamine is known to be s o l v e d  in reward mechanisns (Wise, 
1982).
energyThe subjectively reported data from the Diet_diary_reoords showed 
intake, subjectively r^rted, is si?3portive of laboratory findings of 
reduced intakes with FJCT. The data suggested that effective reducticxis 
in intake are present from about day five onwards. The less consistent 
pattern of reduction in week four may be due to "diary fatigue" as by 
the start of week four, subjects had been keying diarj^ for three 
weeks. With hindsight, it would have been more advantageous to ask 
subjects to k e ^  only weeks one and four. Diet diary record keeping is 
reported as being very variable with respect to accuracy in both 
and normal weic^t subjects (Lansky & Brownell, 1982; Prentice et al., 
1986; Lissner et al., 1989). Hulten et al(1990) examined reported 
intakes of overweight and obese women and using a urine nitrogen test 
for validation, found significant underr^rting of intakes. They 
suggest that dietary surveys should have an ind^jendent validation test 
as described, although as our obese subjects acted as their own 
oontrols, the main focus of interest here concerned differences in 
intakes between conditions, rather than absolute intake. Errors of 
p a r t i n g  in both conditions may not have remained stable however, and
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diet diary records should really only be viewed as cx>rrolDorative 
evidence, although sente studies have relied on them rather more 
conclusively (Fiji et al. 1991).
Diet diary r^x>rts of macrexTutrient intakes in response to treatment 
with FXr are si^jportive of the unit based findings, with all three 
macronutrients being reduced. As with the objectively measured feed 
intakes, there is no evidence from these subjectively reported data that 
FXT acts specifically to reduce a »  or spare protein as reported 
elsewhere (WUrtman & Wurtman, 1977; 1984). Once again, these diet
diary findings need to be ccxisidered with respect to differences between 
drug and plac^so ccxiditicxTs, as opposed to absolute mecisures of 
accurate intakes.
in Feeding behaviour in response to F3CT were similar to those 
seen with the 5-HT agonist fenfluramine described in Chapter 2, with 
reductions in meal size and eating rates, without changes in either 
latency or meal duraticxi (Rogers & Blundell, 1979). The portable 
observer methodology described in Chapter 2 has been suitable for 
analysis of data fron this particular subject populaticxi. The existence 
of a particailar eating style in the obese has never been conclusively 
established (Stunkard & K^lan, 1977), and it is more liJoely that 
there is a wide range of eating styles amcxig individtals, with 2i;^ )ects 
such as deoeleraticMi of rate being present in some individuals and not 
others, irre^jective of wei^t category (Westerterp et aU.., 1990).
/
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Ihe differential effects of F3CT on male/female feeding rate for gran/inin 
may suggest a greater sensitivity in females to manipulation of the 
serotonergic system in response to EXT. Serotonergic system status has 
been shown to be differentially effected 1^ w ei^t loss in and
female subjects. Wei^t loss in both depressed female patients (C3owen & 
Charig, 1987) and normal dieting female volunteers (Goodv/in et ad., 
1987), results in an increased prolactin re^xanse to an infusion of the 
5-HT precursor L-tryptophan. Uie authors suggest that the increased 
prolactin response, whicdi was not present in male dietii^ volunteers, 
indicated that dieting caused changes in the serotonergic system 
feamales, but not in males. A later study in dieting females,
in
in v»hich a
dopamine antagonist did not elicit the above increased prolactin 
re^nse, offered support for serotonergic modulation of this effect 
(Anderson et al., 1989). Reductions in total plasma pryptophan and the 
TOP/LNAA ratio were also found.
4.5 QOMnrnRTnMH
There is sane evidence fron this study that FXT is capable of modulating 
food intake and feeding behaviour in humans, ihe effects on food intake 
and choice are relatively noi-^jecific and do not si:9]port either the 
animal (WUrtman & WOrtman, 1977; Kim & WUrtman, 1988) or human 
literature (Fiji et al., 1991) that suggests that fluoxetine has a 
selective OiO si^pressive effect, while the intake of protein is 
maintained or increased.. It has been possible to establish that FXT, 
liJce d-FT reduces the rate of eating, viiich offers sane si:^ ]port for 
serotonergic modulation of the expression of feeding behaviour. The
/
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measured ciianges in subjective ratings are not robust, or
alternatively, it is possible that the instruments used, VAS, are not 
sensitive enough to detect chronic change. It may be that the subjects 
become tired of the task and althou^ being asked to consider each scale 
f^refully, may become jaded. The reductions in ratings of hunger and 
increases in satiety are marginal, yet cannot be ignored. Years of 
ejq)erimentatic»i with the more potently anorectic qualities of
amphetamine may have obscured our perspective on the role of marginal 
changes.
In order to elucidate seme possible mechanisms whereby FJCT exerts the 
changes in body weight and food intake, the next step was to examine the 
activity of this drug in cuiimals auid make oonparisons with other 
serotcaiergic agents, with ^)ecific reference to feeding and related 
bdiaviours.
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CHAPTER 5
ACUIE EFFECTS OF S-HT AGQKDSTB CM OGNBOMMATOBY 
BEHAVIOUR IN RATS
5.1 INTRODOCnOM
It has been suggested that the capacity to enhcuioe satiety may be a 
feature of serotonergic agents that contributes to their ability to 
reduce food intake (Blundell, 1986). The indirect serotonergic 
agonist, d—fenfluramine is similcurly capable of reducing sensations of 
ii^ viger (Hill & Blundell, 1988) and has been reported to increase 
sensaticais of fullness both before and during a (Hill & BluncJell,
1986a). However, FF may not noticeably effect ratings of satiety 
(Goodall & Silverstone, 1988); similcurly, fluoxetine does not result
in significantly increased levels of satiety ratine^. Observationed 
studies with animals have led to the hypothesis that fenfluramine may 
si^]press food intake by hastening the onset of post-prandicil satiety 
(Thurlby et al., 1983; Blundell, 1986; Kirkham & Blundell, 1986; 
Blundell & Hill, 1987). However, other studies of fenfluramine in 
animals suggest, in fact, that this drug m i ^ t  cilter satie^ 
processes (Montgomery & Willner, 1988; Neill & Cooper, 1988; Willner 
et al., 1990).
/
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The studies described in the present chapter examined the effects of FF 
and m*(as well as other serotonergic anorectics) on satiety in rats, 
using the characteristic sequence of post-prandial behaviours known as 
the "bdiavioural satiety sequence” (Antin et al., 1 9 75).
In the rat the offset of eating is followed by a short period of active 
behaviours such as locorotion, sniffing, and grooming, followed in 
turn by a longer period of resting (Antin et al., 1975; Smith & Gibbs, 
1979). This sequence of behaviours, initially described by Richter in 
1922, is normally seen only in animals that have consumed a caloric 
diet such as food pellets (Richter, 1922), a balanced liquid diet 
(Antin etal., 1975, Smith & Gibbs, 1979), o r a  sucrose solution 
(Montgcnery & Winner, 1988; Winner et al.,i990). The presence of the 
resting component of the sequence is not seen following the consunption 
of saccharin or weak sucrose solutions, or following sham feeding 
(Antin et al., 1975; Kushner & Mook, 1984; Montgomery & Willner, 
1988). The satiety sequence, and in particular, the occurrence of 
post-prandial resting, therefore seems to be a reliable behavioural 
correlate of a state of post-ingestive satiety.
Animal work reported so far has suggested that fluoxetine is able to 
reduce energy intake in the form of lab chew without changing feeding 
btíiaviour, although an early introduction of resting behaviour has 
been r ^ r t e d  (Clifton et al.,1989). Studies on the effects of 
fenfluramine on satiety have produced variable findings; 
dl-fenfluramine has been reported to have no effect cxi resting 
(Blundell & Latham, 1980) ; or to enhance resting (in non-deprived
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animals) (Blundell & Me Arthur, 1981). Other studies i^jort that 
dl-fenfluramine, on the other hand, produce a more disturbed profile 
of post-prandial behaviour; viiich includes st^ressing post-prandial 
resting after a weal of wet mash (Montgomery & Willner, 1988). This 
effect was present with d-fenfluramine, the active isomer (Hudscxi et 
al., 1989) as well cis with racemic dl-fenfluramine (Montgomery & 
Willner, 1988). There is, at present, no direct oonpeoriscai between 
the effects of fenfluramine and fluoxetine on behavioural satiety.
In the present study, five serotonergic agents were examined in order 
to compare the effects of FXT, FF and other serotonergic cuiorectics 
within the same experimental paradigm. In addition to FF and FXT, three 
other drugs studied: paroxetine, femoxetine and eltoprazine. Two of 
these dnjgs paroxetine (Hrdina et al., 1990) and femoxetine (Blundell & 
latham, 1978) are specific 5-HT li^ jtaOce inhibitors vhioh, like F3CT 
reduce food intake on acute administration to rats (Rasmussen et eil, 
1990). The hypophagic actions of fenfluramine (Neill & Cooper, 1989; 
Samanin et al, 1989) and of another 5-HT L?3take inhibitor, sertraline 
(Ijjcki et al., 1988) are known to be mediated by 5HT^ reo^ytors, and 
food intake is reliably decreased by directly acting 5HT^ agonists, 
such as m-chlorophenylpipera2ine(m-CPP), 
trifluororoethylphenylpiperazine (TTMPP), quipazine, and RU24969 
(Fuller et al., 1981; Kennet et al, 1987; Samanin et al., 1979). Wte 
have therefore also examined the effects on satiety behaviour of a 5HT^ 
agonist, eltoprazine (Schipper et al., 1990).
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5,2 MEIHDDS
5.2.1 Subjects:
Msde Lister hooded rats (National Institure for Medical Researxdi, Mill 
Hill), weighing approximately 300g were maintained on a 12h li^t-dark 
cycle (li^ts CTi at 0800h). Animals were housed singly, and exc^Dt as 
described belcw, deprivation times excluded, lab chow(Lillico, Herts.) 
and water were freely available. Ihe three esq)eriments were conducted 
throu^Tcut the months of spring.
5.2.2 Design; Experiments 1 & 2i
In e^q^eriment 1, two grot^ss of rats(n=12 per grot^) were tested under 
either fluoxetine(0, 1.5, 3 or 6mg/kg) or dl-fenfluramine(0, 0.75, 1.5 
or 3mg/kg) conditions. Treatments were administered in a 
counter-balanced order under single-blind conditions, eind there was a 
two-day interval between treatments. At the end of experiment 1 the 24 
animals were again divided into groups of twelve, matched for 
performcince cind previous drug treatment. A drug free period of one 
week followed after vhich E>q)eriment 2 commenced. Fluoxetine(0 and 
6mg/kg) was administered to the two grxxps of animals, in a 
oounter-balcinced order cind single-blind conditions, one groip receiving 
a 35% sucrose solution, v^ile the other received water.
Experiment 3; Three grcxps of animeds (r^l2) were tested following 
acute treatment with peuroxetine (0, 1, 2 or 4mg/kg), femoxetine (0,
2.5, 5 or lOmg/kg) or eltoprazine (0, 0.5, 1 or 2mg/kg),
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respectively. Ttie four doses of eadi drug were administered in a 
single-blind condition and in counterbalanced order, with a miniimm 
of 2 drug-free days between tests.
5.2.3 Procedure
Testing procedure was similar for aLLl three experiments with the 
exception of the starting time of es^jeriments 1 and 2 (approx. 1400h) 
cxanpared to between 1600h and 1800h for e^q^eriment 3. Animals were 
derived of food and water for 4hour prior to testing. At the start of 
the test, animals were presented with a a pre-^i^ed bottle containing 
a 35% sucrose solution, which was available for 40 min. The animals 
were observed for the duration of the test in a compact e3q)erimental 
room which housed the observer, the animals and the observational 
equipment. The observer sat approximately four feet away frtxn the 
cages and using the ke^ iiboard of a BBC microcomputer scored a behaviour 
every 15 seconds. The recorded behaviours were defined as: drinking, 
active, grooming, standing motionless, or lying down. These 
b ^ v i o u r s  were mutually exclusive. For the purpose of analysis the 
categories of standing motionless and lying down were combined to form 
the category 'resting behaviour'. The category 'active', vhich 
includes sniffing, recuring and locomotion, was used when none of the 
other categories was applicable; thus the use of this category Ho o c 
not in itself carry any implication of a stimulcmt effect.
/
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5.2.4 Drugs:
Fluoxetine HCL(Lilly, Indiane^lis, USA) and dl-fenfluramine 
HCL(Sigma, Poole, U.K.), paroxetine HCL, feraoxetine HCL(Ferrosan, 
S ^ r y ,  Denmark), and eltoprazine HCL(Di:?]har, Wee^, Ihe Netherlands), 
were dissolved in physiologicea scdine, and injected i.p., 45 minutes
prior to testing in a volume of Iml/kg. Doses were C2aculated as the 
sadts. Fhysiologic2d  sciline was used for the ocaitrol injections.
5.2.5 Analysis;
Data were analyzed by analysis of variance, supplemented by tests of 
sinple main effects and planned ooirpariscxis (Winer, 1971). Separate 
anedyses were performed for each drug and for each behavioural 
observation category.
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5,3 RESULTS
5.3.1 EXperiinent 1:
On ocHisuming a 35% sucrose soluticm, animals in the vehicle condition 
b^iaved in the e}^)ected feishic^, that is they first engaged in 
drinking, were active, groGniing bdiaviour, for a time and then rested 
for the main part of the ciDservation session (Fig 5.1).
Fenfluramine reduced sucrose intake, but only significantly at 
3mg/kg[F=(3,33)=75.5, p<0.001](Pig 5.1). In keeping with the 
reduction in intalce, fenfluramine caused a reduction in drinking 
bdiaviour frequency[F(3,33)=5.9, P<0.01], vhich was significant at 
both the 1.5 and 3mg/kg doses(Fig 5.1). Significant increases in 
aroondnarFf3.33=14.4. 29.9, P<0.001] and activity were evident, while 
resting was suppressed by all doses of fenfluramine, with the hipest 
dose of 3mg/)og causing great alteration [F(3,33=35.7, P<0.001] (Pig 
5.1). The resting profile may have been related to increased grooming.
FXT, on the other hand, caused a dose d^^endent decrease in sucrose 
intake [F(3,33)=10.3, P<0.001] and resulted in an early introduction 
of resting behaviour, causing a leftward shift in the satiety 
sequenoe(Fig 5.2). These effects are mainly dose d^)endent in the 
drinking, grooming, activity (not shown) and resting bdiaviours(Pig 
5.2).  ^ •
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5.3.2 Experiment 2;
As in experiment 1, v^icle treated anlm2ds cxxisuming the 35% sucrose 
soluticn, di^layed the bdtiavioural satiety sequence of drinking, 
active bdiavicxir, grocming and resting (Fig 5.1) FXT at 6mg/kg
suppressed sucrose oonsuirption [F(l,Il)=8.7, P<0.01], and advanced and 
enhanced post-prandicil resting in animals drinking sucrose (Pig 5.3). 
FXr caused a non-significant decrease in water-drinking vAiich was 
follcwed by initiad significant [F(l,176)=11.0, P<0.001] increases in
grooming; grooming then decreased. F)Cr(water-intake) animals showed a 
significant increase in resting behaviour, evident from 25 minutes 
onwards. Animals in the water only condition did not rest(Fig 5.3, 
right panel).
5.3.3 _Experiment 3;
Paroxetine, ferooxetine and eltoprazine all significantly reduced 
sucrose intake [paroxetine: F(3,33)=3.73, P<0.02; femoxetine:
F(3,33)=3.25, p<0.05; eltoprazine, F(3,33)=12.48, p<0.001] (Pigs 5.4,
5.5, 5.6, left panels). The effects of femoxetine and paroxetine
were slightly greater at the intermediate than at the highest dose, 
thou^ in no case were the differences between effective doses 
significant (Figs 5.5, 5.4, left panels).
Drug effects on the structure of feeding b^iaviour are shown in Table
5.1 and Figs. 5.4-5.6(middle and ri^t panels). As in experiments 1 
and 2, in the vdiicle condition, drinking behaviour constituted the
Table 5.1 Behavioural effects of paroxetine, femos^tine and 
eltoprazine
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Dosedng/kg) Drinking Activity GroGoiing Resting
DEug
Paroxetine 0.0 19.1 9.0 12.8 119.2
1.0 14.0 7.8 21.2 116.8
2.0 10.2** 10.8 12.6 124.0
4.0 12.6* 12.0 16.0 120.0
Feamoxetine 0.0 16.0 9.5 16.2 118.4
2.5 13.6 6.0* 10.5 131.2**
5.0 13.4 4.6** 9.5* 132.0**
10.0 16.0 6.7* 10.7 124.2*
Eltoorazine 0.0 14.1 10.6 18.4 117.2
0.5 8.5* 12.6 9.1* 130.4
1.0 5.1** 16.0 5.0** 133.9*
2.0 5.7** 26.6*** 5.7* 121.4
V E d u e s are the mean number of observaticxis of each type of 
behaviour(max*160). *=^0.05; **=p<0.01; ***«,p<0.001, 
significance of difference fron vehicle.
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main observed behaviour in the early part (evident up to about fifteen 
minutes into the session). (Fig S.4-5 .6 , middle panels). Drinkii^ was 
followed by a period of active behaviours (not shown) and grooming (not 
shown). These behaviours were followed by resting, the incaceasingly 
predominant behaviour in the second half of the sessiOTi(Fig 5.4-5.6, 
right panel).
Paroxetine dose-dependently reduced drinking time [F(3,33)=3.04, 
p<0.05], leading to an early termination of drinking [dose X time 
interactiai, F(21,231)=4.37, p<0.001]. These effeorts were 
significant at the lowest dose tested, which did not significantly 
reduce intake. Paroxetine did not significantly alter activity or 
grooming [F(3,33)=1.51, 1.38, N.S.]. The main effect of paroxetine 
on resting was also nonsignificant [F(3,33)=0.4, N.S. ], but there was 
a significant dose X time interaction [F(21,231)=2.4, pcO.OOl]: all 
doses increased resting in the second 5-min time period (Pig 5.4).
Femoxetine also tended to reduce drinJdng early in the session 
(^^9*5.5). In this case, the overall effect of the drug was 
nonsignificant [F(3,33)=1.3, N.S.], but there was a significcuit 
sijiple main effect of drug in the first 5min time period 
[F(3,264)=5.36, p<0.05]. Femoxetine reduced activity [F(3,33) =4.53, 
p<0.01] and advanced the offset of grooming [dose X time interacticai: 
F(21,231)=1.69, p<0.05; results not shown]. However, the most 
strUcing effect was an increase in resting b ^ v i o u r  [F(3,33)=3.97, 
p=0.02] in the second, third and fourth 5-min time periods (Pig 5.5).
/
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Eltoprazine, like paroxetine, caused a dose-dependent reduction in 
drinking [F(3,33)=7.95, p<0.001], vdiicii was significant at all doses,
including the IcMest, \4iich did not significemtly reduce inteUoe 
(Fig 5,6). The highest dose of eltcpreizine significantly increased 
[F(3,33)=5.25, p<0.01] at the e^g^ense of grocniing
[F(3,33)=5,29, p<0.01]. Frcm informal observaticxis it was «aav that
the highest dose of eltoprazine caused a marked stinulation of 
loocanotor behaviour. As with paroxetine, the main effect of 
eltoprazine on resting was nonsignificant [F(3,33)=2.54, N.S.], but 
there was a significant dose X time interaction [F(21,231)=2.11, 
p<0.01]; all doses increased resting early in the session (Pig 5.6).
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5.4 DISCOBSIOM
In this chapter it has been possible to examine and cxaipare the acute 
effects of fluoxetine and fenfluramine in ejqseriments 1 and 2, and in 
addition, to examine the ocmparative profile of three other 5-HT 
agmists cxn energy intake euxi on the satiety sequence (E>^ ]t. 3).
Experiment 1 shows that fluoxetine appears to differ markedly oonpared 
to fenfluramine with respect to the esqDressim of satiety.
Firstly f FXr treated animals showed a quite clear 
reduction in sucrose intake, and this was attended an early
introduction of the resting coirponent of the behavioural satiety 
sequence. Clifton et 2d.., (1989) have also reported that IQmg/kg of 
fluoxetine, given to free-feeding rats reduced meed size(chow) and 
resulted in an earlier introduction of resting ccnpared to vehicle. In 
the study reported here, the enheincement of the satiety seqiienoe is 
evident in all aspects, from the eeurlier off—set of drinking throuc^ 
to the early introduction of resting b^iaviour. In a further stxxfy not 
here, F5CT caused a dose-d^Dendent suppression of reuidom 
interval operant respcxiding and had a greater effect in a reinforanient 
lean schedule relative to a reinforcement-rich schedule (Willner et al. 
1990). These effects are similar to those seen with a decrease in food 
deprivation time.
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Similarly, the effects evicJent during the b^vioural satiety sequence 
have been argued to be similar to those seen with prefeeding or as a 
result of a reduction in the duration of food derivation Montgomery & 
Willner, unpublished observation). These findings eure si:?3portive of 
the suggestion that 5 ^  plays a significant role in post-prandial 
satiety (Blundell, 1986; Blundell & Hill, 1987). The effect of FXT in 
eeeriment 2, vhere animals were offered water as a ncai-caloric 
alternative to sucrose, is interesting, as FXT treated animals 
responded with a reduction in intiake, an enhanced profile of grooming 
vAiich parallels the response in the vehicle-sucrose condition, auid a 
resting response which is reduced coirpared to sucrose. The net effect 
is suggestive of partial satiation and offers further sipport for the 
role of serotonin in post-prandial satiety (Blundell, 1986, Blundell &
. However, the findings in Experiment 1 suggest that the 
effects of acute fenfluramine alter the process of post-prandial 
satiety, the chserved alterations in resting may be related to 
increased grooming. While the 3.0ng/kg dose of FF clearly reduces 
sucrose intake, and causes an early introduction of resting, the 
resting ocnponent stays sippressed conpared to vehicle levels.
In other studies fenfluramine hcis been reported to increase the resting 
cxmponent of the post-prandial satiety sequence (Blundell & McArthur 
1978; Blundell & latham, 1980). It is difficult to reconcile the 
findings of Experiment 1, i.e. altered resting, with enhanced 
satiety. Some authors have shown that the 1-isomer of dl-fenfluramine 
preferentially affects catecholamines and may have einti-dopaminergic
y
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effects (Invemizzi et al., 1986), and the observation that the 
increased loccniotor activity seen with some serotCTiergic agents may be 
associated with interactions of 5-HT/DA systems (Green & Grahame-Smith, 
1976).
In experment 3, although the effects varied slightly between drugs, 
the acute actions of all three agents in si^ressing COTisunption time 
and advancing the onset of resting are again ocirpatible with an 
enhancement of postprandial satiety (Antin et al., 1975; Smith & Gibbs, 
1979). In the case of paroxetine and eltoprazine, the behavioural 
changes were present at doses that did not significantly reduce the 
(joantity of sucrose consumed. This pattern of effects is very similar 
to that seen with fluoxetine (expts. 1 & 2) (Clifton et al., 1989). 
The effects of femoxetine in particular, which significantly advanced 
grooming as well as resting, were very similar to those of fluoxetine. 
As demonstrated in this chapter, fenfluramine is capable of altering 
the satiety sequence (Montgomery & Willner, 1988). The results of 
esqierimenit 3 suggest that fenfluramine is atypiced, with an effect 
dissimileu: to other serotcxiergic anorectics.
Experiments which have examined the anorectic profile of fenfluramine 
have established that it is possible to antagonize the anorectic effect 
of fenfluramine by nonspecific 5-HT antagonists, or by a lA' IB
antagonist, but not by selective 5-HT2 or S-HT^ antagonists, leading 
to the conclusion that the effects were most likely mediated by 
receptors (O'Nteill & Cooper, 1989; Samanin et al, 1989). The same 
conclusion was reached in a similar study of the 5-HT uptake inhibitor 
sertraline (Lucki, et al., 1988). At this stage the subtype of 
receptor involved in the anorectic action of endogenous 5-«r has not
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yet been determined. Most of the directly acting 5-HT^ agonists kncMi 
to reduce food intake, such as m-CPP (Samanin et al, 1979; Fuller, 
1981) TFMPP, quipazine, and RU24969 (Fuller, 1981; Hutson et al, 
1989; Kennet, et al., 1987; Samanin, 1989) are active, to varying 
degrees, at 5-HT^, 5-HT^^ and 5-HT^^ reo^tors. However, theirIB 1C
5-OT.. activity cannot be re^»nsible for the hypophagic effect, since 
^)ecific 5-HT^ agonists reduce food intake only at h i ^  doses, vAiicii 
elicit the 5-HT syndrome. At lower doses, 5-HT^ agonists increase 
fcxxi intake (Dourish et al, 1986; Sainanin, 1989) These findings 
iiiplicate 5-HT.„ and 5-HT-_ receptors in 5^iT-mediated hypophagia
Xd  XC*
(Hutson et al, 1989; Sainanin, 1989).
The finding that eltcçirazine enhanced satiety bdiaviour is of 
considerable interest in this context. In contrast to other 5-HT^ 
agonists, eltoprazine is an agcaiist at 5-HT^ and 5-HT^ receptors, but 
a 5-HT antagonist (Schipper etal., 1990) This inplies that aJLw
selective stimulation of 5-HT^ reo^tors may be sufficient to elicit 
the b^iavioural satiety sequence. A further inplication is that 5-HT^ 
receptors, possibly localized within the pauraventriculcur nucleus of 
the hypothalamus (Hutson et al, 1989) may be primarily responsible for 
mediating the hypophagic effects of 5-HT rptcike inhibitors.
In suntnary, these eaperiments have examined the effects of 
serotmergic drugs on sucrose intcikes cind the attendant effects on the 
b^iavioural satiety sequence. The results are consistent with the 
suggestion that fluoxetine mdV cause an eeurly introduction of, and 
enhancement of, satiety processes. This effect is shared by 
paroxetine, femoxetine and eltoprazine. Hcwever, fenfluramine does
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CHAPTER 6
CHROMIC EFTECTS OF FUX3XETINE AMD PENFUJRAMIME CM 
OQMBUMMATORY BEHAVIODR AM) BODY WEIGHT IN RATS
6.1 DgnODOCnOM
Acute modulatic^ of feeding psuiaineters by serotonergic drugs cG.lows us 
to examine initial drug effects, eind consequently to single out areas 
for greater focus. The combination of certain findings, namely, the 
ability of acute fluoxetine to advance behavioural satiety; the 
c^trasting ability of acute fenfluramine to alter behavioural satiety 
and the knowledge that a successful anorectic will be used chronically, 
leads to the question of measurable Icxig-term effects of these drugs.
The advantage of the serotonergic drugs as potentiad anorectics is that, 
ootpEured to anorectics available in the 1970's, serotonergic drugs are 
not reported to possess stimulant properties (Silverstone, 1982; 1987b). 
The focus of reseeuxh on these aigents hcis been geared towards 
determining the mechanism for their anorexic effect, with objective 
meaisures of food intake eind food-related subjective meeisureroents as 
variables (Goodall & Silverstone, 1988; Hill & Blundell, 1986a). Yet, 
it is equally important to examine the behavioural effects of 
chronicadly administered serotmergic agents, as observed changes in 
energy intEdoe related b^iaviour may be found to ocxitribute to the total 
effect.
/
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Ocnpared to fluoxetine, fenfluramine has been available as a 
prescription anorectic for a number of years (Munro & Ford, 1982) and 
fairly extensive trials are being conducted to the effects of
long-term use (Guy-Grand et al., 1989, 1990). More recently,
fluoxetine has also been shewn to decrease body wei^t in normal wei^t 
(McGuirk & SilverstOTie, 1990; in Chapter 3) and obese (Levine et ad., 
1987; Pilj et al., 1991; Chapter 4) human subjects. In the previous 
charter, evidence was presented that on acute administration,
fenfluramine and fluoxetine differ in their behavioural mecdicuiisms of 
acute anorectic acticxi. However, as the cliniced usage of anorectics 
necessarily involves chronic drug administration, the effects of chrxxiic 
treatanent in animals cire likely to be of greater relevance thein 
drug effects. The study described in this chapter therefore examined 
the effects of fenfluramine and fluoxetine on food intake, body wei^t 
and the behavioural satiety sequence in rats, during three weeks of 
daily treatment, and also, following withdrawal.
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6.2 MBmODS
6.2.1 Subjects:
Msde Lister hooded rats (National Institute for Medical Research, Mill 
Hill), weighing approximately 350g were maintained on a 12h light-dark 
cycle(li^ts on at OSOOh). Except as described below, they were housed 
singly, with lab chow(Lillioo, Herts.) and water freely available.
%
6.2.2 Procedure
B^iavioural testing was carried out between 1600h and ISOOh, following 
deprivation of food and water for four hours. The test consisted of the 
presentation of a bottle ocxitaining a 35% sucrose solution, which was 
available for forty minutes. Sucrose consumption was meEusured by 
weighing the bottle before and after the test. Aninals were cbserved 
for the forty minutes of the test session, using the method Hocrribod 
in the previous Chapter, for observing the satiety sequence: briefly, 
the animals (housed s^>eu:ately) were observed by the experimenter vho 
used the keij^ soard of a BBC microcoirputer to score a b^iaviour every 15 
seconds. Observed b^iaviours were: drinking, active, grocming and 
resting.
Drug treatment OGmuenoed after sucrose intakes in twice-^weekly tests had 
stabliized(six sessicxis).' Three groips of animals(nFl2) were 
following injections of fluoxetine (6mg/)og), fenfliiramine(3mg/kg) or 
SEdine. Doses were chosen, an the basis of previous studies in this 
laboratory, to produce a oonparable si:ppression of sucrose drihking(40%
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^raojnately) on acute administration. Starting cn the following 
day(day 2), all animals received twenty further daily injeoticns, eadi
animal receiving the same drug thrc^^ut, at the same time eadi day.
Five further intake and observatim sessions were recorded as
above, <xi days 4, 7 14, 17 and 21. Body weight and 24h chow
oonsunption were measured daUy. Fluoxetine treatment terminated cn d ^
21; fenfluramine was administered for a further three days at double the 
previous dose (at 6rog/kg).
«
Follcving the termination of drug 
administration, chow oonsunption was measured daily until day 32, and 
daily body weight records were maintained until day 29. Three further 
sucrose tests and sessions of behavioural observation were carried out 
blind after drug withdrawal, on days 24, 28 and 33.
6.2.3 Drucys
Dl-fluoxetine HCl(Lilly, Indianapolis, U.S.A.) and dl-fenfluramine 
HCl(Sigma, Poole, U.K.) were dissolved in physiological saline, and 
injected i.p., 45 minutes prior to testir^, in a volume of 1 ml/kg.
R^iological saline was used for control injections.
6.2.4 Analysy^y
Data were analyzed by analysis of variance, supplemented by tests of 
sinple main effects. S^>arate analyses were performed c»i data obtained 
during drug treatment (days 1 - 21) and data obtained following 
fluoxetine withdrawal (days 22 onwards). Observational data were
✓
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6.3 RESULTS
6^3 tl Observations during ciironic drucr treatroent
Analysis of boav weight data over the course of chronic drug 
treatment (Pig 6.1) shewed a significant main days effect 
[F(20,660)=3.84, P<0.001] and a treatment x days
interaction [F (40,660) =4.0, P<0.001]. While body wei^t increased
steadily in the control and fenfluramine groups, body weight decreased, 
over the first ten days of treatment, in the fluoxetine grxx?). Over 
the second half of the treatment period, the fluoxetine group maintained 
a constant wei^t differentied, relative to the other two grxx:^, of 
e^roximatl^ 15g, equivalent to around 4% of body weight.
The two drugs 2dso had different effects on chow intake (Pig 6.2) 
Fenfluramine significantly reduced chew intake an day 1 [F(2,33)=6.4, 
p<0.05], but had no significant effect thereafter. By contrast, 
fluoxetine did not reduce chew intake significantly on day 1, but Hjd 
cause significant reducticxis an subsequent days, particularly during the 
first two w e ^  of treatment [treatment main effect: F(2,33)=37.8, 
p<0.001]. When the data ajoe e}q)ressed as the difference in chow intadoe 
between control and drug treatment groups(Fig 6.2, lower panel), some 
tolerance to the hypophagic effect of fluoxetine is evident towards the 
end of the 3^week treatment period, auid there is a treatment x days 
interaction: [F(40,660)=3*2, P<0.001].
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Analysis of 'ths of sucrose intake data across the 6 G^sts(Fijij 6*3), 
revealed a significant effect of treatxaent [F(2,33)=24.1, P<0.001], and
a significant treatment X days interaction [F(10,165) =24.1, P<0.001].
Further analysis of simple main effects showed that there was no 
significant effect of days in either the vehicle or fluoxetine grxxps 
[F(5,165)=1.5, 1.7, N.S., respectively), but a highly significant
effect of days in the fenfluramine groups [F(5,165)=6.8, P<0.001]. On
the first day fluoxetine and fenfluramine suppressed sucrose intake to a 
ocnparable extent, the effect of fenfluramine being slightly, but not 
significantly, greater. Hie effect of fluoxetine remained hi^ily
significant cxi subsequent tests, with the exoepticxi of the final 
test(day 21). By contrast, the effect of fenfluramine was
non-significant on the second and third test(days 4 and 7), and while 
significant effects of fenfluramine were observed on the fourth and 
fifth tests (days 14 and 17), these were greatly reduced relative to day 
1. In the fenfluramine grap, intakes on test days 4, 7,14, 1 7 and 21 
were significanUy higher than day l[Mini2num F(1,165)=5.9, P<0.025]. On
the last day of fenfluramine treatment, when the dose was increased to 
emg/kg, suppression of sucrose intake was evident, but the effect was 
small and only marginally significant (Fig 6.3).
Differences were also apparent in the bdiavioural effects of the two 
drugs. Pig 6.4 summarizes the toted observaticxis of each of the four 
b^viours, across the six test days, and Pig 6.5 provides full t-imo 
cxxirses(five minute bins for for^ minutes) for day 1 (acute 
administration) and for day 14; the day 14 data are typical of those 
obtained in the 5(fluoxetine) or 6 (fenfluramine) tests carried out
/
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during chronic drug ¿Ktodnistxation. In all tests, onrtrol anined-s 
shewed the characteristic pattern of prandied b^iaviour: drinking was 
the predcniinEUTt behavicur at the st^u:^ of the session, followed by a 
brief period of groendng cind other active b^iaviours, superceded by 
resting, vhich was the predendnant behaviour in the seoend half of the 
session (Fig 6,5)^  Ihese ocxiclusicxis' eure sipported by significant linear 
trends, over the course of the forty minute sessic^is, for drinking and 
resting, and significant quadratic trends for activity and 
grooming(miniinum F( 1,231) =14.9, P<0.001).
On acute administratiOTi(dayl) fenfluramine reduced drinking, but 
increased activity and decreased resting (Fig 6.4). The full time 
CGurse(Fig 6.5, left panels) shews a decrease in drinking at the start 
of the sessicn, followed by a brief period of decreased grooming and 
increased resting, superceded by increases, relative to controls, in 
grooming and other active b^iaviour, at the expense of resting. After 
chrmic treatment, fenfluramine no longer decreased drinking; indeed, 
a small increase was apparent in the early part of the sessicn, vhich 
was significant in each of tests 3 (day?) to 7 (day 24). Fig 6.5, top 
right panel for test 5 (day 14) shews this increased drinking). In 
contrast to the late increase in grooming and decrease in resting seen 
with acute treatment, after chronic treatment, fenfluramine decreased 
grooming and increased resting(Fig 6.4). The time course data (Fig
6.5 , right panels) new reveed a sequence in which increased drinking is 
followed by near control levels of activity, but early off-set of 
grooming and increased levels of resting.
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In aocordanoe with the sucrose intake data, fluoxetine decreased 
drinking time; this effect was significant overall [F(l,33)=7.62, 
p<0.01), and within the forty minute sessions, FXT continued to 
suppress drinking behavicxar on all test days(e.g. Pig 6.5, top right 
is typical) Flua>cetine also suppressed grocming on 2U.1 tests 
[F(l,33)=14.8, p<0.001) (Fig 6.4, Fig 6.5, lower ri^it]. The incidence
of active behaviours was sli^tly decreased fluoxetine on day l(Fig
6.5, left peuiel). This reducticxi occurred approximately ten 
minutes into the session; the increases in resting are siirultaneous. 
levels of activity were increased c»i all other test days(Pig 6.4; Pig
6.5, i^jper r i ^ t  panel). Fluoxetine increased resting on day l(Fig 
6.4), by advancing the onset (Pig 6.5, bottom left panel). These 
effects were not seen on any of the subsequent tests: indeed, during 
chronic treatment, fluoxetine tended to decreeise resting behaviour(Pig
6.5, bottom right panel).
Observations after withdrawal of drug treatments
As noted, fenfluramine did not alter chow intake(other than on Day 1, or 
body weight. Consequently, withdrawal of fenfluramine had no 
significant effects on either of these measures (Pigs 6.1/ 2). Similarly, 
no significant effects on sucrose intake or feeding behaviour were 
observed in tests carried out 4 and 9 days following fenfluramine 
withdrawal (Pigs 6.3, 6.4).
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Follof/ing withdrawal from fluoxetine. Yxjdy wei^t recx^vered rz^idly, 
80% of lost wei^t being recovered within four days (Pig 6.1: 
treatnent X days interaction, [F(14,231)=13.5, p>0.001]. During those
first four days of withdrawal, chow intaJce in animeds withdrawn from 
fluoxetine did not differ from that of control animals. However, on 
day five after withdrawal, chow intake increased significantly above 
control level in fluoxetine-withdrawn animals, and this elevation was 
sustained until the end of the e5q)eriment(Pig 6.2).
Sucrose intaJce was non-significantly increased above control levels 
three days after fluoxetine withdrawal, but large increases were 
recorded after seven and twelve days of withdrawal (Pig 6.3). On the 
three day withdrawal test(day 24 from the steirt), drinking was increeised 
early in the session(not shown ) but the overall increase was not 
siginficant (Fig 6.4). Otherwise, the behaviour of 
fluoxetine-withdrawn emimcds was very similcu: to that chserved during 
chrcMiic treatment. Activity was increased, v^iile grooming euid resting 
were decreased (Fig. 6. 4). On subsequent tests(days 7 an5. 12)
drinking b^iaviour was increeised relative to ocxitrols (consonant with the 
increase in sucrose intake), but other bdiaviours were not significantly 
altered(Pig 6.4).
/
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6>4 DISCOSSlflM
The results in this stuc^ have sillied us with an acute '*winc3ow” on 
drug effects ccnparable to the data r^»rted in Chapter 5 and a 
follow-on analysis of chronic treatment effects. The findings support 
the value of continued measurement and observation past the point of 
drug withdrawal, particularly with a drug such as fluoxetine \diich has a 
long half-life and a potent metabolite.
«
In this stuc^ it was confirmed that tolerance to the effects of 
fenfluramine developed fairly rapidly, as described in other studies 
(Mennini et al., 1981; Rowland et al., 1982; Rowland, 1986; Rowland & 
Carlt(xi, 1986b). On acute administratiwi, fenfluramine reduced
sucrose intake by approximately 45% and caused a small (15%) in
overnight chow intake. These effects did not persist although 
fenfluramine continued to show seme nargineil si^pressicxi of sucrose 
intalce. The introduction of a hundred percent increase in dosing on the 
final day of treatment, while decreasing sucrose intake conpared to 
vtìiicle, also had a modest effect. Ifcwever, the observation that
fenfluramine did suppress 35% sucrose intake to some extent following 
chronic treatment is worthy of note. Withdrawal of fenfluramine did not 
result in any noticeable effect on aiy measured variable.
The administration of fluoxetine to either emimals or humans emd the 
measurement of the effecte, must be set within the context of the 
pharmacokinetics. Althou^ the h2d,f life of fluoxetine and 
nor-fluoxetine is considerably shorter in rodents than in humsuis (Caccia
/
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et al., 1990), effects of a single lOrng/kg dose are detectable up to 
48h later (leander, 1987). In the li^t of this observaticn, some 
potentiation of the effect of fluoxetine would be e)q)ected with repeated 
administraticxi, related to an increase in steac^ state plasna levels 
(Rcwland et al,, 1982). In the present study, sippressicxi of sucrose 
intake by fluoxetine was relatively constant over the first two weeks of 
treatment, but the si^ression of overnight chow intake increased up 
until day 6. It is often stated that tolerance does not develop to the 
hypophagic effect of fluoxetine(e.g. Rowland et al., 1982; Clifton et 
al., 1989). However, it is clear in the present data that, from day 6 
cxiwards, tolerance did develcp to the sv;ppression of o v e m i ^ t  chow 
intake. Fluoxetine ocxitinued to exert a significant hypophagic effect 
throughout the three week treatment period, but in the final week, the 
size of the effect was less than hadf that observed at 3 - 6 days. 
Exactly oorparable data were reported in an earlier study, in vhich the 
hypophagic effects of fluoxetine peaked at 5 - 8 d a ^  and decreased 
thereafter (Wong et al,, 1985). Ihe early increase in response to 
fluoxetine, vhich presumably reflects an increase in plasma levels 
rather than a genuine pharmacological sensitizaticxi(cf. Willner, 1989), 
tends to obscure the later development of tolerance. Ifowever, it is 
clear that a mode of tolerance does develop to the hypophagic effect of 
fluoxetine, provided that the assessment of tolerance begins from a 
point at \hich steady state plasma levels can be assumed.
Ihe loss of bo(^ weight in FXT-treated animals increased until 
approximately ten days into medication, when an undulating plateau of 
body weight was reached, which persisted until fluoxetine withdrawed on 
day 21. A  study with mice (Morley & Flood, 1987), showed a similar
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effect on body weight. In another study in ad lib fed lean and obese 
mice, Djbuc & Peterson (1990) found that initiad. si^^pressions in food 
intake and body wei^t in re^x^nse to three weeks treatment with 
subcutaneous FXT did not persist.
Animals in the present study lost approximatly 4% of bocfy wei^t, 
relative to controls. This figure was greater than that observed in lean 
humans following two weeks treatment with fluoxetine (described in 
Ch^Dter 3. Cásese subjects taJdng F3CT for one noith lost near to 4% (in 
absolute, not drug minus placebo terms), of body wei^t(Chapter 4). 
Weight loss in depressed patients treated with F3CT vary; an overview of 
some studies suggests about 2% (Kinney-Parker et al., 1989), and wei^t 
loss has been r^x>rted as being relative to starting wei^t with 
overwei^t patients losing the most, underwei^t patients showing no 
consistent trend, vhile normal wei^t patients have been reported to 
gain wei^t (Qrzack et al., 1990). D^ressed patients in these tri¿ü.s 
were taking doses of FXT ranging from 20mg to 80mg daily.
In this currently described animal stu^, withdrawal of fluoxetine 
resulted in a <^niamic wei^t ohange, with rapid re-gain over four days. 
There is a suggestion, from the ohow intake data, that fluoxetine 
treated animals were gradually showing a "claw-back” in intake, \Aiile 
still being significantly below vehicle and day 1 values. Five days 
after relecuse from fluoxetine, euiimals were ocxisuming significantly 
greater amounts of chow.
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It is possible that the wei^t gain following withdrawal frcxa fluoxetine 
results from an increase in metabolic efficiency. The fact that in seme 
circumstances fluoxetine can reduce boc^ wei^t in the absence of a 
decrease in food intake (Morley & Flood, 1987) suggests that fluoxetine 
may decrease metabolic efficiency, in addition to its hypophagic 
effect. It is also inportant to consider the role that homeostatic 
meohanisms will play in any sudden loss of either weic^t or appetite. 
Daily wei^t-reoords of fluoxetine treated animals may show that there 
is a stepr^ i6e response; with wei^t-loss, then plateau and recovery, 
then further wei^t loss.
The advantaige of continuing measurements is apparent in that five days 
after fluoxetine withdrawal, a prolcxiged hyperphagia was observed. This 
effect followed the period of recovery from w ei^t loss, and continued 
to the end of the experiment seven days later. Rebound hyperphaigia has 
not been r^xDrted in previous studies of chrmic fluoxetine 
administration (Rowland et al., 1982; Clifton et al., 1989), v ^ c h  used 
shorter withdrawad periods. Rebound hyperphagia could constitute a 
problem if it occurred in patients treated with fluoxetine. Obese 
patients have been shewn to initially regain more wei^t compared to 
placebo, vhen d-fenfluramine has been stopped after one year of 
treatment (Guy-Grand et al., 1990).
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Thus, the overall pattern could reflect two indi^)endent effects; a 
decxeeise in drinking rate and an enhancement of satiety. On the other 
hemd, both a rate decreaise emd an increeuse in resting ramiid egu2dLly 
reflect non-^)ecific sedative effects. In either ceise, the pzenounced 
increeises in resting in the ccxitext of non-significeuit or marginally 
significant decreases in intake suggest that the presumed relationship 
between post-prandial resting and post-^randial satiety should be 
treated with caution.
The behavioural effects of fluoxetine eiLso point in this direction. On 
acute administration, fluoxetine sli^tly decrecused drinking time, 
altered grooming emd advEUhced the onset of resting. These results, 
%ftiioh are consistent with a potentiation of the post-^randial satiety, 
are simileu: to those previously obtained following acute exiministration
of fluoxetine (Clifton et al., 1989; Willner et al., 1990), and were 
with femoxetine, paroxetine, and the 5-HT.cliso seen lA/lB agonist,
eltoprazine (Ghs^Dter 5). Hcwever, following chronic administration of
FXr. there was no Imger any evidence of an increase in resting. If
anything, there was a tendency for resting to be decreased or delayed. 
The major behavioural effect of chrtxhic fluoxetine, relative to control 
animals, was an increase in 'other active behaviours', largely at the 
expense of grooming. Thus, in contrast to the effect of acute treatment, 
following chrcxhic administration of fluoxetine there was no evidence of 
potentiaticxh of the behavioural satiety sequence, despite a persistent 
decrease in sucrose intake.
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These results illustrate an iiiportant principle; that the use of the 
behavioural satiety sequence as a marker for post-prandial satiety is 
inherently unreliable. Consider first the case of fluoxetine. The 
effects of acute fluoxetine are conpatible with enhanced satiety, but 
those of chronic fluoxetine are not. However, there is no evidence that 
any tolerance to fluoxetine develops between day 1 and day 7 (when the 
tendency for chronic fluoxetine to decrease post-prandial resting was 
clearly present; see Pig 6.4); on the contrary, the effects on intake 
intensify during this period. It follows that the dise^jpearance of a 
satiety-enhancing effect of fluoxetine during the course of the first 
week of treatment is unlikely to result from tolerance, and more 
probably reflects the emergence of some new effect that masks the 
expression of postprandied resting behaviour.
A similar argument applies, in reverse, to fenfluramine. The effects 
of chronic fenfluramine may be coitpatible with an enhancement of 
satiety (subject to the reservations espressed above), but the effects 
of acute fenfluramine certainly are not. However, the effects of 
fenfluramine undergo extensive tolerance with repeated treatment. 
Therefore, it is unlikely that the enhancement of post-prandial resting 
following chronic treatment represents the emergence of a new effect; 
more liJcely, the effect on resting was present all along, but was TnasVgd 
on acute administration by some other action of fenfluramine, to which 
tolerance must develop before aui increase in resting can be observed. 
In other words, vhen the behaivioural data are considered in the context 
of known tolerance and sensitization effects, it is apparent that both 
drugs could enhance post-prandiad satiety b^iaviour, both acutely and
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chronically, but that in some cirxxirnstanoes(acute fenfluramine; chrmic 
fluoxetine), other, as yet unkown processes, interfere with the 
e^^ressicxi of the satiety sequence.
Clearly, these conclusions require further investigation, particularly 
in relation to the identity of the putative 'masking effects'. A 
starting point may be provided ‘ by the observaticxi that systemic 
administration of the 5 - H T ^ g  agonist HJ24969 causes both hypophagia 
looorooter hyperactivity, but these two effects are by
different receptor mechanisms and at different neuroanatonical 
locations (Kennett et al., 1987; Hutson et al., 1988).
The purpose of presenting this analysis in detail is not primarily to 
draw conclusions about the actions of fenfluramine and fluoxetine, but 
rather to easphasize the general point that the absence of a tenporal 
shift in the behavioural satiety sequence cannot be used to infer the 
absence of drug effects on satiety processes. The presence of a 
tenporal shift would appear to provide stronger evidence in favour of an 
effect on satiety, thou^ clecurly, inferences drawn from such data 
should adso be treated as tentative until sipported by evidence of 
extensive similarities between the effects of the drug and those of 
non-pharmaoological manipulations such as pre-feeding. The inability to 
draw reliable conclusions from studies in \diich drug effects are not 
expressed siirply as tenporad shifts in the sequence of post-^jrandial 
b ^ v i o u r s  seriously limits the usefulness of this technique.
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7.2 Considerations of experimental m e t h o d o lo g y
It was ocx^idered iroportant to take cbserver measurement methods out 
of the laboratory and into field settings for a varied of resusons.
behaviours, particularly feeding, are less likely to be 
subject to demand characteristics if occurring in naturalistic 
settings (Rolls & Heatheringtoi, 1990). Secondly, by developing a 
portable methodology, it becomes fecisible to consider resesuxii of a 
more oonplex nature, e.g. patients suffering from 
neuroleptic-induced obesity (Silverstone, 1983; Silverstone et al., 
1988) may show gradual changes which would be evident under 
longer-term observatiŒi. Alternatively, the reported changes in 
^petite and body weic^t vAiich may occur in patients suffering from 
major depression have been viewed largely as diagnostic criteria 
(DQl-III-R) as opposed to valuable indices in themselves. Yet 
changes in cppetite and bocty wei^t have been shown to be associated 
with greater severity of d^ression (Paykel, 1977) and 
symptoms of anxiety, retardation and cognitive impairment (Casper 
et al., 1985). Additionally, Nelscxi et al. (1984) found that post 
treatment eppetite symptom severity (rated with the Hamilton 
Depression Rating Scede), correlated with treatment re^xsnse to the 
antidepressant desimipramine during a three-week treatment period. A 
prospective study, using a combination of ward-based observer 
methodology and interview/rating scales, may elucidate the nature of 
the relationship between changes in mood and appetite and cleorify 
the extent to vAiich improvement in appetite may be used to predict 
improvement in affective state, and hew these changes eu?e expressed.
/
194
Observer methodology has found VEduod uses in varied clinical 
settings, such as categorizing self-injurious behaviour in 
mentally-handicapped and autistic (Goodall & Corbett, 1982), or 
hyperkinetic (Hutt & Hutt, 1970), children. Additiorally, 
mc3ther-child interactions have been the focus of observation (Olvera 
et al., 1990). The experimental questions in this thesis resulted in 
work being carried out in a variety of settings, and upon different 
subject grxx^. of the total of 64 subjects vho took part in the 
ocnplete series of studies, 53 subjects were observed during lunch, 
ocnprizing 20 (37.7%) normal, 20 (37.7%) obese, and 13 (24.5%)
psychiatric patients, thus establishing the flexibility of the 
methodology.
The initial validaticxi of the observational methodology confirmed 
previously r ^ r t e d  differences between the actions of
d-fenfluramine and d-airphetamine (Rogers & Blundell, 1979). The 
behavioural and anorectic effects of fenfluramine were also
ocxifirmed as residing in the d-isomer (Garattini et ad., 1986). As 
previously reported, d-fenfluramine reduced eatii^ rate, while 
d-airphetamine reduced the time spent eating. In addition, FXT also 
reduced eating rate selectively. The action of d-FF auid FXT in 
slowing eating rate, while holding the structure of the 
intact, may possibly be considered of therapeutic advantage, as 
the strategy of slewing rate of consunption is part of behavioural 
modification treatment in obesity. In keeping with this, it ryxd d  
be beneficial to let female patients know that FXT will reduce the 
amount consumed by slowing eating rate, thus actirg as an adjunct to 
behavioural modification.
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Additional support for using field data to cxanfirm laboratory-4>ased 
findings cxmes frcm diet diary data. Findii^ reported here
(Chapter 4), and by others (Obarzanek et al., 1985) suggest field 
data collected in this way parallel laboratory-^aased intake. 
Hcwever, diet dairy data frcm Chapter 4 suggest that asking 
subjects to keep records for Icaig periods of t-iino is 
counter-productive. Apparent massive swii^ in intake are 
by records for week 4 of diet diary intakes (Pig 4.8), yet perhaps 
this is more likely to be evidence of diary-keying fatigue as 
opposed to real changes in intake.
By examining placdDO data paLy from normal wei^t and obese male 
subjects frcin Chapter 2, Chapter 3 and Chapter 4, some ccnparison 
of both intake and feeding behaviour data is possible. There is no 
ind ication from the lunch—meal food intake or feeding bdiaviour 
recorded on experimental days, that the obese male subjects (Chapter 
4) either coisume more than their lean counterparts (Chapter 2, 
Chapter 3), or exhibit faster eatir^ rates than normal volunteers 
(Chapter 2). Table 7.1 shews both food intake and feeding rate data 
frcin obese and normal wei^t male subjects recorded under 
conditions.
1/
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Tabi« 7.1 Eating in noxnal «eight (Ch 2) and obese (Gh 4) men^
Kilojoules Grams g/knin kj/knin
Placebo conditicxi
WOtmal (rr=l2) 4644(453) 582(52) 39.5(3.7) 318(34)
Obese (n=10) 4074(281) 473(49) 30.8(3.5) 260(19)
^edues are means (±s.e.)> Vedues for normed subjects represent 
one observation. Values for obese are the mean (±s.e) across the 
five test days.
Normal wei^t subjects taJcing part in the FXT study in Chapter 3 
«ere not video-taped, so eating rate could not be calculated, but 
their median energy intaJce on the three placebo test days «as 
5400kj, 4877kj and 4914kj respectively [mean; 5064]: some 20% hic^ier 
than in the obese subjects.
It appears from these placebo data that the obese male subjects may 
actually consume less than lean subjects in these triads. Hc«ever, 
obese male siA>jects increase their intaJce across each experimental 
day (as do obese fenale subjects), «ith a finad test day intake of 
4378kj cn day 29. This amounts to an increase of 13.5% (589kj) 
relative to day 1 inthke (3789kj), but even so, these finad intakes 
remain lo«er than those recorded in normal-«ei^t subjects. 
Consequently, the indication from the data is that the intake of the
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obese males may actually be less than that of the lean males. 
Ocnparison of diary intake is not possible in this instance. As 
discussed in Chapter 1, laboratory studies of single meals have not 
consistently demonstrated that obese subjects either consume more, 
or possess different eating behaviour, than lean controls. 
(Spitzer & Rodin, 1981; Kissileff, 1989). There is some 
indication that obese subjects actually reguire more energy relative 
to lean counter-parts, in order to maintain their greater 
wei^t/lean tissue (Lean & James, 1988; Welle et al. 1992).
Interestingly, the intake data for both day 22 and day 29 begin to 
approach placebo intakes for normal males (Table 7.1) in Chapter 2, 
and the mean of three day intaJoes of 5064kj in Chapter 3. De^ite a 
familiarization day, obese subjects may start the triad with a 
si^pressed intake due to inhibiticxi, from v^iioh a gradual release 
occurs as the tried progresses. Support for this comes from the 
observation that increases in intcike across esperimentad days aigr> 
oocured in the FXr oonditicn.
7,3 Serotonin - mediated effects on food intake and body weight
The objective of the fluoxetine study in normad volunteers (Chapter 
3), was to examine the anorectic potential of this 5-HT reputake 
inhibitor in a headthy, ncxv-depressed ncn-dieting groip). CXir 
findings of maurginad' reductions in food intake, and small 
unsustained adterations in ratings of hunger and satiety over a two 
week FXT treatment period were aoconpanied by reasonable reductions 
in boc^ weic^Tt of approximately 1.5%(±0.37%).
/
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The obese group of subjects (Chapter 4), treated with FOT for a 
period of one month, responded with a more cleai^-cut anorectic 
effect, shewing reductions in food intake, relative to placebo on 
most treatment days. Again, the measured ratings of both hunger and 
satiety in respc»ise to FOT and relative to plao^x>, were marginally 
changed and shewed some evidence of reduced levels of hunger and 
increased levels of satiety, mainly an day 8 and day 22 (Fig 4.11, 
Chapter 4).
However, significant reductions in body wei^t were occurring 
throu^Kxit the treatment period vAiile concurrent subjective ratings 
of hunger and satiety appeared marginally changed. This may 
indicate that there are disassociable aspects to the effects of FOT 
on body weight and feelings of hunger and satiety. E>^)eriments in 
Chapter 3 and Chs^iter 4 shew that fluoxetine is CE^)able of reducing 
body weight and may reduce food intake by mechanisms which do not 
primarily effect the above ratings. By the end of one month's 
treatment with FOT both the experimental data from day 29, (-9.0% 
relative to plac^x>) and the mean diet diary intake from week four 
(-16.1% relative to placebo), suggest that food intake is still 
being reduced by FOT (edthou^ reservaticxis about accuracy during 
the last week of diet diary records need to be borne in mind).
One potentied e)q>lanation of these discrepancies is that FOT may be 
capable of ¿dtering body-weight set point (Keesey, 1986; 1989). In 
this case, the observed reductions in food intake would constitute 
secondary mechanisms brought into play to support the new lowered
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bcxJy weight (Stunkard, 1982). There is clear evidence of continued 
weight loss (Pig 4,2) running concurrently with less potent changes 
in intake (Pig 4.3) and subjective ratings (Pig 4.11), evidence of 
both a dissociation, and the possible emergence of some tolerance to 
the anorectic effect of FXT. However, it may be necessary to 
consider the possibility that Visual Analogue Scales, while 
sensitive enouc^i to detect absolute charges in subjective ratings, 
are not sensitive enouc^ to detect more subtle changes which may be
, occurring within either of these areas of feelings of hunger and 
satiety.
Nevertheless, the animal data in Chapter 6 are supportive of the 
view that FXT may induce alteratic»Ts in bocfy wei^t set-point. Boc^ 
wei^t in FXI treated animals remains suppressed relative to both FF 
treated animals and controls (Pig 6.1), while chow intake, 
althouc^ still below OOTtrol, starts to climb towards control levels 
fron day seven onwards (Pig 6.2). On cessation of FXT treatment, 
body weic^t increased several days prior to increases in chow 
intake, shewing a possible dissociation of the effects of FXT on 
body weight and intake.
Cessation of treatment with FXT resulted in a rapid weight regain in 
animals, and most likely wei^t regain euLso occurred in most 
RCT-treated obese humans. It may be advisable to consider long-term 
drug treatment to sustain a reduced set-point, and unfortunately, 
the gradual increases in food intake seen in both the placebo and 
the F3CT conditiais may indicate attempts to defend original boc^
/
200
wei^'t. It has also been noted that long- term treatment with FXT 
does not ^]pear to result in sustained bcxiy w ei^t loss (Darga et 
al., 1991).
Of oGurse, caritics of set-point theory would prefer greater 
darificatiai about the meohanisms v^ich purportedly regulate Yxydy 
weic^t, hody fat and lean tissue. Vanitellie & Kissileff (1990) 
suggest that with the enormous variation in fuel supply and
reserves, there is no biological cause for set-point regulation. It 
is also argued that bodily demand for fuel, oti i^iich survival may 
d^jend, should take precedence over a regulatory set-point 
mechanism, vhich could perhaps be counter^regulatory for survival. 
These arguments are countered by the suggestion, by Nioolaidis, of a 
cxaic^jtually more flexible regulatory mechanism which is 
'*hcroeorhetic”, allowing for dynamic conponents of both ascending 
and descending movements within the regulated system (Stallone & 
Stunkard, 1991).
The examination of the effects of FXT on food selection in the 
obese, is not supportive of the work of others (Fiji et al, 1991) 
vhich r^»rts a ^)ecific carbohydrate sippressive effect for this 
drug. In the study of Fiji et al. (1991), unfortunately only 
subjects' self reported int2doe was assessed as opposed to the 
objective data gained vhile subjects attended for lunch. AnEdysis 
of the diet diary data in Chc^pter 4 was based on total intsJce and 
macronutrient intakes, and did not differentiate between snaoiks and 
meals, eis these may be determined either by manufacturer criteria 
or subjective preferenoe. The reduction in inteOoe of protein is not
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supportive of a protein-sparing effect for F5CT, this may not be 
advantageous, as the oonbination of protein and d-fenfluramine have 
been shown to possess greater anorectic potency relative to 
d-fenfluramine vhen paired with CHO (Hill & Blundell, 1990). If, in 
addition to the generally si^jpressive effects of rar on other 
macronutrients, the effects FXT on si^ression of fat intake are 
validated elsewhere, this could be seen as a valuable attribute for 
this dnjg, for reasons menticxied before, e.g. energy density of 
fat, and the metabolic efficiency with which fat consumed is stored 
as body fat (Danforth, 1985). it was interestij^ to see a robust
suppressive effect of FXT on the oonsuroption of savoury kj in nale 
subjects (Pig 4.7).
The availability of an antidepressant which has anorectic potential 
is advantageous on three main counts; firsUy, it means there is 
an available treatment which, unlike tricyclics, does not cause 
unwanted wei^t gain and jeopardize conplianoe (Russ & Ackerman, 
1988). Secondly, depressed patients who are already overwei^t may 
benefit from a treatment vhich addresses both their cliniced. 
d^ressed state and their obesity. Thirdly, FXr may be used to 
treat obesity itself. From the subjective ratings of mood there 
does not appear to be a risk of inducing mania. De^ite the 
administration of three times the clinical therapeutic dose, there 
was no evidence of mood alteration (Fig 4.13).
However, considering both the chronicity and refractory nature of 
obesilqr, monitoring Icmg-term effects on body weight is essential. 
Darga et al. (1991), rqjorted on m  treated obese subjects who.
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having attained maxirrum wei^t loss at week 29 of a 52 week tried, 
started to regain weight (Fig 7.1). The gradual weight "claw-back'' 
seen in these patients is similar to the body-wei^t regain seen in 
the chronic FXT study in rats in Chapter 6 (Fig 6.1), and is 
strcxigly suggestive of partial tolerance to the effects of F3CT. In 
addition, on cessation of medication, and after wash-out had 
occurred, FXT treated auiimals esdiibited wei^t regain prior to the 
increases in intake of sucrose and chew. Taking body wei^t on day 0 
as a baseline, and looking at percentage weight change vhich had 
occurred by day 29 (approximately one week after treatment stopped), 
ccxitrol animals had gained 3.1%, FXT animals 3.1% and FF animals 
4.0%.
Effectively, body weight changes in control and FXT treated animals 
did not differ markedly vhen observaticais continued well beyond 
treatment cessaticxi. Again, these findings do appeeu: to offer fsrma 
support for the operation of a set-point mechanism. FOr a 
obese populaticai, wei^t regain may be eui unwelccme euid 
disheartening prospect on cessaticxi of medication (Guy-Grand et al., 
1990).
Drugs vhich reduce body-wei^t may be seen as emtinuing to be 
therapeutic if, despite a wei^t-loss plateau, wei^t regain is 
avoided. For exainple, d-fenfluramine has been r^xsrted as being 
succesful at keying weight regain at bay oenpared to placebo on 
cessation of a very low calorie diet (Finer et al,, 1987). The 
use of d-fenfluramine in addition to an initial (apprxax. 4 months) 
very low calorie diet during a one year tried caused greater
/
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FLUOXETINE AND WEIGHT LOSS
Plocebo
riuoxeline
Week number
Fig 7.1 Progress of weight-loss during a one year trial in obese 
subjects. Taken from Darga et al. (1991). American Journal of 
Clinical Nutrition, 54, 321-25
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percentage wei^t loss relative to a very low calorie diet alone.
Hcwever, in this trial, wei^t regain began to occur after six 
inonths (Andersen et ad., 1992).
Of cx3urse, the more objective question to ask is vihether there is a 
place for anorectic and weight reducing agents in the Icxig-term 
treatment of obesity. Practitioners with considerable esqjerienoe in
obesity research suggest that perhaps by viewing the treatment of
obesity as a long-term regime, needing a skilful eclectic treatment
approach, using altemavive/mixed treatment apprxaaches, it may be
possible to sustain weight loss (Silverstone & Goodall, 1992). A
study ooirpleted over a decade ago in which Stunkard et al., (I980b)
ocnpared six months of either behaviour therapy, pharmacotherapy
(FF) or a ocnbination of the two, found that although FF and the
cxmbined treatments caused greater weight loss than behavioural
modification during the trial, a one year fdllow-up showed small
weight regain levels in b^vioural modification group cxmpared to
the other treatment. However, analysis of weight status five years
after a study in vhich individuals used either low calorie diets,
b^vioural modification, or a ocnbination, showed disappointing
results, with weic^t regain the usual pattern (Wadden et al., 1989).
These studies enphasize the importance of a long-term treatment
perspective, with regular monitoring when weight loss had actually 
occurred.
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Sgrptcnetqig effects on oonsunnatoiv hahavif^ ir-
Acute administration of fluoxetine, dl-fenfluramine, paroxetine, 
femoxetine and eltcprazine, resulted in reduced intake and 
alterations in the behavioural satiety sequence (BSS). 5^
agonists, with the e x o ^ i o n  of fenfluramine, all appear to result 
in an early introduction of resting during the BSS. The effect of 
acute FF on the BSS may be considered atypical relative to the other 
serotonergic drugs being examined, in that the resting oonponent is 
si¥t>i:assed is a dose-dependent manner (Pig 5 .I). lookirg at this 
initial effect of fenfluramine on the BSS, it would have been 
difficult to predict the long-term effects seen on resting.
It has been of some value to examine the anorectic and ocnsumaatory
behavicxiral effects of the 5-wr le.txie D agonist, eltcprazine.
Eltoprazine was found to possess a satiety-enhancing effect with
reductions in sucrose intake and increases in resting bdiaviour (Pig
S.«). W h U e  eltcprazine acts at both receptors, it is
also a antagonist. Evidence that stimulation of 5 ^ , »
autoreoqjtors results in hypcphcigia has been seen with the
agonist, 8-CH-t»Kr (Dourish et al., 1986). Decreases in intake in
re^xsise to administraticm of 8-OH-DEftT occur at high doses, which
also elicits the 5-«T bdiavioural syndrome, ihis analysis
that drugs which act as agonists at S-HTj^ receptors may advance the 
behavioural satiety sequence.
/
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Hcwefver, the results frcra both the acute and the chronic studies 
(belcw) shov the limitations inherent in assessing the significance 
of drug-induced changes in oonsuninatary behaviour, in the context of 
the behavioural satiety secpience (BSS). The effects of acutely 
administered FXr appear consistent with ertianoed satiety vhile the 
acute effects of fenfluramine appear to alter it, and yet the 
reverse is seen in response to chronic administration of either 
drug. It becomes necessary.to consider that in both the acute FF 
and in the chronic FXr regimes, the satiety-erihancing c e c i t y  of 
each drug may be masked by carpeting re^xxises.
The effects of chronically administered FF further highlight the 
weaknesses in using the BSS as an index of satiety. Animals treated 
chronically with FF esdiibited an enhanced BSS, in the cxnponents of 
suppression of grooming and a very clear early introdiaction of 
resting. However, as b^iavioural observations on ciay 14 show (pjg 
6.5), drinking b^iaviour was above ccntrol levels, debits intake 
of sucrose being reducsed. There is a possible e>g)leaiation for these 
secpienca of events vhich would suggest that FF acts more to induce 
sedation as opposed to enhancing satiety. As early introduction of 
resting b^iaviour is present from observations by Day 4. Animals may 
"learn" that their drinking time of sucrose will be cut short due to 
encroaching sedation, and cxxisequently attempt to cxxisume as much 
sucrose as possible before this cxxurs.
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The increase in non-specific activity seen in réponse to chronic
treatment with F5CT (Pig 6.4), may be similar to the effects of other
serotonergic drugs on the motor conponent of behaviour, and points
to possible interaction between 5-HT and DA systeas. Like
eltoprazine, at the highest dose tested (TïûîleS.l), the 5^11._IB
agonist PU 24969 also induces hyperloocmotion, an effect suggested 
as being the result of reduced 5-flT inhibitory influences 
dopaminergic neurons (Bendotti & Samanin, 1987). Pretreatment with 
the DA antagonist haloperidol has been shown to block the 
hyperloccmotive effect of PU 24969 without effecting the hypophagia 
(Bendotti & Samanin, 1987). Serotcaiergic antagc»iists do not block 
the hyperlocomotion induced by PU 24969 (Green et ad. 1984; 
Kennet et ad. 1987).
Althcu^ acute FXT did not r ^ r t e d l y  adter psychorootor function in 
normad volunteers (Hindmaurch, 1987), some psychiatric patients 
treated with FXT, are described as having extra$)yramidad synpitoms 
such as restlessness (Lipinski et ad. 1989). "Restlessness” could 
have been an appropriate descriptive category in the chronic rat 
stuc^, as the cbserved bdiaviour conprized continuad movement, 
without a notably stimulant aspect.
The liJoelihood of being able to draw a comprehensive conclusion to 
explain the emergence of dissimilar effects of d-FF and FXT in the 
chronic rat study is* limited on two counts. Firstly, the 
cbservaticn methodology used in this stuc^ was designed to examine 
drug effects on four related consumnatory b^iaviours of drinking.
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9 i^ocndJXf, activi'ty and rGstln^. This xnaxiinally engaged 'tha 
attention ^ a n  of the observer and v ^ l e  the end result was a good 
gaieral descripticxi of overall behavioural oocurrenoe, it was not 
possible to "fine tune” to any peu±icular b^viour. Secxjndly, the 
observation periods were limited to 40 minutes on test days, and 
b^iaviours occurring outside of this period were not observed. This 
uipossible to establish vhether any of the behavioural 
differences, from COTtrol values, were present at other times. It 
is likely that the alterations in nai-OMisuinnatory activity, 
grocming and resting were present at times outside the observation 
period, but this cannot be stated conclusively.
There are at least two possible developnents in an eiQierimental 
methodology vhich would cleurify the picture of results here: A 
methodology of continuous recording (Blundell fie McArthur, 1981) 
would allow measurements over longer periods of time. Additiorally, 
as initial observations hi^ilighted signnificant deviations from 
control values in. for example, levels of non-specific activity in 
FXT treated animals, particular focus could be trained on selected 
b^iaviour using categories with more descriptive levels, of
the attention ^ a n  described above, some behavioural categor* 
were condensed for descriptive purposes. The category of behaviour 
scored as 'active' (activity) actually included sniffing, rearing 
and locomotion, vhile the category of b^iaviours scored ais resting 
included both standing motionless emd lying down. An observer 
methodology which focussed on a particular behaviour at several 
levels, and benefited from ooirputer-eissisted meeisurement could 
refine the descriptive categories and reduce the ambiguity of the
/
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more general categorization used in the study here. For example, 
Qiagraoui et al., (1990), examined the effects of acute 
antidepressant and chrmic dopamine agonist treatment cm motor 
re^xxises in mice using a oonputerized Digiscan actimeter v ^ c h  
measured horizont2d  and verticzd activity, and the number of small 
movements occurring.
In addition, further examination of the possible mechanisns behind
the effects of FXT may be possible by using drugs to determine that
the observed effects are definitely ^»cific to 5-HT receptors, as
opposed to acting on another system, e.g. histamine antagcxiists
should cleuri^ that the einorectic effect is not histaminergic. Tato-r
development may see clarification of the source of FXT-induoed
effects. The anorectic effect of F3CT may largely reside in one
isom er, as with FF (Garattini et al., 1986), and the dopaminergic
effects may be largely present in the other. Wong et al (1988),
have shown that both the R and S-enantioroers of fluoxetine lower
food int2dce in meal-fed and in rats made hyperphagic by«
2-deooqgluoose, they report that the S-enantioroer is sli^tly more 
potent at suppressing food intake than the R-enantiomer.
2.5 Final Oonment
Stellar (1989), acknowledging himself as one of the "oldest living 
mentoers” in the field of feeding research, suggested that while 
there have been advances in knowledge concerning the physiology of 
feeding, there 2ure few success stories in the search for sound 
treatment, (since his entry into research in 1938), for the
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cx3nditic3ns of anorexia nervosa, bulimia nervosa or obesity. 
Whether the condition of obesity should be placed in DSM-lll-R 
alongside the other eating disorders is a contentious point. More 
recently, there are reports of suggested reclassification of 
diagnosis, to include identification of obese people who binge 
(Wilson & Waish, 1991). At present, it is not determined what 
percentage of obese people are eating disordered.
A  prophylactic approach to the avoidance of obesity is one way of 
acknowledging the gene-environment interaction mentioned in Qiapter 
1 (Ward, 1990), it is clear that obesity aurises from a variety of 
sources (Blundell, 1990). Some researchers are atternpting to 
identify early risk factors. For example, a study whioh divided 
children into either h i ^  risk (with <xie or both paunents overwei^t) 
or low risk (normal weight parents) groups, shewed that the h i ^  
risk grxxç consumed more fat throuc^out the course of a year, and 
wei^ied more than the low risk grotç), by the end of the year (Frk 
et al., 1992). Another study which examined the relationship between 
temperament status and the development of obesity in children, 
found correlations between weight gain and parent-rated difficult 
behavioural style. A cross-sectional section of the same stuc^ 
found obese ohildren to be less predictable and persistent than 
matched controls (Carey et al., 1988). Obviously bdiaviourists and 
geneticists yculd hold differing views on what is occurring in these 
children, and would consec^iently recomnend differing treatment 
regimes. As both childhood 2isthma emd hyperkinesia are treated with 
drugs, perhaps there is -a role for pheumiaoological interventicxi when 
the alternative would be the development of obesity. Alternatively,
/
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of OOUTS0 , alterations in dietary intake are nanTwimaiy^^^ eo^erts 
in cxxintries, such as Japan, in vhich leirge increases in childhood 
obesities are occurring (Kinugasa & Kusunoki, 1990).
For adult obesities, classificaticxi and treatment ocxitinues to be 
randomly d^endent on persuasion of the clinican, yet there is 
every possibility that refining diagnostic criteria and using this 
as a basis for a treatment plan, would assist in treatment success. 
Classification of obesity based on wei^t or EMI is useful, but too 
siXDplistic (Bjorntorp, 1990). Some attempts are being made to 
develop a more sophisticated typology of obesity vhich would help 
determine treatment approaches. For example, Allison & Heshka (1991) 
identified compment aspects of either lifestyle, or physiology 
(gynoi<Vandroid), which appeared to contribute to the presenting 
obesity. Their suggestion was that lifestyle obesities may benefit 
from, for example, a bdiavioural modificaticxi approach, vhile gynoid 
cbesi"^ would, perhaps, merit a pharmacological intervention.
%
The likelihood of successful treatment for obesity is additionally 
confounded by the probability that obese patients, presenting 
thanselves for treatment, are a heterogeneous group with respect to 
aetiology. Figure 7.2 shews hew the gene-envirorment interactiai may 
be expressed for the development and maintenance of obesi'ty to
/
Figures from G.H. Anderson(ed): Diet & Behavior; Hultidisciplinary Approaches (1990) ^12
METABOLISM
DELETERIOUSDIET
ECOLOGICENVIRONMENT
genetics b e h a v i o r
D ia g r a m  o f  a n e g a tiv e  fe e d b a ck  lo o p  w ith  ben e H cia l e ffe c t. In  th is p a rt ic u la r  n a ra d le m  
P  ‘ o  «"O d ific a tio n  o f  b e h a v io r  tha t c u lm in a te s  in  a v i id a n e f  o f
in to le ra n c e  P*’ « " ® " ’ « " «  '"c'**de th e  a lc o h o l flush re a c tio n  a n d  lactose
ENVIRONMENT
NEUROPHYSIOLOGY.
DELETERIOUSOUTCOME
GENETICS BEHAVIOR
INAPPROPRIATEDIET
METABOLISM
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Feedback loops with beneflcial(top) and de1eterious(middle, bottom)outcome
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(bottom panel); exaivples of both beneficied (alcxshol avoidance) and 
another deleterious interactioi (alcohol abuse) are shown (top and 
middle panels respectively) (Ward, 1990).
Psychologiccil assessment, prior to treatment for obesity, may be 
beneficiad in determining either suitable treatment for that 
individued, or likelihood of success as predicted by psychologiced 
profile. Clark et al, (1991), have been attempting to identify 
psychologicad self-efficacy ccmistr\x±s present in the obese before 
and after treatment. Self efficacy (Bandura, 1977), defined as a 
person's judgement of their own ability to efficiently manage a 
situation, has been a useful construct in predicting outcome in 
studies of addictive behaviour e.g. drinking, smoking. Clark et 
2d  (1991), vho developed and vedidated a Wei^t Efficacy Life-Style 
Oiestionnaire, suggest that this questicxinaire is used to identify 
i^)ecific aspects; e.g. negative emoticais, positive activities, 
v ^ c h  may contribute to dieting outcome. Use of such questionnaires 
could edso pinpoint areas of vulnerability which would necessarily 
differ between individueds. Blair et 2d., (1990), reported that 
a reducticmi in levels of "emotiai2d" eating was associated with 
greater success in wei^t loss, again pin-pointing <xi the cruci2d  
role of psychologic2d  variables for weight control.
Individu2d  reports and spontaneous comnents from the obese subjects
in the present study suggest that perhaps long-term treatment
regimes will need to be conprehensively tailored to the need and
%
afwessed status of that particular individual. For example, some 
siA^jects reported eating vhether they felt hungry or not.
/
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PBrticailarly foods (fenale). Single male subjects ri^x^fted 
eating taJœ-away foods and drinking beer frequently, vAiile married 
men consumed hone-cooked meals, the ooitent of which was largely 
determined by their wives, and also ooisumed beer. This intake 
bdiavicur is not aberrant, but was obviously contributing to the 
static obese state. Alcohol ooisunptioi has been suggested as 
playing a contributory role in the development and maintenance of 
obesity in males (Seidell et al, 1988). It can be seen that drastic 
and possibly unattractive changes of lifestyle are necessary if 
weic^t loss is to occur.
At present obese patients presenting for treatment are assessed for 
degree of overweic^t and general health status. The treatment 
offered will depend on the persuasion of the clinician and this 
treatment will most likely be lansuccessful in the long-run. The 
possible ocmbinatic»! of energy intake restriction, behaviour 
therapy and exercise would, no doubt, be successful v^ile it lasted, 
but would require tremendous motivation for patients thenselves, 
siçjport from relatives, and a sound environmental context (Ward, 
1990). The singular most hopeful aspect for those for whom obesity 
is an afflicticxi, is in the diverse research areas vhich are 
consistently active auid likely to o^tinue so.
/
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